(80000132,'26098901','HbA1c','HbA1c','','Extreme Levels of HbA1c Increase Incident ESRD Risk in Chinese Patients with Type 2 Diabetes: Competing Risk Analysis in National Cohort of Taiwan Diabetes Study','protein','serum','','experiment','T2DM(51681)','< 6.0%, 6.0%–6.9%, 7.0%–7.9%, 8.0%–8.9%, 9.0%–9.9%, and 10.0%','< 6.0%:6.0%–6.9%','ESRD','','','HR, 4.42(3.80 to 5.14)','multivariate','','<0.001','Cox','worse','','','','','','','','','','','','','','','','','','','',''),(80000133,'24819633','SOD2','SOD2','P04179','Manganese superoxide dismutase (SOD2) polymorphisms, plasma advanced oxidation protein products (AOPP) concentration and risk of kidney complications in subjects with type 1 diabetes','gene','plasma','','KASP','T1DM(SURGENE(340))','','','renal events (new cases of microalbuminuria or progression to a more severe stage of nephropathy)','','event-free curves','HR, 1.99(1.24 to 3.12)','multivariate','','0.004','Cox','worse','','rs4880','Low','Supported','Medium','Supported','tissue','Superoxide dismutase 2','Cancer-related genes;Disease related genes;Enzymes;Plasma proteins;Potential drug targets;Predicted intracellular proteins','Intracellular','11','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','General cytoplasmic expression with a granular pattern.','RNA low, Protein medium in Kidney','SOD2 ','6','q25.3','P04179 (UniProt - Evidence at protein level)','DB03297; DB04436'),(80000134,'24819633','SOD2','SOD2','P04179','Manganese superoxide dismutase (SOD2) polymorphisms, plasma advanced oxidation protein products (AOPP) concentration and risk of kidney complications in subjects with type 1 diabetes','gene','plasma','','KASP','T1DM(SURGENE(340))','','','renal events (new cases of microalbuminuria or progression to a more severe stage of nephropathy)','','','HR, 1.90(1.19鈥?.98)','multivariate','','0.007','Cox','worse','','rs8031','Low','Supported','Medium','Supported','tissue','Superoxide dismutase 2','Cancer-related genes;Disease related genes;Enzymes;Plasma proteins;Potential drug targets;Predicted intracellular proteins','Intracellular','11','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','General cytoplasmic expression with a granular pattern.','RNA low, Protein medium in Kidney','SOD2 ','6','q25.3','P04179 (UniProt - Evidence at protein level)','DB03297; DB04436'),(80000135,'24819633','SOD2','SOD2','P04179','Manganese superoxide dismutase (SOD2) polymorphisms, plasma advanced oxidation protein products (AOPP) concentration and risk of kidney complications in subjects with type 1 diabetes','gene','plasma','','KASP','T1DM(SURGENE(340))','','','renal events (new cases of microalbuminuria or progression to a more severe stage of nephropathy)','','','HR, 1.94(1.22 to 3.04)','multivariate','','0.006','Cox','worse','','rs2758329','Low','Supported','Medium','Supported','tissue','Superoxide dismutase 2','Cancer-related genes;Disease related genes;Enzymes;Plasma proteins;Potential drug targets;Predicted intracellular proteins','Intracellular','11','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','General cytoplasmic expression with a granular pattern.','RNA low, Protein medium in Kidney','SOD2','6','q25.3','P04179 (UniProt - Evidence at protein level)','DB03297; DB04436'),(80000136,'25894587','hepcidin','HAMP','P81172','Hepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease','protein','serum','','experiment','T1DM,T2DM(249)','hepcidin <44 ng/ml,44鈥?6 ng/ml,>76 ng/ml','H:M:L','CKD progression (ESRD or doubling of serum creatinine) ','','event-free curves','HR, 1.134(1.041 to 1.235)','multivariate','','<0.05','Cox','worse','','','','','','','RNA tissue','Hepcidin antimicrobial peptide','Disease related genes;Potential drug targets;Predicted secreted proteins;Transporters','Secreted','2','HPA. Tissue enriched (liver);GTEx. Tissue enriched (liver);FANTOM5. Tissue enriched (liver)','Evidence at protein level','','RNA not detected, Protein N.A in Kidney.','HAMP (HGNC Symbol)','19','q13.12','P81172 (UniProt - Evidence at protein level)',''),(80000137,'18609080','Interleukin-6','IL6','P05231','Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study','protein','plasma','','experiment','T2DM(269)','','','onset of diabetic nephropathy (persistent albuminuria >200 渭g/min in two out of three consecutive overnight urine samples and at least 30 % higher than the baseline level)','microalbuminuria','','HR, 1.72(1.12 to 2.66)','multivariate','','0.014','Cox','worse','early','','Not detected','Supported','Not detected','Supported','tissue','Interleukin 6','Cancer-related genes;Candidate cardiovascular disease genes;Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted secreted proteins','Intracellular,Secreted','7','HPA. Tissue enhanced (adipose tissue);GTEx. Tissue enhanced (adipose tissue, lung);FANTOM5. Tissue enhanced (appendix)','Evidence at protein level','Extracellular deposits and cytoplasmic expression in subsets of lymphoid cells in several tissues.','RNA low, Protein not detected in Kidney','IL6 (HGNC Symbol)','7','p15.3','P05231 (UniProt - Evidence at protein level)','DB01404; DB05017; DB05470; DB05513; DB05744; DB05767; DB06083; DB09036; DB09221; DB11967; DB12140'),(80000138,'18609080','vWf','VWF','P04275','Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study','protein','plasma','','experiment','T2DM(269)','','','onset of diabetic nephropathy (persistent albuminuria >200 渭g/min in two out of three consecutive overnight urine samples and at least 30 % higher than the baseline level)','microalbuminuria','','HR, 1.69(1.10 to 2.59) ','multivariate','','0.016','Cox','worse','early','','Not detected','Supported','Not detected','Supported','tissue','Von Willebrand factor','Cancer-related genes;Candidate cardiovascular disease genes;Disease related genes;FDA approved drug targets;Plasma proteins;Predicted secreted proteins','Secreted','1','HPA. Tissue enhanced (adipose tissue);GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Plasma positivity and selective cytoplasmic expression in endothelial cells and megakaryocytes.','RNA low, Protein not detected in Kidney.','VWF (HGNC Symbol)','12','p13.31','P04275 (UniProt - Evidence at protein level)','DB00025; DB05202; DB06081; DB09108; DB09329; DB11606; DB11607; DB13998; DB13999'),(80000139,'18609080','sVCAM-1','VCAM1','P19320','Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study','protein','plasma','','experiment','T2DM(269)','','','onset of diabetic nephropathy (persistent albuminuria >200 渭g/min in two out of three consecutive overnight urine samples and at least 30 % higher than the baseline level)','microalbuminuria','','HR, 2.06(1.26 to 3.36)','multivariate','','0.004','Cox','worse','early','','Not detected','Supported','Not detected','Supported','tissue','Vascular cell adhesion molecule 1','Cancer-related genes;CD markers;Plasma proteins;Predicted membrane proteins','Membrane','4','HPA. Tissue enriched (spleen);GTEx. Tissue enhanced (spleen);FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic expression in subsets of immune cells and vascular endothelium.','RNA low, Protein not detected in Kidney.','VCAM1 (HGNC Symbol)','1','p21.2','P19320 (UniProt - Evidence at protein level)','DB00898; DB01136; DB05399'),(80000140,'18609080','sICAM-1 ','ICAM1','P05362','Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study','protein','plasma','','experiment','T2DM(269)','','','onset of diabetic nephropathy (persistent albuminuria >200 渭g/min in two out of three consecutive overnight urine samples and at least 30 % higher than the baseline level)','microalbuminuria','','HR, 1.99(1.04 to 3.82)','multivariate','','0.038','Cox','worse','early','','High','Supported','Not detected','Supported','tissue','Intercellular adhesion molecule 1','Cancer-related genes;Candidate cardiovascular disease genes;CD markers;FDA approved drug targets;Plasma proteins;Predicted membrane proteins;Predicted secreted proteins','Membrane,Secreted','3','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Distinct membranous expression mainly in endothelial cells, pneumocytes and subsets of lymphoid cells.','RNA low, Protein high in Kidney, lower than in Lung.','ICAM1 (HGNC Symbol)','19','p13.2','P05362 (UniProt - Evidence at protein level)','DB00108; DB08818; DB12598'),(80000141,'18609080','Endothelial Z-score','','','Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study','score','plasma','','experiment','T2DM(269)','Endothelial Z-score of -0.056','H:L','onset of diabetic nephropathy (persistent albuminuria >200 渭g/min in two out of three consecutive overnight urine samples and at least 30 % higher than the baseline level)','microalbuminuria','cumulative incidences','HR, 3.20(1.56 to 6.56)','multivariate','','0.001','Cox','worse','early','','','','','','','','','','','','','','','','','','',''),(80000142,'17907053','THP','UMOD','P07911','Decreased urinary concentration of Tamm-Horsfall protein is associated with development of renal failure and cardiovascular death within 20 years in type 1 but not in type 2 diabetic patients','protein','urine','','experiment','T1DM,T2DM(T1DM(131))','u-THP of 38.2mg/l','H:L','uraemia/dialysis/transplantation','','cumulative incidences','','','','<0.001','log rank','better','','','Not detected','Supported','High','Supported','tissue','Uromodulin','Disease related genes;Plasma proteins;Predicted intracellular proteins;Predicted membrane proteins;Predicted secreted proteins','Intracellular,Membrane,Secreted','12','HPA. Tissue enriched (kidney);GTEx. Tissue enriched (kidney);FANTOM5. Tissue enriched (kidney)','Evidence at protein level','Selective cytoplasmic expression in distal renal tubules.','Both high (only) in Kidney.','UMOD ','16','p12.3','P07911 (UniProt - Evidence at protein level)',''),(80000143,'21820220','TnT ','TNNT1','P13805','Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD','protein','serum','','experiment','T2DM(1000)','NT-proBNP of 605pg/mL,TnT of 0.01 ng/mL,NT-proBNP of 605pg/mL','HBHT:LBHT:HBLT:LBLT','ESRD','eGFR, 20-60mL/min/1.73 m2','cumulative incidences','','','','<0.001','log rank','worse','advanced','','Not detected','Supported','Not detected','Supported','tissue','Troponin T1, slow skeletal type','Disease related genes;Predicted intracellular proteins','Intracellular','14','HPA. Tissue enriched (skeletal muscle);GTEx. Tissue enriched (skeletal muscle);FANTOM5. Tissue enriched (skeletal muscle)','Evidence at protein level','Selective cytoplasmic expression in skeletal muscle.','RNA low, Protein not detected in Kidney, lower than in Muscle tissues.','TNNT1 (HGNC Symbol)','19','q13.42','P13805 (UniProt - Evidence at protein level)',''),(80000144,'21820220','NT-proBNP','NPPB','P16860','Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD','protein','serum','','experiment','T2DM(1000)','NT-proBNP of 605pg/mL,TnT of 0.01 ng/mL,NT-proBNP of 605pg/mL','','ESRD','eGFR, 20-60mL/min/1.73 m2','','HR, 2.20(1.37 to 3.52)','multivariate','','0.001','Cox','worse','advanced','','','','','','RNA tissue','Natriuretic peptide B','Candidate cardiovascular disease genes;Plasma proteins;Predicted secreted proteins','Secreted','1','HPA. Tissue enriched (heart muscle);GTEx. Tissue enriched (heart muscle);FANTOM5. Tissue enriched (heart muscle)','Evidence at protein level','','RNA not detected, Protein N.A in Kidney.','NPPB ','1','p36.22','P16860 (UniProt - Evidence at protein level)','DB01136; DB06412'),(80000145,'21820220','NT-proBNP','NPPB','P16860','Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD','protein','serum','','experiment','T2DM(1000)','NT-proBNP of 605pg/mL,TnT of 0.01 ng/mL,NT-proBNP of 605pg/mL','','ESRD','eGFR, 20-60mL/min/1.73 m2','','HR, 1.90(1.12 to 3.22)','multivariate','','0.01','Cox','worse','advanced','','','','','','RNA tissue','Natriuretic peptide B','Candidate cardiovascular disease genes;Plasma proteins;Predicted secreted proteins','Secreted','1','HPA. Tissue enriched (heart muscle);GTEx. Tissue enriched (heart muscle);FANTOM5. Tissue enriched (heart muscle)','Evidence at protein level','','RNA not detected, Protein N.A in Kidney.','NPPB ','1','p36.22','P16860 (UniProt - Evidence at protein level)','DB01136; DB06412'),(80000146,'21820220','NT-proBNP','NPPB','P16860','Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD','protein','serum','','experiment','T2DM(1000)','NT-proBNP of 605pg/mL,TnT of 0.01 ng/mL,NT-proBNP of 605pg/mL','','ESRD','eGFR, 20-60mL/min/1.73 m2','','HR, 2.820(1.449 to 5.485)','multivariate','','0.01','Cox','worse','advanced','','','','','','RNA tissue','Natriuretic peptide B','Candidate cardiovascular disease genes;Plasma proteins;Predicted secreted proteins','Secreted','1','HPA. Tissue enriched (heart muscle);GTEx. Tissue enriched (heart muscle);FANTOM5. Tissue enriched (heart muscle)','Evidence at protein level','','RNA not detected, Protein N.A in Kidney.','NPPB ','1','p36.22','P16860 (UniProt - Evidence at protein level)','DB01136; DB06412'),(80000147,'21346330','apo E ','APOE','P02649','Apolipoprotein E polymorphism and the progression of diabetic nephropathy in type 2 diabetes','gene','serum','','experiment','T2DM(525)','','E4 carrier:non-E4 carrier','progression of DN(shift to a higher stage of DN or a doubling of the baseline serum creatinine level by the end of the study)','','cumulative incidences','HR, 1.94(1.16 to 3.27)','multivariate','','0.002','Cox','worse','','E4 carrier','Not detected','Supported','Low','Supported','tissue','  Apolipoprotein E','Cancer-related genes;Candidate cardiovascular disease genes;Disease related genes;Plasma proteins;Predicted secreted proteins','Secreted','4','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Distinct plasma positivity. Cytoplasmic expression in hepatocytes, renal tubules, Leydig cells, adrenal gland and subset of neurons.','RNA medium, Protein low in Kidney','APOE (HGNC Symbol)','19','q13.32','P02649 (UniProt - Evidence at protein level)','DB00062; DB01593; DB09130'),(80000148,'26067713','D-scores','','','A pathological scoring system to predict renal outcome in diabetic nephropathy','score','renal tissue','','experiment','DM(205)','D-score <= 14, 15–18, 19–21, and 22–25 ','<= 14: 15–18:19–21:22–25 ','ESRD','','event-free curves','','','','<0.001','log rank','worse','','The D-scores of glomerular classes 1, 2A, 2B, 3, and 4 were, respectively, 0, 3, 4, 6, and 6. Those ','','','','','','','','','','','','','','','','','',''),(80000149,'26067713','D-scores','','','A pathological scoring system to predict renal outcome in diabetic nephropathy','score','renal tissue','','experiment','DM(205)','D-score <= 14, 15–18, 19–21, and 22–25 ','<= 14: 15–18:19–21:22–25 ','ESRD','','','HR, 16.21(1.86 to 140.90)','multivariate','','0.01','Cox','worse','','The D-scores of glomerular classes 1, 2A, 2B, 3, and 4 were, respectively, 0, 3, 4, 6, and 6. Those ','','','','','','','','','','','','','','','','','',''),(80000150,'26067713','D-scores','','','A pathological scoring system to predict renal outcome in diabetic nephropathy','score','renal tissue','','experiment','DM(205)','D-score <= 14, 15–18, 19–21, and 22–25 ','<= 14: 15–18:19–21:22–25 ','ESRD','','','HR, 19.78(2.15 to 182.40)','multivariate','','0.008','Cox','worse','','The D-scores of glomerular classes 1, 2A, 2B, 3, and 4 were, respectively, 0, 3, 4, 6, and 6. Those ','','','','','','','','','','','','','','','','','',''),(80000151,'26067713','D-scores','','','A pathological scoring system to predict renal outcome in diabetic nephropathy','score','renal tissue','','experiment','DM(205)','D-score <= 14, 15–18, 19–21, and 22–25 ','<= 14: 15–18:19–21:22–25 ','ESRD','','','HR, 45.46(4.63 to 446.68)','multivariate','','0.001','Cox','worse','','The D-scores of glomerular classes 1, 2A, 2B, 3, and 4 were, respectively, 0, 3, 4, 6, and 6. Those ','','','','','','','','','','','','','','','','','',''),(80000152,'25154422','MCP-1','CCL2','P13500','Monocyte chemoattractant protein-1 (MCP-1) g.-2518A>G polymorphism and susceptibility to type 2 diabetes (T2D) and end stage renal disease (ESRD) in the North-West Indian population of Punjab','gene','serum','','experiment','T2DM(350)','','','ESRD ','','','HR, 4.03(1.6 to 10.2)','multivariate','','0.011','Cox','worse','','rs1024611','Not detected','Approved','Medium','Approved','tissue','C-C motif chemokine ligand 2','Cancer-related genes;Candidate cardiovascular disease genes;FDA approved drug targets;Plasma proteins;Predicted secreted proteins','Secreted','2','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Extracellular deposits and cytoplasmic expression in most tissues.','RNA low, Protein medium in Kidney.','CCL2 (HGNC Symbol)','17','q12','P13500 (UniProt - Evidence at protein level)','DB01055; DB01406; DB09301'),(80000153,'25154422','MCP-1','CCL2','P13500','Monocyte chemoattractant protein-1 (MCP-1) g.-2518A>G polymorphism and susceptibility to type 2 diabetes (T2D) and end stage renal disease (ESRD) in the North-West Indian population of Punjab','gene','serum','','experiment','T2DM(female(157))','','','ESRD ','','','HR, 2.14(1.19 to 3.86)','multivariate','','0.003','Cox','worse','','rs1024611','Not detected','Approved','Medium','Approved','tissue','C-C motif chemokine ligand 2','Cancer-related genes;Candidate cardiovascular disease genes;FDA approved drug targets;Plasma proteins;Predicted secreted proteins','Secreted','2','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Extracellular deposits and cytoplasmic expression in most tissues.','RNA low, Protein medium in Kidney.','CCL2 (HGNC Symbol)','17','q12','P13500 (UniProt - Evidence at protein level)','DB01055; DB01406; DB09301'),(80000154,'25154422','MCP-1','CCL2','P13500','Monocyte chemoattractant protein-1 (MCP-1) g.-2518A>G polymorphism and susceptibility to type 2 diabetes (T2D) and end stage renal disease (ESRD) in the North-West Indian population of Punjab','gene','serum','','experiment','T2DM(female(157))','','','ESRD ','','','HR, 3.51(1.37 to 9.01)','multivariate','','0.009','Cox','worse','','rs1024611','Not detected','Approved','Medium','Approved','tissue','C-C motif chemokine ligand 2','Cancer-related genes;Candidate cardiovascular disease genes;FDA approved drug targets;Plasma proteins;Predicted secreted proteins','Secreted','2','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Extracellular deposits and cytoplasmic expression in most tissues.','RNA low, Protein medium in Kidney.','CCL2 (HGNC Symbol)','17','q12','P13500 (UniProt - Evidence at protein level)','DB01055; DB01406; DB09301'),(80000155,'21147957','HbA1c','HbA1c','','Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A1c)','protein','serum','','experiment','T2DM(2314)','','','progression of nephropathy','','','HR, 1.201(1.089 to 1.320)','multivariate','','<0.0001','Cox','worse','','u.m. HbA1c( updated mean)','','','','','','','','','','','','','','','','','',''),(80000156,'21147957','glycation gap','','','Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A2c)','score','serum','','experiment','T2DM(2314)','','','progression of nephropathy','','','HR, 1.358(1.168 to 1.577)','multivariate','','<0.0001','Cox','worse','','','','','','','','','','','','','','','','','','','',''),(80000157,'21147957','glycation gap','','','Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A3c)','score','serum','','experiment','T2DM(2314)','GG of characteristic mean calculated for each patient by averaging his or her raw gg value','H:M:L','progression of nephropathy','','cumulative incidences','HR, 2.52','multivariate','','<0.001','Cox','worse','','glycation gap was defined for each patient as the mean of the values for the raw glycation gap (gg) ','','','','','','','','','','','','','','','','','',''),(80000158,'21147957','glycation gap','','','Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A4c)','score','serum','','experiment','T2DM(2314)','GG of characteristic mean calculated for each patient by averaging his or her raw gg value','H:M:L','progression of nephropathy','','cumulative incidences','HR, 1.61','multivariate','','0.001','Cox','worse','','glycation gap was defined for each patient as the mean of the values for the raw glycation gap (gg) ','','','','','','','','','','','','','','','','','',''),(80000159,'18083536','HGB','HBB','P68871','Hemoglobin and overt nephropathy complications in type 1 diabetes','protein','serum','','experiment','T1DM(174)','HGB of 13.75 g/L in women, 15.85 in men','H:L','ESRD','albumin excretion rate >200 渭g/min in multiple urine samples','event-free curves','HR, 0.72(0.61 to 0.85)','multivariate','','0.001','Cox','better','middle,advanced','','Not detected','Supported','Not detected','Supported','tissue','Hemoglobin subunit beta','Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Transporters','Intracellular','2','HPA. Tissue enriched (bone marrow);GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Expression in erythrocytes.','RNA low, Protein not detected in Kidney.','HBB (HGNC Symbol)','11','p15.4','P68871 (UniProt - Evidence at protein level)','DB00893; DB01593; DB02126; DB07427; DB07428; DB07645; DB08077; DB08262; DB08486; DB08632; DB09112; DB09130; DB09140; DB09147; DB09517; DB13995'),(80000160,'23492569','TKT','TKT','P29401','Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality','gene','serum','','experiment','T2DM(314)','','','','','','','','','','','','','rs11130362','Low','Supported','High','Supported','tissue','  Transketolase','Disease related genes;Enzymes;Plasma proteins;Potential drug targets;Predicted intracellular proteins','Intracellular','4','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Ubiquitous nuclear expression.','RNA low, Protein high in Kidney','TKT ','3','p21.1','P29401 (UniProt - Evidence at protein level)','DB09130'),(80000161,'23492569','FN3K','FN3K','Q9H479','Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality','gene','serum','','experiment','T2DM(314)','','','','','','','','','','','','','rs1056534','Not detected','Supported','Not detected','Supported','tissue','Fructosamine 3 kinase','Plasma proteins;Predicted intracellular proteins','Intracellular','1','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic expression in several tissues, distinct positivity in red blood cells.','RNA medium, Protein not detected in Kidney','FN3K ','17','q25.3','Q9H479 (UniProt - Evidence at protein level)',''),(80000162,'23492569','Combination of risk genotypes','','','Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality','score','serum','','experiment','T2DM(314)','','Combination of risk genotypes:Other combination','Progression of DN','','event-free curves','','multivariate','','0.00645','log rank','worse','','rs11130362 in TKT and rs1056534 in FN3K','','','','','','','','','','','','','','','','','',''),(80000163,'25701507','SLC2A1','SLC2A1','P11166','Association of single nucleotide polymorphisms in the gene encoding GLUT1 and diabetic nephropathy in Brazilian patients with type 1 diabetes mellitus','gene','serum','','experiment','T1DM(155)','','TT/TA:AA','new cases of microalbuminuria or progression to a more severe stage of DN','','event-free curves','HR, 0.22(0.03 to 0.70)','multivariate','','0.009','cox','better','','rs3820589','Not detected','Supported','Not detected','Supported','tissue','Solute carrier family 2 member 1','Cancer-related genes;Disease related genes;Plasma proteins;Potential drug targets;Predicted intracellular proteins;Predicted membrane proteins;Transporters','Intracellular,Membrane','4','HPA. Tissue enhanced (placenta);GTEx. Expressed in all;FANTOM5. Group enriched (placenta, retina)','Evidence at protein level','Cytoplasmic expression most abundant in endothelial and trophoblastic cells.','RNA low, Protein not detected in Kidney','SLC2A1 (HGNC Symbol)','1','p34.2','P11166 (UniProt - Evidence at protein level)','DB02709'),(80000164,'25701507','SLC2A1','SLC2A1','P11166','Association of single nucleotide polymorphisms in the gene encoding GLUT1 and diabetic nephropathy in Brazilian patients with type 1 diabetes mellitus','gene','serum','','experiment','T1DM(155)','','','new cases of microalbuminuria or progression to a more severe stage of DN','','','HR, 0.20(0.03 to 0.71)','multivariate','','0.007','cox','better','','rs3820589','Not detected','Supported','Not detected','Supported','tissue','Solute carrier family 2 member 1','Cancer-related genes;Disease related genes;Plasma proteins;Potential drug targets;Predicted intracellular proteins;Predicted membrane proteins;Transporters','Intracellular,Membrane','4','HPA. Tissue enhanced (placenta);GTEx. Expressed in all;FANTOM5. Group enriched (placenta, retina)','Evidence at protein level','Cytoplasmic expression most abundant in endothelial and trophoblastic cells.','RNA low, Protein not detected in Kidney','SLC2A1 (HGNC Symbol)','1','p34.2','P11166 (UniProt - Evidence at protein level)','DB02709'),(80000165,'20711718','CNDP1','CNDP1','Q96KN2','A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus','gene','serum','','experiment','T1DM,T2DM(T1DM(864))','','5L–5L: all other genotypes','ESRD(need to start chronic dialysis or kidney transplantation)','','cumulative incidences','HR, 1.71(1.11 to 2.65)','multivariate','','<0.05','cox','worse','','Homozygosity for a five leucine repeat (5L鈥?L)','Not detected','Supported','Not detected','Supported','tissue','Carnosine dipeptidase 1','Enzymes;Plasma proteins;Predicted intracellular proteins;Predicted secreted proteins','  Intracellular,Secreted','2','HPA. Group enriched (cerebral cortex, liver);GTEx. Tissue enhanced (caudate, hippocampus, hypothalamus);FANTOM5. Group enriched (brain, caudate, cerebellum, hippocampus)','Evidence at protein level','Distinct expression in CNS and positivity in plasma.','RNA low, Protein not detected in Kidney','CNDP1 (HGNC Symbol)','18','q22.3','Q96KN2 (UniProt - Evidence at protein level)',''),(80000166,'20711718','CNDP1','CNDP1','Q96KN2','A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus','gene','serum','','experiment','T1DM,T2DM(T1DM(864))','','5L–5L: all other genotypes','ESRD(need to start chronic dialysis or kidney transplantation)','','cumulative incidences','HR, 2.19(1.21 to 4.01)','multivariate','','<0.05','cox','worse','','Homozygosity for a five leucine repeat (5L鈥?L)','Not detected','Supported','Not detected','Supported','tissue','Carnosine dipeptidase 1','Enzymes;Plasma proteins;Predicted intracellular proteins;Predicted secreted proteins','  Intracellular,Secreted','2','HPA. Group enriched (cerebral cortex, liver);GTEx. Tissue enhanced (caudate, hippocampus, hypothalamus);FANTOM5. Group enriched (brain, caudate, cerebellum, hippocampus)','Evidence at protein level','Distinct expression in CNS and positivity in plasma.','RNA low, Protein not detected in Kidney','CNDP1 (HGNC Symbol)','18','q22.3','Q96KN2 (UniProt - Evidence at protein level)',''),(80000167,'22266663','TNFR1','TNFRSF1A','P19438','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR1 (pg/ml): 1049 for the 25th percentile, 1310 for the 50th percentile, and 1837 for the 75th percentile','Q4:Q1-3','ESRD','','cumulative incidences','HR, 7.11(2.13 to 23.69)','multivariate','','0.0004','cox','worse','','','Low','Approved','Medium','Approved','tissue','TNF receptor superfamily member 1A','Cancer-related genes;Candidate cardiovascular disease genes;CD markers;Disease related genes;Plasma proteins;Predicted membrane proteins;Predicted secreted proteins','Membrane,Secreted','6','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic expression in all tissues at variable levels.','RNA low, Protein medium in Kidney.','  TNFRSF1A (HGNC Symbol)','12','p13.31','P19438 (UniProt - Evidence at protein level)','DB03507; DB11626'),(80000168,'22266663','TNFR1','TNFRSF1A','P19438','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR1 (pg/ml): 1049 for the 25th percentile, 1310 for the 50th percentile, and 1837 for the 75th percentile','Q4:Q1-3','ESRD','','cumulative incidences','HR, 7.05(2.23 to 22.30) ','multivariate','','0.0018','cox','worse','','','Low','Approved','Medium','Approved','tissue','TNF receptor superfamily member 1A','Cancer-related genes;Candidate cardiovascular disease genes;CD markers;Disease related genes;Plasma proteins;Predicted membrane proteins;Predicted secreted proteins','Membrane,Secreted','6','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic expression in all tissues at variable levels.','RNA low, Protein medium in Kidney.','  TNFRSF1A (HGNC Symbol)','12','p13.31','P19438 (UniProt - Evidence at protein level)','DB03507; DB11626'),(80000169,'22266663','TNFR2','TNFRSF1B','P20333','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR2 (pg/ml): 2017 for the 25th percentile, 2527 for the 50th percentile, and 3363 for the 75th percentile.','','ESRD','','','HR, 3.82 (1.59 to 9.20) ','multivariate','','0.0008','cox','worse','','','Not detected','Approved','High','Approved','tissue','TNF receptor superfamily member 1B','Cancer-related genes;Candidate cardiovascular disease genes;CD markers;Plasma proteins;Predicted membrane proteins;Predicted secreted proteins','Membrane,Secreted','2','HPA. Tissue enhanced (appendix);GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic and membranous expression in several different cell types with additional extracellular positivity.','RNA low, Protein high in Kidney.','TNFRSF1B (HGNC Symbol)','1','p36.22','P20333 (UniProt - Evidence at protein level)','DB00005; DB11626'),(80000170,'22266663','TNFR2','TNFRSF1B','P20333','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR2 (pg/ml): 2017 for the 25th percentile, 2527 for the 50th percentile, and 3363 for the 75th percentile.','','ESRD','','','HR, 5.88(2.10 to 16.43)','multivariate','','0.0013','cox','worse','','','Not detected','Approved','High','Approved','tissue','TNF receptor superfamily member 1B','Cancer-related genes;Candidate cardiovascular disease genes;CD markers;Plasma proteins;Predicted membrane proteins;Predicted secreted proteins','Membrane,Secreted','2','HPA. Tissue enhanced (appendix);GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic and membranous expression in several different cell types with additional extracellular positivity.','RNA low, Protein high in Kidney.','TNFRSF1B (HGNC Symbol)','1','p36.22','P20333 (UniProt - Evidence at protein level)','DB00005; DB11626'),(80000171,'22266663','free TNFa','TNF','P01375','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR2 (pg/ml): 2017 for the 25th percentile, 2527 for the 50th percentile, and 3363 for the 75th percentile.','','ESRD','','','HR, 2.22(1.20 to 4.12)','multivariate','','0.01','cox','worse','','','','','','','RNA tissue','Tumor necrosis factor','Cancer-related genes;Candidate cardiovascular disease genes;Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins','Intracellular','1','HPA. Tissue enhanced (bone marrow);GTEx. Tissue enhanced (spleen);FANTOM5. Tissue enhanced (appendix, spleen, tonsil)','Evidence at protein level','','RNA not detected, Protein N.A in Kidney.','TNF (HGNC Symbol)','6','p21.33','P01375 (UniProt - Evidence at protein level)','DB00005; DB00051; DB00065; DB00608; DB00668; DB00852; DB01041; DB01296; DB01407; DB01411; DB01427; DB02325; DB04956; DB05017; DB05207; DB05218; DB05303; DB05412; DB05470; DB05513; DB05676; DB05744; DB05758; DB05767; DB05869; DB05879; DB05968; DB05992; DB06444; DB06495; DB06674; DB08904; DB08910; DB09221; DB11967; DB12140'),(80000172,'22266663','total TNFa','TNF','P01375','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR2 (pg/ml): 2017 for the 25th percentile, 2527 for the 50th percentile, and 3363 for the 75th percentile.','','ESRD','','','HR, 2.53(1.25 to 5.13)','multivariate','','0.01','cox','worse','','','','','','','RNA tissue','Tumor necrosis factor','Cancer-related genes;Candidate cardiovascular disease genes;Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins','Intracellular','1','HPA. Tissue enhanced (bone marrow);GTEx. Tissue enhanced (spleen);FANTOM5. Tissue enhanced (appendix, spleen, tonsil)','Evidence at protein level','','RNA not detected, Protein N.A in Kidney.','TNF (HGNC Symbol)','6','p21.33','P01375 (UniProt - Evidence at protein level)','DB00005; DB00051; DB00065; DB00608; DB00668; DB00852; DB01041; DB01296; DB01407; DB01411; DB01427; DB02325; DB04956; DB05017; DB05207; DB05218; DB05303; DB05412; DB05470; DB05513; DB05676; DB05744; DB05758; DB05767; DB05869; DB05879; DB05968; DB05992; DB06444; DB06495; DB06674; DB08904; DB08910; DB09221; DB11967; DB12140'),(80000173,'22266663','total TNFa','TNF','P01375','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR2 (pg/ml): 2017 for the 25th percentile, 2527 for the 50th percentile, and 3363 for the 75th percentile.','','ESRD','','','HR, 2.61(1.42 to 4.81)','multivariate','','0.002','cox','worse','','','','','','','RNA tissue','Tumor necrosis factor','Cancer-related genes;Candidate cardiovascular disease genes;Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins','Intracellular','1','HPA. Tissue enhanced (bone marrow);GTEx. Tissue enhanced (spleen);FANTOM5. Tissue enhanced (appendix, spleen, tonsil)','Evidence at protein level','','RNA not detected, Protein N.A in Kidney.','TNF (HGNC Symbol)','6','p21.33','P01375 (UniProt - Evidence at protein level)','DB00005; DB00051; DB00065; DB00608; DB00668; DB00852; DB01041; DB01296; DB01407; DB01411; DB01427; DB02325; DB04956; DB05017; DB05207; DB05218; DB05303; DB05412; DB05470; DB05513; DB05676; DB05744; DB05758; DB05767; DB05869; DB05879; DB05968; DB05992; DB06444; DB06495; DB06674; DB08904; DB08910; DB09221; DB11967; DB12140'),(80000174,'22266663','TNFR1','TNFRSF1A','P19438','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR1 (pg/ml): 1049 for the 25th percentile, 1310 for the 50th percentile, and 1837 for the 75th percentile','','ESRD','','','HR, 4.7(1.3 to 17.0)','multivariate','','<0.05','cox','worse','','','Low','Approved','Medium','Approved','tissue','TNF receptor superfamily member 1A','Cancer-related genes;Candidate cardiovascular disease genes;CD markers;Disease related genes;Plasma proteins;Predicted membrane proteins;Predicted secreted proteins','Membrane,Secreted','6','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic expression in all tissues at variable levels.','RNA low, Protein medium in Kidney.','  TNFRSF1A (HGNC Symbol)','12','p13.31','P19438 (UniProt - Evidence at protein level)','DB03507; DB11626'),(80000175,'11978681','urinary albumin excretion rate','','','Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study','biochemical','urine','','experiment','T1DM(537)','baseline values above the median for urinary albumin excretion rate (10 mg/24 h) as risk marker','H:L','progression to microalbuminuria or macroalbuminuria','','cumulative incidence','HR, 2.63(1.65 to 4.19)','multivariate','','<0.0001','Cox','worse','','','','','','','','','','','','','','','','','','','',''),(80000176,'11978681','HbA1c','HbA1c','','Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study','protein','plasma','','experiment','T1DM(537)','baseline values above the median for HbA1c(8.6%) as risk marker','H:L','progression to microalbuminuria or macroalbuminuria','','cumulative incidence','HR, 1.13(1.04 to 1.23)','multivariate','','<0.01','Cox','worse','','','','','','','','','','','','','','','','','','','',''),(80000177,'12882861','urinary albumin excretion rate','','','Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: a 10-year prospective study','biochemical','urine','','experiment','T2DM(1408)','normoalbuminuric(AER<20g/min),microalbuminuric (AER 20鈥?00g/min),macroalbuminuric(AER>200g/min)','M:L','incidence of ESRD (need for dialysis) or chronic renal failure','','','HR, 1.86(0.93 to 3.73)','multivariate','','<0.0001','Cox','worse','','','','','','','','','','','','','','','','','','','',''),(80000178,'12882861','urinary albumin excretion rate','','','Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: a 11-year prospective study','biochemical','urine','','experiment','T2DM(1408)','normoalbuminuric(AER<20g/min),microalbuminuric (AER 20鈥?00g/min),macroalbuminuric(AER>201g/min)','H:L','incidence of ESRD (need for dialysis) or chronic renal failure','','','HR, 5.52(2.90 to 10.51)','multivariate','','<0.0001','Cox','worse','','','','','','','','','','','','','','','','','','','',''),(80000179,'12631367','Urine albumin:creatinine','','','The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study','biochemical','urine','','experiment','T2DM(1513)','','','doubling of serum creatinine or the development of ESRD ','','K-M','HR, 6.2(4.4 to 8.7)','multivariate','','<0.0001','Cox','worse','','','','','','','','','','','','','','','','','','','',''),(80000180,'12631367','Serum creatinine','','','The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study','biochemical','serum','','experiment','T2DM(1513)','','','doubling of serum creatinine or the development of ESRD ','','K-M','HR, 2.1(1.7 to 2.5)','multivariate','','<0.0001','Cox','worse','','','','','','','','','','','','','','','','','','','',''),(80000181,'12631367','Serum albumin','ALB','P02768','The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study','protein','serum','','experiment','T2DM(1513)','','','doubling of serum creatinine or the development of ESRD ','','K-M','HR, 0.70(0.61 to 0.80)','multivariate','','<0.0001','Cox','better','','','Not detected','Supported','Medium','Supported','tissue','Albumin','Cancer-related genes;Candidate cardiovascular disease genes;Disease related genes;Plasma proteins;Predicted intracellular proteins;Predicted secreted proteins','Intracellular,Secreted','9','HPA. Tissue enriched (liver);GTEx. Tissue enriched (liver);FANTOM5. Tissue enriched (liver)','Evidence at protein level','Positivity in plasma and extracellular material with additional cytoplasmic expression in several tissues.','RNA low, Protein medium in Kidney.','ALB ','4','q13.3','P02768 (UniProt - Evidence at protein level)','DB00199; DB00276; DB00493; DB00545; DB01045; DB03255; DB06713; DB06728; DB11359; DB11638'),(80000182,'12631367','Hemoglobin','HBB','P68871','The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study','protein','serum','','experiment','T2DM(1513)','','','doubling of serum creatinine or the development of ESRD ','','K-M','HR, 0.89(0.84 to 0.95)','multivariate','','0.0001','Cox','better','','','Not detected','Supported','Not detected','Supported','tissue','Hemoglobin subunit beta','Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Transporters','Intracellular','2','HPA. Tissue enriched (bone marrow);GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Expression in erythrocytes.','RNA low, Protein not detected in Kidney.','HBB (HGNC Symbol)','11','p15.4','P68871 (UniProt - Evidence at protein level)','DB00893; DB01593; DB02126; DB07427; DB07428; DB07645; DB08077; DB08262; DB08486; DB08632; DB09112; DB09130; DB09140; DB09147; DB09517; DB13995'),(80000183,'14569094','ACE','ACE','P12821','Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy','gene','blood','','experiment','T1DM(169)','the D allele (ACE/ID)','','doubling of s-creatinine or ESRD','','K-M','HR, 1.81perallele(1.09 to 3.03)','multivariate','','0.02','Cox','worse','','D allele of the ACE/ID polymorphism','Not detected','Supported','High','Supported','tissue','Angiotensin I converting enzyme','Candidate cardiovascular disease genes;CD markers;Disease related genes;Enzymes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted membrane proteins;Predicted secreted proteins','Intracellular,Membrane,Secreted','7','HPA. Tissue enhanced (duodenum, small intestine);GTEx. Tissue enhanced (small intestine, testis);FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic and membranous expression in selected tissues, including lung capillaries, small intestine, renal tubules, uterus and male genitalia.','RNA low, Protein high in Kidney','ACE (HGNC Symbol)','17','q23.3','P12821 (UniProt - Evidence at protein level)','DB00178; DB00492; DB00519; DB00542; DB00584; DB00616; DB00691; DB00722; DB00790; DB00881; DB00886; DB01180; DB01197; DB01340; DB01348; DB02032; DB03740; DB08836; DB09477; DB13166'),(80000184,'12716817','serum albumin','ALB','P02768','Factors affecting progression of renal failure in patients with type 2 diabetes','protein','serum','','experiment','T2DM(85)','','','doubling of serum creatinine (s-Cr)','','','HR, 0.484(0.284 to 0.823)','multivariate','','0.0074','Cox','better','','','Not detected','Supported','Medium','Supported','tissue','Albumin','Cancer-related genes;Candidate cardiovascular disease genes;Disease related genes;Plasma proteins;Predicted intracellular proteins;Predicted secreted proteins','Intracellular,Secreted','9','HPA. Tissue enriched (liver);GTEx. Tissue enriched (liver);FANTOM5. Tissue enriched (liver)','Evidence at protein level','Positivity in plasma and extracellular material with additional cytoplasmic expression in several tissues.','RNA low, Protein medium in Kidney.','ALB ','4','q13.3','P02768 (UniProt - Evidence at protein level)','DB00199; DB00276; DB00493; DB00545; DB01045; DB03255; DB06713; DB06728; DB11359; DB11638'),(80000185,'12716817','hemoglobin','HBB','P68871','Factors affecting progression of renal failure in patients with type 2 diabetes','protein','serum','','experiment','T2DM(85)','','','doubling of serum creatinine (s-Cr)','','','HR, 0.841(0.728 to 0.972)','multivariate','','0.0194','Cox','better','','','Not detected','Supported','Not detected','Supported','tissue','Hemoglobin subunit beta','Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Transporters','Intracellular','2','HPA. Tissue enriched (bone marrow);GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Expression in erythrocytes.','RNA low, Protein not detected in Kidney.','HBB (HGNC Symbol)','11','p15.4','P68871 (UniProt - Evidence at protein level)','DB00893; DB01593; DB02126; DB07427; DB07428; DB07645; DB08077; DB08262; DB08486; DB08632; DB09112; DB09130; DB09140; DB09147; DB09517; DB13995'),(80000186,'15029097','triglyceride','','','Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes','biochemical','blood','','experiment','T1DM(297)','lowest tertile (range:0.31-0.75 mmol/l), second tertile (range: 0.76-1.14 mmol/l), highest tertile (range: 1.15-11.10 mmol/l).','H:M+L','occurrence of a renal event,the renal event was defined as the progression from one stage of nephropathy to a higher one','','','HR, 2.01(1.07 to 3.77)','multivariate','','0.0294','Cox','worse','','','','','','','','','','','','','','','','','','','',''),(80000187,'15327408','hemoglobin','HBB','P68871','Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy','protein','blood','','experiment','T2DM(1513)','first quartile <11.3 g/dL, second quartile 11.3 to 12.5 g/dL, third quartile 12.6 to 13.8 g/dL, and fourth quartile 鈮?3.8 g/dL','first quartile:fourth quartile','ESRD defined as the need for chronic dialysis or renal transplantation','','K-M(cumulative incidence)','HR, 1.99(1.34 to 2.95)','multivariate','','0.001','Cox','better','','','Not detected','Supported','Not detected','Supported','tissue','Hemoglobin subunit beta','Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Transporters','Intracellular','2','HPA. Tissue enriched (bone marrow);GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Expression in erythrocytes.','RNA low, Protein not detected in Kidney.','HBB (HGNC Symbol)','11','p15.4','P68871 (UniProt - Evidence at protein level)','DB00893; DB01593; DB02126; DB07427; DB07428; DB07645; DB08077; DB08262; DB08486; DB08632; DB09112; DB09130; DB09140; DB09147; DB09517; DB13995'),(80000188,'15327408','hemoglobin','HBB','P68871','Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy','protein','blood','','experiment','T2DM(1513)','first quartile <11.3 g/dL, second quartile 11.3 to 12.5 g/dL, third quartile 12.6 to 13.8 g/dL, and fourth quartile 鈮?3.8 g/dL','second quartile:fourth quartile ','ESRD defined as the need for chronic dialysis or renal transplantation','','K-M(cumulative incidence)','HR, 1.61(1.08 to 2.41)','multivariate','','0.02','Cox','better','','','Not detected','Supported','Not detected','Supported','tissue','Hemoglobin subunit beta','Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Transporters','Intracellular','2','HPA. Tissue enriched (bone marrow);GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Expression in erythrocytes.','RNA low, Protein not detected in Kidney.','HBB (HGNC Symbol)','11','p15.4','P68871 (UniProt - Evidence at protein level)','DB00893; DB01593; DB02126; DB07427; DB07428; DB07645; DB08077; DB08262; DB08486; DB08632; DB09112; DB09130; DB09140; DB09147; DB09517; DB13995'),(80000189,'15327408','hemoglobin','HBB','P68871','Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy','protein','blood','','experiment','T2DM(1513)','first quartile <11.3 g/dL, second quartile 11.3 to 12.5 g/dL, third quartile 12.6 to 13.8 g/dL, and fourth quartile 鈮?3.8 g/dL','third quartile:fourth quartile ','ESRD defined as the need for chronic dialysis or renal transplantation','','K-M(cumulative incidence)','HR, 1.87(1.25 to 2.80)','multivariate','','0.002','Cox','better','','','Not detected','Supported','Not detected','Supported','tissue','Hemoglobin subunit beta','Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Transporters','Intracellular','2','HPA. Tissue enriched (bone marrow);GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Expression in erythrocytes.','RNA low, Protein not detected in Kidney.','HBB (HGNC Symbol)','11','p15.4','P68871 (UniProt - Evidence at protein level)','DB00893; DB01593; DB02126; DB07427; DB07428; DB07645; DB08077; DB08262; DB08486; DB08632; DB09112; DB09130; DB09140; DB09147; DB09517; DB13995'),(80000190,'15327408','hemoglobin','HBB','P68871','Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy','protein','blood','','experiment','T2DM(1513)','as a continuous variable','','ESRD defined as the need for chronic dialysis or renal transplantation','','K-M(cumulative incidence)','HR, 0.90(0.84 to 0.96)','multivariate','','0.0013','Cox','better','','','Not detected','Supported','Not detected','Supported','tissue','Hemoglobin subunit beta','Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Transporters','Intracellular','2','HPA. Tissue enriched (bone marrow);GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Expression in erythrocytes.','RNA low, Protein not detected in Kidney.','HBB (HGNC Symbol)','11','p15.4','P68871 (UniProt - Evidence at protein level)','DB00893; DB01593; DB02126; DB07427; DB07428; DB07645; DB08077; DB08262; DB08486; DB08632; DB09112; DB09130; DB09140; DB09147; DB09517; DB13995'),(80000191,'12542725','AR','AKR1B1','P15121','Aldose reductase gene polymorphism is associated with progression of diabetic nephropathy in Japanese patients with type 1 diabetes mellitus','gene','blood','','experiment','T1DM(125)','','','incidence of diabetic nephropathy','','K-M','','','','0.031','log rank','worse','','Homozygosity for the Z+2 allele frequenty\r','Not detected','Supported','Not detected','Supported','tissue','Aldo-keto reductase family 1 member B','Cancer-related genes;Enzymes;Plasma proteins;Predicted intracellular proteins','Intracellular','1','HPA. Tissue enriched (adrenal gland);GTEx. Tissue enriched (adrenal gland);FANTOM5. Tissue enriched (seminal vesicle)','Evidence at protein level','Distinct expression in adrenal gland.','RNA low, Protein not detected in Kidney','AKR1B1 (HGNC Symbol)','7','q33','P15121 (UniProt - Evidence at protein level)','DB00143; DB00157; DB00605; DB01689; DB02007; DB02020; DB02021; DB02101; DB02132; DB02383; DB02518; DB02712; DB02834; DB02994; DB03461; DB04272; DB05327; DB05383; DB05533; DB06246; DB07028; DB07030; DB07063; DB07093; DB07139; DB07187; DB07450; DB07498; DB07999; DB08000; DB08084; DB08098; DB08449; DB08772'),(80000192,'15111511','PND','NPPA','P01160','Investigation of the human ANP gene in type 1 diabetic nephropathy: case-control and follow-up studies','gene','','','experiment','T1DM(489(GENEDIAB),301(SURGENE))','','','progression to a further stage of nephropathy','','K-M','HR, 1.93(1.15 to 3.24)','multivariate','','0.012','Cox','worse','','SNP','Not detected','Supported','Not detected','Supported','tissue','Natriuretic peptide A','Candidate cardiovascular disease genes;Disease related genes;Plasma proteins;Predicted intracellular proteins;Predicted secreted proteins','Intracellular,Secreted','3','HPA. Tissue enriched (heart muscle);GTEx. Tissue enriched (heart muscle);FANTOM5. Tissue enriched (heart muscle)','Evidence at protein level','Distinct expression in heart.','both not detected in Kidney','NPPA (HGNC Symbol)','1','p36.22','P01160 (UniProt - Evidence at protein level)',''),(80000193,'14693713','Retinal Vessel Diameters','','','Retinal Vessel Diameters and the Incidence of Gross Proteinuria and Renal Insufficiency in People With Type 1 Diabetes','clinical','','','experiment','T1DM(557)','','4th:1st to 3rd quartiles','Incident gross proteinuria was defined as the development of  鈮?.3 g/l protein excretion in a casual urine specimen','','','RR, 1.53(1.19 to 1.97)','multivariate','','','multivariable logistic regression models','worse','','','','','','','','','','','','','','','','','','','',''),(80000194,'14693713','Retinal Vessel Diameters','','','Retinal Vessel Diameters and the Incidence of Gross Proteinuria and Renal Insufficiency in People With Type 1 Diabetes','clinical','','','experiment','T1DM(557)','','4th:1st to 3rd quartiles','incident renal insufficiency was defined as the development of estimated GFR<60 ml.min鈥?.1.73 m 2','','','RR, 1.51(1.05 to 2.17)','multivariate','','','multivariable logistic regression models','worse','','','','','','','','','','','','','','','','','','','',''),(80000195,'15492856','GSTT1','GSTT1','P30711','Glutathione S-transferase T1 deletion is a risk factor for developing end-stage renal disease in diabetic patients','gene','blood','','experiment','T2DM(230(DM2),475(hypertension))','type 2 diabetes mellitus patients with or without diabetic-related ESRD','type 2 diabetes mellitus patients with diabetic-related ESRD:type 2 diabetes mellitus patients witho','The diagnostic criterion for ESRD was chronic renal failure with serum creatinine >8.0 mg/dl or creatinine clearance <5 ml/min, needed to start dialysis.','','','OR, 2.18(1.29 to 3.70)','multivariate','','0.004','unconditional logistic regression','worse','','homozygous deletion\r','','','','','','','','','','','','','','','','','','DB00143'),(80000196,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','II:DI','Persistent microalbuminuria was defined as an AER鈮?0.8 渭g/min on two consecutive assessments','','','HR, 0.62(0.43 to 0.89)','multivariate','','0.009','Cox','better','','insertion/deletion','Not detected','Supported','High','Supported','tissue','Angiotensin I converting enzyme','Candidate cardiovascular disease genes;CD markers;Disease related genes;Enzymes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted membrane proteins;Predicted secreted proteins','Intracellular,Membrane,Secreted','7','HPA. Tissue enhanced (duodenum, small intestine);GTEx. Tissue enhanced (small intestine, testis);FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic and membranous expression in selected tissues, including lung capillaries, small intestine, renal tubules, uterus and male genitalia.','RNA low, Protein high in Kidney','ACE (HGNC Symbol)','17','q23.3','P12821 (UniProt - Evidence at protein level)','DB00178; DB00492; DB00519; DB00542; DB00584; DB00616; DB00691; DB00722; DB00790; DB00881; DB00886; DB01180; DB01197; DB01340; DB01348; DB02032; DB03740; DB08836; DB09477; DB13166'),(80000197,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','II:DI','severe nephropathy is based on repeated measures of AER and represents the progression from persistent microalbuminuria to an AER鈮?08 渭g/min or renal replacement therapy','','','HR, 0.56(0.32 to 0.96)','multivariate','','0.033','Cox','better','','insertion/deletion','Not detected','Supported','High','Supported','tissue','Angiotensin I converting enzyme','Candidate cardiovascular disease genes;CD markers;Disease related genes;Enzymes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted membrane proteins;Predicted secreted proteins','Intracellular,Membrane,Secreted','7','HPA. Tissue enhanced (duodenum, small intestine);GTEx. Tissue enhanced (small intestine, testis);FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic and membranous expression in selected tissues, including lung capillaries, small intestine, renal tubules, uterus and male genitalia.','RNA low, Protein high in Kidney','ACE (HGNC Symbol)','17','q23.3','P12821 (UniProt - Evidence at protein level)','DB00178; DB00492; DB00519; DB00542; DB00584; DB00616; DB00691; DB00722; DB00790; DB00881; DB00886; DB01180; DB01197; DB01340; DB01348; DB02032; DB03740; DB08836; DB09477; DB13166'),(80000198,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','TT:CT','Persistent microalbuminuria was defined as an AER鈮?0.8 渭g/min on two consecutive assessments','','','HR, 0.61(0.44 to 0.84)','multivariate','','0.003','Cox','better','','rs1800764','Not detected','Supported','High','Supported','tissue','Angiotensin I converting enzyme','Candidate cardiovascular disease genes;CD markers;Disease related genes;Enzymes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted membrane proteins;Predicted secreted proteins','Intracellular,Membrane,Secreted','7','HPA. Tissue enhanced (duodenum, small intestine);GTEx. Tissue enhanced (small intestine, testis);FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic and membranous expression in selected tissues, including lung capillaries, small intestine, renal tubules, uterus and male genitalia.','RNA low, Protein high in Kidney','ACE (HGNC Symbol)','17','q23.3','P12821 (UniProt - Evidence at protein level)','DB00178; DB00492; DB00519; DB00542; DB00584; DB00616; DB00691; DB00722; DB00790; DB00881; DB00886; DB01180; DB01197; DB01340; DB01348; DB02032; DB03740; DB08836; DB09477; DB13166'),(80000199,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','TT:CT','severe nephropathy is based on repeated measures of AER and represents the progression from persistent microalbuminuria to an AER鈮?08 渭g/min or renal replacement therapy','','','HR, 0.62(0.39 to 0.98)','multivariate','','0.043','Cox','better','','rs1800764','Not detected','Supported','High','Supported','tissue','Angiotensin I converting enzyme','Candidate cardiovascular disease genes;CD markers;Disease related genes;Enzymes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted membrane proteins;Predicted secreted proteins','Intracellular,Membrane,Secreted','7','HPA. Tissue enhanced (duodenum, small intestine);GTEx. Tissue enhanced (small intestine, testis);FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic and membranous expression in selected tissues, including lung capillaries, small intestine, renal tubules, uterus and male genitalia.','RNA low, Protein high in Kidney','ACE (HGNC Symbol)','17','q23.3','P12821 (UniProt - Evidence at protein level)','DB00178; DB00492; DB00519; DB00542; DB00584; DB00616; DB00691; DB00722; DB00790; DB00881; DB00886; DB01180; DB01197; DB01340; DB01348; DB02032; DB03740; DB08836; DB09477; DB13166'),(80000200,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','CC:CT','Persistent microalbuminuria was defined as an AER鈮?0.8 渭g/min on two consecutive assessments','','','HR, 0.65(0.49 to 0.88)','multivariate','','0.005','Cox','better','','rs9896208','Not detected','Supported','High','Supported','tissue','Angiotensin I converting enzyme','Candidate cardiovascular disease genes;CD markers;Disease related genes;Enzymes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted membrane proteins;Predicted secreted proteins','Intracellular,Membrane,Secreted','7','HPA. Tissue enhanced (duodenum, small intestine);GTEx. Tissue enhanced (small intestine, testis);FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic and membranous expression in selected tissues, including lung capillaries, small intestine, renal tubules, uterus and male genitalia.','RNA low, Protein high in Kidney','ACE (HGNC Symbol)','17','q23.3','P12821 (UniProt - Evidence at protein level)','DB00178; DB00492; DB00519; DB00542; DB00584; DB00616; DB00691; DB00722; DB00790; DB00881; DB00886; DB01180; DB01197; DB01340; DB01348; DB02032; DB03740; DB08836; DB09477; DB13166'),(80000201,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','CC:CT','severe nephropathy is based on repeated measures of AER and represents the progression from persistent microalbuminuria to an AER鈮?08 渭g/min or renal replacement therapy','','','HR, 0.54(0.34 to 0.85)','multivariate','','0.008','Cox','better','','rs9896208','Not detected','Supported','High','Supported','tissue','Angiotensin I converting enzyme','Candidate cardiovascular disease genes;CD markers;Disease related genes;Enzymes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted membrane proteins;Predicted secreted proteins','Intracellular,Membrane,Secreted','7','HPA. Tissue enhanced (duodenum, small intestine);GTEx. Tissue enhanced (small intestine, testis);FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic and membranous expression in selected tissues, including lung capillaries, small intestine, renal tubules, uterus and male genitalia.','RNA low, Protein high in Kidney','ACE (HGNC Symbol)','17','q23.3','P12821 (UniProt - Evidence at protein level)','DB00178; DB00492; DB00519; DB00542; DB00584; DB00616; DB00691; DB00722; DB00790; DB00881; DB00886; DB01180; DB01197; DB01340; DB01348; DB02032; DB03740; DB08836; DB09477; DB13166'),(80000202,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','TIC/TIC:CDT/TIC','Persistent microalbuminuria was defined as an AER鈮?0.8 渭g/min on two consecutive assessments','','','HR, 0.49(0.32 to 0.75)','multivariate','','0.0009','Cox','better','','Haplotype(rs1800764, insertion/deletion, and rs9896208)','Not detected','Supported','High','Supported','tissue','Angiotensin I converting enzyme','Candidate cardiovascular disease genes;CD markers;Disease related genes;Enzymes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted membrane proteins;Predicted secreted proteins','Intracellular,Membrane,Secreted','7','HPA. Tissue enhanced (duodenum, small intestine);GTEx. Tissue enhanced (small intestine, testis);FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic and membranous expression in selected tissues, including lung capillaries, small intestine, renal tubules, uterus and male genitalia.','RNA low, Protein high in Kidney','ACE (HGNC Symbol)','17','q23.3','P12821 (UniProt - Evidence at protein level)','DB00178; DB00492; DB00519; DB00542; DB00584; DB00616; DB00691; DB00722; DB00790; DB00881; DB00886; DB01180; DB01197; DB01340; DB01348; DB02032; DB03740; DB08836; DB09477; DB13166'),(80000203,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','TIC/TIC:CDT/TIC','severe nephropathy is based on repeated measures of AER and represents the progression from persistent microalbuminuria to an AER鈮?08 渭g/min or renal replacement therapy','','','HR, 0.41(0.22 to 0.78)','multivariate','','0.006','Cox','better','','Haplotype(rs1800764, insertion/deletion, and rs9896208)','Not detected','Supported','High','Supported','tissue','Angiotensin I converting enzyme','Candidate cardiovascular disease genes;CD markers;Disease related genes;Enzymes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted membrane proteins;Predicted secreted proteins','Intracellular,Membrane,Secreted','7','HPA. Tissue enhanced (duodenum, small intestine);GTEx. Tissue enhanced (small intestine, testis);FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic and membranous expression in selected tissues, including lung capillaries, small intestine, renal tubules, uterus and male genitalia.','RNA low, Protein high in Kidney','ACE (HGNC Symbol)','17','q23.3','P12821 (UniProt - Evidence at protein level)','DB00178; DB00492; DB00519; DB00542; DB00584; DB00616; DB00691; DB00722; DB00790; DB00881; DB00886; DB01180; DB01197; DB01340; DB01348; DB02032; DB03740; DB08836; DB09477; DB13166'),(80000204,'16123488','HCV','HCV','','Hepatitis C Is a Predictor of Poorer Renal Survival in Diabetic Patients','biochemical','','','experiment','T1DM,T2DM(1127)','HCV status','HCV subjects:Non-HCV subjects','Initiation of renal replacement therapy','','K-M','HR, 3.49(1.27 to 9.57)','multivariate','','0.015','Cox','worse','','','','','','','','','','','','','','','','','','','',''),(80000205,'16249462','CCR5','CCR5','P51681','Risk of Diabetic Nephropathy in Type 1 Diabetes Is Associated With Functional Polymorphisms in RANTES Receptor Gene (CCR5)','gene','blood','','experiment','T1DM(794)','','Male carriers:noncarriers','Patients were considered case subjects if they had persistent proteinuria or if they had ESRD due to diabetic nephropathy','','','OR, 1.9(1.2 to 3.0)','univariate','','0.005','Logistic models','worse','','male carriers of the 59029G allele\r','','','','','RNA tissue','C-C motif chemokine receptor 5 (gene.pseudogene)','CD markers;Disease related genes;FDA approved drug targets;G-protein coupled receptors;Predicted membrane proteins','Membrane','2','HPA. Mixed;GTEx. Tissue enhanced (spleen);FANTOM5. Mixed','Evidence at protein level','','RNA low, Protein N.A in Kidney','CCR5 (HGNC Symbol)','3','p21.31','P51681 (UniProt - Evidence at protein level)','DB04835; DB05501; DB06652; DB12698; DB12960'),(80000206,'16249462','CCR5','CCR5','P51681','Risk of Diabetic Nephropathy in Type 1 Diabetes Is Associated With Functional Polymorphisms in RANTES Receptor Gene (CCR5)','gene','blood','','experiment','T1DM(794)','','Male carriers:noncarriers','Patients were considered case subjects if they had persistent proteinuria or if they had ESRD due to diabetic nephropathy','','','OR, 2.3(1.3 to 4.2)','univariate','','0.009','Logistic models','worse','','male carriers of the 32-bp deletion\r','','','','','RNA tissue','C-C motif chemokine receptor 5 (gene.pseudogene)','CD markers;Disease related genes;FDA approved drug targets;G-protein coupled receptors;Predicted membrane proteins','Membrane','2','HPA. Mixed;GTEx. Tissue enhanced (spleen);FANTOM5. Mixed','Evidence at protein level','','RNA low, Protein N.A in Kidney','CCR5 (HGNC Symbol)','3','p21.31','P51681 (UniProt - Evidence at protein level)','DB04835; DB05501; DB06652; DB12698; DB12960'),(80000207,'15983325','lipoprotein(a) ','LPA','P08519','Prospective Study of Lipoprotein(a) as a Risk Factor for Deteriorating Renal Function in Type 2 Diabetic Patients With Overt Proteinuria','protein','serum','','experiment','T2DM(81)','','','Progression of diabetic nephropathy was defined as a greater than twofold increase of follow-up serum creatinine concentration from the baseline value','','','OR, 1.418(1.040 to 1.934)','multivariate','','0.027','Multiple logistic regression','worse','','','Not detected','Supported','Not detected','Supported','tissue','  Lipoprotein(a)','Candidate cardiovascular disease genes;Enzymes;Plasma proteins;Predicted intracellular proteins;Predicted secreted proteins','  Intracellular,Secreted','3','HPA. Tissue enriched (liver);GTEx. Tissue enriched (liver);FANTOM5. Tissue enriched (liver)','Evidence at protein level','Distinct positivity in plasma and cytoplasmic and membranous expression in hepatocytes.','RNA low, Protein not detected in Kidney, lower than in liver & gallbladder.','LPA (HGNC Symbol)','6','','P08519 (UniProt - Evidence at protein level)','DB00513'),(80000208,'15677791','ACE','ACE','P12821','Prognostic Effect of Insertion/Deletion Polymorphism of the ACE Gene on Renaland Cardiovascular Clinical Outcomes in Chinese Patients With Type 2 Diabetes','gene','blood','','experiment','T2DM(1281)','','DD versus II','Renal end points were defined as dialysis or doubling of plasma creatinine if the baseline value was 鈮?50渭mol/l or the absolute value was 鈮?00渭mol/l','','K-M(cumulative incidence)','HR, 2.80(1.49 to 5.29)','multivariate','','0.001','Cox','worse','','insertion/deletion (I/D) polymorphism','Not detected','Supported','High','Supported','tissue','Angiotensin I converting enzyme','Candidate cardiovascular disease genes;CD markers;Disease related genes;Enzymes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted membrane proteins;Predicted secreted proteins','Intracellular,Membrane,Secreted','7','HPA. Tissue enhanced (duodenum, small intestine);GTEx. Tissue enhanced (small intestine, testis);FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic and membranous expression in selected tissues, including lung capillaries, small intestine, renal tubules, uterus and male genitalia.','RNA low, Protein high in Kidney','ACE (HGNC Symbol)','17','q23.3','P12821 (UniProt - Evidence at protein level)','DB00178; DB00492; DB00519; DB00542; DB00584; DB00616; DB00691; DB00722; DB00790; DB00881; DB00886; DB01180; DB01197; DB01340; DB01348; DB02032; DB03740; DB08836; DB09477; DB13166'),(80000209,'27324705','uric acid','','','Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus','biochemical','serum','','experiment','T2DM(422)','hyperuricemia(serum uric acid(SUA)鈮?420 渭mol/l for men and 鈮?60 渭mol/l for women and/or allopurinol treatment)','High SUA or allopurinol/normal SUA, without treatment','onset or progression of DKD, i.e. (i) the decline of GFR below 60 ml/min per 1.73 m2 during the follow-up period for those with GFR>60 ml/min per 1.73 m2 at baseline or achieving ESRD or (ii) development of overt proteinuria in normo- and microalbuminuric subjects at baseline or (iii) progression of CKD by at least stage for those with CKD III and IV at baseline','','K-M(Time-to-event analysis)','HR, 2.14(1.40 to 3.26)','multivariate','','<0.001','Cox','worse','','','','','','','','','','','','','','','','','','','',''),(80000210,'27500547','IL-6','IL6','P05231','Interleukin-6 gene polymorphisms correlate with the progression of nephropathy in Chinese patients with type 2 diabetes: A prospective cohort study','gene','blood','','experiment','T2DM(568)','','GG : CC + CG','progression to diabetic nephropathy','','K-M','HR, 2.02(1.08 to 3.75)','multivariate','','0.027','Cox','worse','','rs1800796','Not detected','Supported','Not detected','Supported','tissue','Interleukin 6','Cancer-related genes;Candidate cardiovascular disease genes;Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted secreted proteins','Intracellular,Secreted','7','HPA. Tissue enhanced (adipose tissue);GTEx. Tissue enhanced (adipose tissue, lung);FANTOM5. Tissue enhanced (appendix)','Evidence at protein level','Extracellular deposits and cytoplasmic expression in subsets of lymphoid cells in several tissues.','RNA low, Protein not detected in Kidney','IL6 (HGNC Symbol)','7','p15.3','P05231 (UniProt - Evidence at protein level)','DB01404; DB05017; DB05470; DB05513; DB05744; DB05767; DB06083; DB09036; DB09221; DB11967; DB12140'),(80000211,'27500547','IL-6','IL6','P05231','Interleukin-6 gene polymorphisms correlate with the progression of nephropathy in Chinese patients with type 2 diabetes: A prospective cohort study','gene','blood','','experiment','T2DM(568)','','','progression to diabetic nephropathy','','K-M','HR, 2.37(1.15 to 4.87)','multivariate','','0.019','Cox','worse','','rs2069837','Not detected','Supported','Not detected','Supported','tissue','Interleukin 6','Cancer-related genes;Candidate cardiovascular disease genes;Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted secreted proteins','Intracellular,Secreted','7','HPA. Tissue enhanced (adipose tissue);GTEx. Tissue enhanced (adipose tissue, lung);FANTOM5. Tissue enhanced (appendix)','Evidence at protein level','Extracellular deposits and cytoplasmic expression in subsets of lymphoid cells in several tissues.','RNA low, Protein not detected in Kidney','IL6 (HGNC Symbol)','7','p15.3','P05231 (UniProt - Evidence at protein level)','DB01404; DB05017; DB05470; DB05513; DB05744; DB05767; DB06083; DB09036; DB09221; DB11967; DB12140'),(80000212,'27500547','IL-6','IL6','P05231','Interleukin-6 gene polymorphisms correlate with the progression of nephropathy in Chinese patients with type 2 diabetes: A prospective cohort study','gene','blood','','experiment','T2DM(568)','','','progression to diabetic nephropathy','','K-M','HR, 2.08(1.12 to 3.89)','multivariate','','0.021','Cox','worse','','rs1524107','Not detected','Supported','Not detected','Supported','tissue','Interleukin 6','Cancer-related genes;Candidate cardiovascular disease genes;Disease related genes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted secreted proteins','Intracellular,Secreted','7','HPA. Tissue enhanced (adipose tissue);GTEx. Tissue enhanced (adipose tissue, lung);FANTOM5. Tissue enhanced (appendix)','Evidence at protein level','Extracellular deposits and cytoplasmic expression in subsets of lymphoid cells in several tissues.','RNA low, Protein not detected in Kidney','IL6 (HGNC Symbol)','7','p15.3','P05231 (UniProt - Evidence at protein level)','DB01404; DB05017; DB05470; DB05513; DB05744; DB05767; DB06083; DB09036; DB09221; DB11967; DB12140'),(80000213,'27003829','TNFR1','TNFRSF1A','P19438','High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy','protein','serum','','experiment','T2DM(101)','The distribution in tertiles of the baseline circulating levels was 2165 pg/ml and 2873 pg/ml for the TNFR1','H:M+L','a >50% increase in baseline serum creatinine, end-stage renal disease, or death','','K-M(Time-to-event)','HR, 2.60(1.11 to 6.34)','multivariate','','0.03','Cox','worse','','','Low','Approved','Medium','Approved','tissue','TNF receptor superfamily member 1A','Cancer-related genes;Candidate cardiovascular disease genes;CD markers;Disease related genes;Plasma proteins;Predicted membrane proteins;Predicted secreted proteins','Membrane,Secreted','6','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic expression in all tissues at variable levels.','RNA low, Protein medium in Kidney.','  TNFRSF1A (HGNC Symbol)','12','p13.31','P19438 (UniProt - Evidence at protein level)','DB03507; DB11626'),(80000214,'26607824','RAGE','AGER','Q15109','RAGE and CYBA polymorphisms are associated with microalbuminuria and end-stage renal disease onset in a cohort of type 1 diabetes mellitus patients over a 20-year follow-up','gene','blood','','experiment','T1DM(162)','','AA:TA+TT','ESRD','','K-M','HR, 3.3(1.09 to 10.04)','multivariate','','0.035','Cox','worse','','374AA','Not detected','Approved','Not detected','Approved','tissue','Advanced glycosylation end-product specific receptor','Cancer-related genes;Plasma proteins;Predicted membrane proteins;Predicted secreted proteins','Membrane,Secreted','11','HPA. Tissue enriched (lung);GTEx. Tissue enriched (lung);FANTOM5. Tissue enriched (lung)','Evidence at protein level','Membranous expression in pneumocytes and endothelial cells.','both not detected in Kidney','AGER (HGNC Symbol)','6','p21.32','Q15109 (UniProt - Evidence at protein level)',''),(80000215,'26607824','CYBA','CYBA','P13498','RAGE and CYBA polymorphisms are associated with microalbuminuria and end-stage renal disease onset in a cohort of type 1 diabetes mellitus patients over a 20-year follow-up','gene','blood','','experiment','T1DM(162)','','TT+TC:CC','ESRD','','K-M','HR, 3.2(1.13 to 8.53)','multivariate','','0.028','Cox','worse','','242TT+TC','Not detected','Supported','Not detected','Supported','tissue','Cytochrome b-245 alpha chain','Disease related genes;Potential drug targets;Predicted intracellular proteins;Predicted membrane proteins;Transporters','Intracellular,Membrane','6','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Selective cytoplasmic expression in immune cells.','RNA low, Protein not detected in Kidney','CYBA (HGNC Symbol)','16','q24.2','P13498 (UniProt - Evidence at protein level)','DB00514'),(80000216,'26818011','HbA1c','HbA1c','','Glycated Hemoglobin and Outcomes in Patients with Advanced Diabetic Chronic Kidney Disease','protein','blood','','experiment','T2DM(2401)','HbA1c >9%','(>9%):(<6%)','ESRD(initiation of hemodialysis, peritoneal dialysis, or renal transplantation)','3-4 stage','','HR, 1.6(1.07 to 2.38)','multivariate','','<0.05','Cox','worse','early,middle','','','','','','','','','','','','','','','','','','',''),(80000217,'26845338','VAP-1','AOC3','Q16853','Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes','protein','serum','','experiment','T2DM(604)','','','ESRD','','K-M by tertile','HR, 1.55(1.12 to 2.14)','multivariate','','<0.01','Cox','worse','','','Not detected','Supported','Not detected','Supported','tissue','Amine oxidase, copper containing 3','Cancer-related genes;Enzymes;FDA approved drug targets;Plasma proteins;Predicted intracellular proteins;Predicted secreted proteins','Intracellular,Secreted','6','HPA. Tissue enhanced (adipose tissue);GTEx. Expressed in all;FANTOM5. Mixed','Evidence at protein level','Selective cytoplasmic expression in smooth muscle, adipocytes, adrenal gland and alveolar cells.','RNA low, Protein not detected in Kidney, lower than in Adipose & soft tissue.','AOC3 (HGNC Symbol)','17','q21.31','Q16853 (UniProt - Evidence at protein level)','DB00780; DB01275; DB04334'),(80000218,'26773925','GPX1','GPX1','P07203','Glutathione peroxidase-1 gene (GPX1) variants,oxidative stress and risk of kidney complications in people with type 1 diabetes','gene','','','experiment','T1DM(340)','','','new cases of microalbuminuria or progression to more severe stage of diabetic nephropathy','','','HR, 1.81(1.16 to 2.84) ','multivariate','','0.008','Cox','worse','','rs3448','Not detected','Approved','Medium','Approved','tissue','Glutathione peroxidase 1','Cancer-related genes;Enzymes;Plasma proteins;Predicted intracellular proteins','Intracellular','3','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic expression in most tissues. High expression in monocyte-derived cells in several tissues, including lung and placenta.','RNA low, Protein medium in Kidney','GPX1 ','3','p21.31','P07203 (UniProt - Evidence at protein level)','DB00143'),(80000219,'26773925','GPX1','GPX1','P07203','Glutathione peroxidase-1 gene (GPX1) variants,oxidative stress and risk of kidney complications in people with type 1 diabetes','gene','','','experiment','T1DM(703)','','','ESRD(defined as the new cases of renal replacement therapy)','','','HR, 3.34(1.69 to 6.98) ','multivariate','','0.0004','Cox','worse','','rs3448','Not detected','Approved','Medium','Approved','tissue','Glutathione peroxidase 1','Cancer-related genes;Enzymes;Plasma proteins;Predicted intracellular proteins','Intracellular','3','HPA. Expressed in all;GTEx. Expressed in all;FANTOM5. Expressed in all','Evidence at protein level','Cytoplasmic expression in most tissues. High expression in monocyte-derived cells in several tissues, including lung and placenta.','RNA low, Protein medium in Kidney','GPX1 ','3','p21.31','P07203 (UniProt - Evidence at protein level)','DB00143'),(80000220,'26952289','sulfate','','','High urinary sulfate concentration is associated with reduced risk of renal disease progression in type 2 diabetes','biochemical','urine','','experiment','T2DM(1004)','1st:4.9 (3.7卤5.8);2nd: 8.0 (7.1卤9.0) ;3rd13.3 (11.4卤16.1)','3rd:2nd:1st','a confirmed doubling of serum creatinine, serum creatinine >6.0 mg/dL, or end-stage renal disease','','K-M','','multivariate','','0.037','log rank','better','','','','','','','','','','','','','','','','','','','',''),(80000221,'26952289','sulfate','','','High urinary sulfate concentration is associated with reduced risk of renal disease progression in type 2 diabetes','biochemical','urine','','experiment','T2DM(1004)','','','a confirmed doubling of serum creatinine, serum creatinine >6.0 mg/dL, or end-stage renal disease','','K-M','HR, 0.81(0.66 to 0.99)','multivariate','','0.036','Cox','better','','','','','','','','','','','','','','','','','','','',''),(80000222,'27033561','adiponectin','ADIPOQ','Q15848','Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria','protein','urine','','experiment','T2DM(200)','','','a decline in the eGFR of >30%','','','HR, 1.5(1.1 to 2.2)','multivariate','','0.007','Cox','worse','','','Low','Uncertain','Not detected','Uncertain','tissue','Adiponectin, C1Q and collagen domain containing','Candidate cardiovascular disease genes;Disease related genes;Plasma proteins;Predicted secreted proteins','Secreted','2','HPA. Tissue enriched (adipose tissue);GTEx. Group enriched (adipose tissue, breast);FANTOM5. Tissue enhanced (adipose tissue, breast)','Evidence at protein level','Cytoplasmic and plasma positivity in several tissues.','RNA not detected, Protein low in Kidney.','ADIPOQ (HGNC Symbol)','3','q27.3','Q15848 (UniProt - Evidence at protein level)',''),(80000223,'16505253','SLC12A3','SLC12A3','P55017','SLC12A3 (solute carrier family 12 member [sodium/chloride] 3) polymorphisms are associated with end-stage renal disease in diabetic nephropathy.','gene','serum','','experiment','T2DM(177)','','A:G','ESRD','','','OR, 1.47(1.05 to 2.06)','','','0.023','','worse','','g.-950A>G','Not detected','Supported','Medium','Supported','tissue','Solute carrier family 12 member 3','Disease related genes;FDA approved drug targets;Plasma proteins;Predicted membrane proteins;Transporters','Membrane','4','HPA. Tissue enriched (kidney);GTEx. Tissue enriched (kidney);FANTOM5. Tissue enriched (kidney)','Evidence at protein level','Selective expression in a subset of renal tubules.','Both medium (only) in Kidney','SLC12A3 (HGNC Symbol)','16','q13','P55017 (UniProt - Evidence at protein level)','DB00436; DB00524; DB00562; DB00880; DB00999; DB01119; DB01324; DB01325');

--
-- Table structure for table `surbk`
--

CREATE TABLE `surbk` (
  `id` int(11) NOT NULL DEFAULT '0',
  `pmid` varchar(20) DEFAULT NULL,
  `originalid` varchar(100) DEFAULT NULL,
  `symbol` varchar(100) DEFAULT NULL,
  `uniprot` varchar(100) DEFAULT NULL,
  `descript` varchar(1000) DEFAULT NULL,
  `moltype` varchar(100) DEFAULT NULL,
  `tissue` varchar(200) DEFAULT NULL,
  `celltyep` varchar(500) DEFAULT NULL,
  `tech` varchar(200) DEFAULT NULL,
  `disease` varchar(200) DEFAULT NULL,
  `cutoff` varchar(1000) DEFAULT NULL,
  `g1vsg2` varchar(100) DEFAULT NULL,
  `hend` varchar(500) DEFAULT NULL,
  `send` varchar(500) DEFAULT NULL,
  `static` varchar(100) DEFAULT NULL,
  `staticvalue` varchar(100) DEFAULT NULL,
  `umormu` varchar(100) DEFAULT NULL,
  `factors` varchar(1000) DEFAULT NULL,
  `pval` varchar(100) DEFAULT NULL,
  `testmet` varchar(200) DEFAULT NULL,
  `survival` varchar(100) DEFAULT NULL,
  `ckd` varchar(100) DEFAULT NULL,
  `expression` varchar(100) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=utf8;

--
-- Dumping data for table `surbk`
--

INSERT INTO `surbk` VALUES (0,'11744801','IFNα','IFNA2','P01563','Interferon alpha-2','protein','blood','not mention','time-resolved immunoassay','IgAN[in the active phase](32)','N','N','N','serum Cr ','r','0.58','univariate','N','<0.001 ','correlation and linear regression;Pearson\'s correlation analyse','worse\r',NULL,NULL),(2000002,'11744801','IFNα','IFNA2','P01563','Interferon alpha-2','protein','blood','not mention','time-resolved immunoassay','IgAN[in the active phase](32)','N','N','N','CCr ','r','-0.478','univariate','N','＜0.01','correlation and linear regression;Pearson\'s correlation analyse','worse\r',NULL,NULL),(2000003,'11744801','IFNα','IFNA2','P01563','Interferon alpha-2','protein','blood','not mention','time-resolved immunoassay','IgAN[in the active phase](32)','N','N','N','BUN','r','0.405','univariate','N','＜0.03','correlation and linear regression;Pearson\'s correlation analyse','worse\r',NULL,NULL),(2000004,'11744801','IFNα','IFNA2','P01563','Interferon alpha-2','protein','blood','not mention','time-resolved immunoassay','IgAN[in the active phase](32)','N','N','N','s-β2MG','r','0.418','univariate','N','＜0.03','correlation and linear regression;Pearson\'s correlation analyse','worse\r',NULL,NULL),(2000005,'11840384','CD44','CD44','P16070','CD44 antigen','protein','renal biopsy specimens ','tubulointerstitial compartment ','Immunohistochemistry ','IgAN(25)','N','N','N','degree of protein- uria ','r','0.642','univariate','N','＜0.01','Spearman rank correlation coefficient ','worse\r',NULL,NULL),(2000006,'16105038','fibroblast-specific protein 1 (FSP1) ','S10A4','P26447','S100 calcium binding protein A4','protein','renal biopsy ','not mention','immuno- histochemistry ','IgAN(153)','N','N','N','Urinary excretion of protein for 24 hours','r','0.28','univariate','N','0.0005','Linear regression analysis,one-way analysis of variance (ANOVA) with the Bonferroni correction. ','worse\r',NULL,NULL),(2000007,'16105038','fibroblast-specific protein 1 (FSP1) ','S10A4','P26447','S100 calcium binding protein A4','protein','renal biopsy ','not mention','immuno- histochemistry ','IgAN(153)','N','N','N','Serum creatinine','r','0.74','univariate','N','<0.0001','Linear regression analysis,one-way analysis of variance (ANOVA) with the Bonferroni correction. ','worse\r',NULL,NULL),(2000008,'16105038','fibroblast-specific protein 1 (FSP1) ','S10A4','P26447','S100 calcium binding protein A4','protein','renal biopsy ','not mention','immuno- histochemistry ','IgAN(153)','N','N','N','Creatinine clearance ','r','−0.54','univariate','N','<0.0001','Linear regression analysis,one-way analysis of variance (ANOVA) with the Bonferroni correction. ','worse\r',NULL,NULL),(2000009,'16105038','fibroblast-specific protein 1 (FSP1) ','S10A4','P26447','S100 calcium binding protein A4','protein','renal biopsy ','not mention','immuno- histochemistry ','IgAN[whose serum creatinine concentrations were normal at the time of renal biopsy](142)','20 FSP1+ fibroblasts per HPF','H:L','100% increase in serum creatinine from baseline ','N','Kaplan-Meier ','N','univariate','N','< 0.0001','log-rank test ','worse\r',NULL,NULL),(2000010,'17943082','EGF','EGF','P01133','Pro-epidermal growth factor','protein','urine','not mention','sandwich-ELISA','IgAN(132)','N','N','ESRD and/or doubling of sCr.','N','HR','0.95 (0.92–0.98)','univariate','N','0.002','cox','better\r',NULL,NULL),(2000011,'17943082','EGF','EGF','P01133','Pro-epidermal growth factor','protein','urine','not mention','sandwich-ELISA','IgAN(132)','N','N','ESRD and/or doubling of sCr.','N','HR','0.95 (0.92–0.98)','multivariate','eCrCl,uPr,hypertension,and histologic grade','0.002','cox','better\r',NULL,NULL),(2000012,'17943082','MCP-1 ','CCL2','P13500','C-C motif chemokine 2','protein','urine','not mention','sandwich-ELISA','IgAN(132)','N','N','ESRD and/or doubling of sCr.','N','HR','1.35 (1.04–1.80) ','multivariate','eCrCl,uPr,hypertension,and histologic grade','0.024','cox','worse\r',NULL,NULL),(2000013,'18334740','α-SMA','HDAC8','Q9BY41','Histone deacetylase 8','protein','renal biopsy (Glomerula)','not mention','Immunohistochemical','IgAN(62)','degree of the Glomerular expression of α-SMA:0/1(low) or 2/3/4(high)','H:L','ESRD requiring dialysis or transplant','N','Kaplan-Meier ','N','univariate','N','＜0.01','log-rank test ','worse\r',NULL,NULL),(2000014,'19143943','EGF','EGF','P01133','Pro-epidermal growth factor','protein','urine','not mention','sandwich-ELISA','IgAN(33)','0.5pg/mgUcr','H:L','Progression of renal function ','N','Kaplan-Meier ','N','univariate','N','＜0.008','log-rank test ','better\r',NULL,NULL),(2000015,'19143943','GADD45γ','GA45G','O95257','Growth arrest and DNA damage-inducible protein GADD45 gamma','protein','urine','not mention','2% agarose gel electrophoresis,ethidium bromide staining,PCR','IgAN(62)','positive or negative','positive:negative','an increase of 50% or more in serum creatinine concentration above baseline ','N','Kaplan-Meier ','N','univariate','N','0.03','log-rank test ','worse\r',NULL,NULL),(2000016,'20649878','Nestin','NEST','P48681','Nestin','protein','Renal biopsy specimens ','not mention','Immunohistochemistry(using an avidin–biotin immunoperoxidase technique and a Vectastain Elite ABC kit )','IgAN(41)','quartiles','4th:1st','worsening renal function ','N','Kaplan-Meier ','N','univariate','N','0.01','log-rank test ','worse\r',NULL,NULL),(2000017,'20649878','Nestin','NEST','P48681','Nestin','protein','Renal biopsy specimens ','not mention','Immunohistochemistry(using an avidin–biotin immunoperoxidase technique and a Vectastain Elite ABC kit )','IgAN(41)','N','N','N','degree of tubulointerstitial fibrosis','r','0.546','univariate','N','＜0.001','linear','worse\r',NULL,NULL),(2000018,'20649878','Nestin','NEST','P48681','Nestin','protein','Renal biopsy specimens ','not mention','Immunohistochemistry(using an avidin–biotin immunoperoxidase technique and a Vectastain Elite ABC kit )','IgAN(41)','N','N','N','Serum creatinine ','r','0.51','univariate','N','0.001','linear','worse\r',NULL,NULL),(2000019,'20649878','Nestin','NEST','P48681','Nestin','protein','Renal biopsy specimens ','not mention','Immunohistochemistry(using an avidin–biotin immunoperoxidase technique and a Vectastain Elite ABC kit )','IgAN(41)','N','N','N','eGFR ','r','-0.471','univariate','N','0.002','linear','worse\r',NULL,NULL),(2000020,'20649878','Nestin','NEST','P48681','Nestin','protein','Renal biopsy specimens ','not mention','Immunohistochemistry(using an avidin–biotin immunoperoxidase technique and a Vectastain Elite ABC kit )','IgAN(41)','N','N','N','Urinary protein','r','0.329','univariate','N','0.036','linear','worse\r',NULL,NULL),(2000021,'21402675','KIM-1 ','HAVR1','Q96D42','Hepatitis A virus cellular receptor 1','protein','urine','not mention','sandwich-ELISA','IgAN[followed up for >12 months](107)','4.17 ng/mg urinary Cr','H:L','renal failure','N','Kaplan-Meier ','N','univariate','N','0.02','log-rank test ','worse\r',NULL,NULL),(2000022,'21467131','KIM-1 ','HAVR1','Q96D42','Hepatitis A virus cellular receptor 1','protein','urine','not mention','ELISA','IgAN[serum creatinine≤135umol/L](29)','1.7 ng/ min','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','0.045','log-rank test ','worse\r',NULL,NULL),(2000023,'21467131','KIM-1 ','HAVR1','Q96D42','Hepatitis A virus cellular receptor 1','protein','urine','not mention','ELISA','IgAN(65)','1.7 ng/ min','H:L','ESRD','N','HR','1.132 (1.035–1.238) ','univariate','N','not mention','cox','worse\r',NULL,NULL),(2000024,'21467131','NGAL ','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','urine','not mention','ELISA','IgAN(65)','47 ng/min','H:L','ESRD','N','HR','1.007 (1.002–1.012) ','univariate','N','not mention','cox','worse\r',NULL,NULL),(2000025,'21467131','KIM-1 ','HAVR1','Q96D42','Hepatitis A virus cellular receptor 1','protein','urine','not mention','ELISA','IgAN(65)','1.7 ng/ min','H:L','ESRD','N','HR','1.217 (1.087–1.302) ','multivariate','MAP,Serum albumin,Serum cholesterol,Serum creatinine,eGFR,Proteinuria,Urinary NGAL,Urinary α1m,Urinary β2m,Urinary IgG,Urinary albumin,Immunosuppressive therapy','not mention','cox','worse\r',NULL,NULL),(2000026,'21490589','CD248','CD248','Q9HCU0','Endosialin','protein','Renal biopsy specimens( tubulointerstitial)','not mention','Immunohistochemistry,an interactive image analysis system','IgAN(93)','4.4%,9.8%','H:M:L','ESRD','N','Kaplan-Meier ','N','univariate','N','0.0001','log-rank test ','worse\r',NULL,NULL),(2000027,'21490589','CD248','CD248','Q9HCU0','Endosialin','protein','Renal biopsy specimens( tubulointerstitial)','not mention','Immunohistochemistry,an interactive image analysis system','IgAN(93)','N','N','N','urinary albumin–creatinine ratio (ACR) ','β','0.329','multivariate','index of chronic damage,serum creatinine ','0.002','linear regression analysis ','worse\r',NULL,NULL),(2000028,'21490589','CD248','CD248','Q9HCU0','Endosialin','protein','Renal biopsy specimens( tubulointerstitial)','not mention','Immunohistochemistry,an interactive image analysis system','IgAN(93)','N','N','N','eGFR ','β','-0.225','multivariate','urinary albumin–creatinine ratio (ACR) ,index of chronic damage','0.019','linear regression analysis ','worse\r',NULL,NULL),(2000029,'21490589','CD248','CD248','Q9HCU0','Endosialin','protein','Renal biopsy specimens( tubulointerstitial)','not mention','Immunohistochemistry,an interactive image analysis system','IgAN(93)','N','N','ESRD','N','Exp(B) ','2.120 (1.428–3.146) ','univariate','N','＜0.0001','linear regression analysis ','worse\r',NULL,NULL),(2000030,'21846944','NF-κB','NFKB1','P19838','Nuclear factor NF-kappa-B p105 subunit','protein','renal biopsies ','not mention','SWH','IgAN(62)','the score of NF-κB:0/1(low),2/3(high)','H;L','ESRD requiring dialysis or transplant.','N','Kaplan-Meier ','N','univariate','N','0.03','log-rank test ','worse\r',NULL,NULL),(2000031,'21846944','NF-κB','NFKB1','P19838','Nuclear factor NF-kappa-B p105 subunit','protein','renal biopsies ','not mention','IHC','IgAN(62)','the score of NF-κB:0/1(low),2/3(high)','H;L','ESRD requiring dialysis or transplant.','N','Kaplan-Meier ','N','univariate','N','＜0.01','log-rank test ','worse\r',NULL,NULL),(2000032,'21940483','IL-2Ra ','IL2RA','P01589','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[chronic kidney disease (CKD) Stages 1–4 at baseline](179)','153.2 pg/mL ','H:L','the development of CKD Stage 5 (GFR <15 mL/min/1.73m2), a 50% decline in GFR during the follow-up period or a 30% GFR decline within 5 years of follow-up. ','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000033,'21940483','IL-2Ra ','IL2RA','P01589','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[chronic kidney disease (CKD) Stages 1–4 at baseline](179)','153.2 pg/mL ','H:L','the development of CKD Stage 5 (GFR <15 mL/min/1.73m2), a 50% decline in GFR during the follow-up period or a 30% GFR decline within 5 years of follow-up. ','N','HR','7.50 (3.40–16.54) ','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000034,'21940483','IL-2Ra ','IL2RA','P01589','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[chronic kidney disease (CKD) Stages 1–4 at baseline](179)','153.2 pg/mL ','H:L','the development of CKD Stage 5 (GFR <15 mL/min/1.73m2), a 50% decline in GFR during the follow-up period or a 30% GFR decline within 5 years of follow-up. ','N','HR','4.81(2.17–10.70) ','multivariate','eGFR','＜0.001','cox','worse\r',NULL,NULL),(2000035,'21940483','IL-2Ra ','IL2RA','P01589','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[chronic kidney disease (CKD) Stages 1–4 at baseline](179)','153.2 pg/mL ','H:L','the development of CKD Stage 5 (GFR <15 mL/min/1.73m2), a 50% decline in GFR during the follow-up period or a 30% GFR decline within 5 years of follow-up. ','N','HR','7.02(3.00–16.48) ','multivariate','time average during  follow-up(TA) albuminuria','＜0.001','cox','worse\r',NULL,NULL),(2000036,'21940483','IL-2Ra ','IL2RA','P01589','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[chronic kidney disease (CKD) Stages 1–4 at baseline](179)','153.2 pg/mL ','H:L','the development of CKD Stage 5 (GFR <15 mL/min/1.73m2), a 50% decline in GFR during the follow-up period or a 30% GFR decline within 5 years of follow-up. ','N','HR','5.35(2.28–12.56) ','multivariate','time average during  follow-up(TA) albuminuria,eGFR','＜0.001','cox','worse\r',NULL,NULL),(2000037,'21940483','IL-2Ra ','IL2RA','P01589','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[chronic kidney disease (CKD) Stages 1–4 at baseline](179)','153.2 pg/mL ','H:L','the development of CKD Stage 5 (GFR <15 mL/min/1.73m2), a 50% decline in GFR during the follow-up period or a 30% GFR decline within 5 years of follow-up. ','N','HR','5.67(2.17–14.84) ','multivariate','time average during  follow-up(TA) albuminuria,eGFR,age','＜0.001','cox','worse\r',NULL,NULL),(2000038,'21940483','IL-2Ra ','IL2RA','P01589','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[chronic kidney disease (CKD) Stages 1–4 at baseline](179)','N','N','N','rate of renal function declinea(eGFR, estimated GFR by four-parameter MDRD formula)','β','-0.239(\'-0.384 to \'-0.094)','univariate','N','0.001','Linear regression ','worse\r',NULL,NULL),(2000039,'21940483','IL-2Ra ','IL2RA','P01589','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[chronic kidney disease (CKD) Stages 1–4 at baseline](179)','N','N','N','rate of renal function declinea(eGFR, estimated GFR by four-parameter MDRD formula)','β','-0.227(\'-0.376  to \'-0.079)','multivariate',' eGFR baseline','0.003','Linear regression ','worse\r',NULL,NULL),(2000040,'21940483','IL-2Ra ','IL2RA','P01589','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[chronic kidney disease (CKD) Stages 1–4 at baseline](179)','N','N','N','rate of renal function declinea(eGFR, estimated GFR by four-parameter MDRD formula)','β','-0.220(\'-0.365  to \'-0.074)','multivariate','time average during  follow-up(TA) MAP','0.003','Linear regression ','worse\r',NULL,NULL),(20001000,'26989120','PLA2R,PLA2R','PLA2R,PLA2R','Q13018,Q13018','Secretory phospholipase A2 receptor','protein,protein','blood,Renal biopsy','not mention','ELISA,Immunohistological staining','IMN(514）','positive or negative','positive+positive：negative+positive ','CR','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse',NULL,NULL),(2000041,'21940483','IL-2Ra ','IL2RA','P01589','Interleukin-2 receptor subunit alpha','protein','plasma ','not mention','performed on the Luminex-100 system ','IgAN[chronic kidney disease (CKD) Stages 1–4 at baseline](179)','N','N','N','rate of renal function declinea(eGFR, estimated GFR by four-parameter MDRD formula)','β','-0.166(\'-0.310  to \'-0.022)','multivariate','time average during  follow-up(TA) albuminuria','0.024','Linear regression ','worse\r',NULL,NULL),(2000042,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','N','time-averaged albuminuria (g/24 hr) ','Regression Coefficient ','0.26 (0.05–0.47) ','multivariate','age, sex, serum albumin, calcium, phosphate,PTH, 25(OH) vitamin D, baseline albuminuria, base- line eGFR, MAP, BMI, and the use of ACEIs or ARBs','0.02','Spearman rank test ','worse\r',NULL,NULL),(2000043,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','entering CKD stage 5 or $50% reduction in eGFR ','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000044,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','entering CKD stage 5 or $25% reduction in estimated GFR  within 10 years','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000045,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','12.53 (2.82–55.6) ','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000046,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','7.47 (1.60–35.01) ','multivariate','Baseline Albuminuria','0.01','cox','worse\r',NULL,NULL),(2000047,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','5.49 (1.16–25.94) ','multivariate','albumin, phosphate, log parathyroid hormone','0.03','cox','worse\r',NULL,NULL),(2000048,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','11.07 (4.67–26.21) ','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000049,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','3.70 (1.31–10.41) ','multivariate','Baseline eGFRa and MAP','0.01','cox','worse\r',NULL,NULL),(2000050,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','7.52 (3.22–17.5) ','multivariate','Baseline Albuminuria','＜0.001','cox','worse\r',NULL,NULL),(2000051,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','4.07 (1.38–12.07)','multivariate','albumin, phosphate, log parathyroid hormone','＜0.001','cox','worse\r',NULL,NULL),(2000052,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','8.59 (3.92–18.84) ','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000053,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','3.84 (1.50–9.82)','multivariate','Baseline eGFRa and MAP','0.005','cox','worse\r',NULL,NULL),(2000054,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','6.13 (2.78–13.42) ','multivariate','Baseline Albuminuria','＜0.001','cox','worse\r',NULL,NULL),(2000055,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','3.68 (1.37–9.85)','multivariate','albumin, phosphate, log parathyroid hormone','0.01','cox','worse\r',NULL,NULL),(2000056,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','ntering CKD stage 5 or $50% reduction in estimated GFR ','N','HR','3.05 (1.13–8.20)','multivariate','baseline eGFR, baseline albuminuria, and mean arterial BP [MAP]','0.03','cox','worse\r',NULL,NULL),(2000057,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','3.92 (1.94–7.92) ','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000058,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.28 (1.06–4.90) ','multivariate','Baseline eGFRa and MAP','0.03','cox','worse\r',NULL,NULL),(2000059,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','3.02 (1.41–6.50)','multivariate','Baseline Albuminuria','0.005','cox','worse\r',NULL,NULL),(2000060,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','15,23','H:M/L(3rd:2nd/1st)','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.32 (1.09–4.94)','multivariate','entering CKD stage 5 or $50% reduction in estimated GFR ','0.03','cox','worse\r',NULL,NULL),(2000061,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','4.58 (2.66–7.86) ','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000062,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.92 (1.55–5.53) ','multivariate','Baseline eGFRa and MAP','＜0.001','cox','worse\r',NULL,NULL),(2000063,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','3.90 (2.22– 6.82) ','multivariate','Baseline Albuminuria ','＜0.001','cox','worse\r',NULL,NULL),(2000064,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.74 (1.43–5.24) ','multivariate','albumin, phosphate, log parathyroid hormone ','0.002','cox','worse\r',NULL,NULL),(2000065,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.94 (1.51–5.74) ','multivariate','baseline eGFR, baseline albuminuria, and mean arterial BP [MAP] ','0.002','cox','worse\r',NULL,NULL),(2000066,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','4.21 (2.52–6.99) ','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000067,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.91 (1.61–5.27) ','multivariate','Baseline eGFRa and MAP','＜0.001','cox','worse\r',NULL,NULL),(2000068,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','3.62 (2.14–6.12) ','multivariate','Baseline Albuminuria','＜0.001','cox','worse\r',NULL,NULL),(2000069,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.58 (1.40–4.76)','multivariate','albumin, phosphate, log parathyroid hormone ','0.002','cox','worse\r',NULL,NULL),(2000070,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','progression to CKD stage 5 or $25% reduction in eGFR over 10 years ','N','HR','2.88 (1.54–5.36) ','multivariate','baseline eGFR, baseline albuminuria, and mean arterial BP [MAP] ','＜0.001','cox','worse\r',NULL,NULL),(2000071,'22383747','Fibroblast growth factor-23 (FGF23) ','FGF23','Q9GZV9','Fibroblast growth factor 23','protein','blood','not mention','C- terminal ELISA','IgAN(180)','N','N','N','negative eGFR slope ','Regression Coefficient ','1.50 (0.40–2.60) ','multivariate','age, sex, serum albumin, baseline albuminuria, baseline estimated GFR, calcium, phosphate, parathyroid hormone, 25-hydroxyvitamin D, mean arterial BP, body mass index, and the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers ','0.008','Spearman rank test ','worse\r',NULL,NULL),(2000072,'27068226','TNF superfamily member 13 (TNFSF13) ','TNFSF13','O75888','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:2nd:1st:N','ESRD','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000073,'27068226','TNF superfamily member 13 (TNFSF13) ','TNFSF13','O75888','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:2nd:1st:N','doubling of serum creatinine ','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000074,'27068226','TNF superfamily member 13 (TNFSF13) ','TNFSF13','O75888','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:N','ESRD','N','HR','28.65 (3.835-214.076)','univariate','N','0.001','cox','worse\r',NULL,NULL),(2000075,'27068226','TNF superfamily member 13 (TNFSF13) ','TNFSF13','O75888','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:N','ESRD','N','HR','9.47 (1.176 -76.315)','multivariate','age, sex, baseline creatinine, proteinuria, hematuria','0.04','cox','worse\r',NULL,NULL),(2000076,'27068226','TNF superfamily member 13 (TNFSF13) ','TNFSF13','O75888','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:N','ESRD','N','HR','10.67 (1.129-100.770)','multivariate','age, sex, baseline creatinine, proteinuria, hematuria,smoking, hypertension, diabetes, autoimmune disease, hepatitis B antigen, anti-hepatitis C antibody, and the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or steroids','0.04','cox','worse\r',NULL,NULL),(2000077,'27068226','TNF superfamily member 13 (TNFSF13) ','TNFSF13','O75888','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:N','doubling of serum creatinine ','N','HR','11.97 (3.591-39.871)','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000078,'27068226','TNF superfamily member 13 (TNFSF13) ','TNFSF13','O75888','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:N','doubling of serum creatinine ','N','HR','5.21 (1.428 to 19.034)','multivariate','age, sex, baseline creatinine, proteinuria, hematuria','0.01','cox','worse\r',NULL,NULL),(2000079,'27068226','TNF superfamily member 13 (TNFSF13) ','TNFSF13','O75888','tumor necrosis factor superfamily member 13','mRNA','plasma ','not mention','RNA sequencing,quantitative PCR','IgAN[with the required follow-up time] (411)','the undetectable group (N) and three tertile groups, each comprised of a tertile with detectable TNFSF13 levels ','3rd:N','doubling of serum creatinine ','N','HR','5.31 (1.377 to 20.464)','multivariate','age, sex, baseline creatinine, proteinuria, hematuria,smoking, hypertension, diabetes, autoimmune disease, hepatitis B antigen, anti-hepatitis C antibody, and the use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers or steroids','0.01','cox','worse\r',NULL,NULL),(2000080,'27055509','C3','C3','P01024','Complement C3','protein','Renal biopsy specimens(in the mesangia area of glomeruli)','not mention','Immunofluorescence','IgAN[with microalbuminuria,followed up for >6 months](127)','the deposition of C3 in the mesangial area of glomeruli  is detectable(positive) or undetectable(negative)','positive:negative','24h urine quantitative protein being more than 1 g, or serum creatinine level becoming abnormal or double by renal biopsy','N','Kaplan-Meier ','N','univariate','N','0.019','log-rank test ','worse\r',NULL,NULL),(2000081,'26177311','TNFR1','TNR1A','P19438','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN(347)','N','N','N','eGFR','r','-0.646','univariate','N','＜0.001','correlation analysis','worse\r',NULL,NULL),(2000082,'26177311','TNFR1','TNR1A','P19438','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN(347)','N','N','N','urine protein-creatinine ratio(uPCR)','r','0.489','univariate','N','＜0.001','correlation analysis','worse\r',NULL,NULL),(2000083,'26177311','TNFR2','TRAF2','Q12933','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN(347)','N','N','N','eGFR','r','-0.582','univariate','N','＜0.001','correlation analysis','worse\r',NULL,NULL),(2000084,'26177311','TNFR2','TRAF2','Q12933','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN(347)','N','N','N','urine protein-creatinine ratio(uPCR)','r','0.407','univariate','N','＜0.001','correlation analysis','worse\r',NULL,NULL),(2000085,'26177311','TNFR1','TNR1A','P19438','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN(347)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000086,'26177311','TNFR1','TNR1A','P19438','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000087,'26177311','TNFR1','TNR1A','P19438','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN[with eGFR＜60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000088,'26177311','TNFR2','TRAF2','Q12933','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN(347)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000089,'26177311','TNFR2','TRAF2','Q12933','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','Kaplan-Meier ','N','univariate','N','0.035','log-rank test ','worse\r',NULL,NULL),(2000090,'26177311','TNFR2','TRAF2','Q12933','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN[with eGFR＜60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000091,'26177311','TNFR1','TNR1A','P19438','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN(347)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','HR','7.48 (3.70–15.14)','multivariate','age, sex, systolic BP, uPCR, eGFR ','＜0.001','cox','worse\r',NULL,NULL),(2000092,'26177311','TNFR2','TRAF2','Q12933','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN(347)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','HR',' 2.51 (1.15–5.48)','multivariate','age, sex, systolic BP, uPCR, eGFR ','0.021','cox','worse\r',NULL,NULL),(2000093,'26177311','TNFR1','TNR1A','P19438','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','HR','11.39 (3.26–39.85)','multivariate','age, sex, systolic BP, uPCR, eGFR ','＜0.001','cox','worse\r',NULL,NULL),(2000094,'26177311','TNFR2','TRAF2','Q12933','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','HR',' 3.25 (1.00–10.54)','multivariate','age, sex, systolic BP, uPCR, eGFR ','0.05','cox','worse\r',NULL,NULL),(2000095,'26177311','TNFR1','TNR1A','P19438','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN[with eGFR＜60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','HR','10.32 (3.94–27.02)','multivariate','age, sex, systolic BP, uPCR, eGFR ','＜0.001','cox','worse\r',NULL,NULL),(2000096,'26177311','TNFR2','TRAF2','Q12933','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN[with eGFR＜60 ml/min/1.73 m2] (not mention)','quartile ','Q4:Q1/Q2/Q3','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','HR',' 3.96 (1.60–9.82)','multivariate','age, sex, systolic BP, uPCR, eGFR ','0.003','cox','worse\r',NULL,NULL),(2000097,'26177311','TNFR1','TNR1A','P19438','Tumor necrosis factor receptor superfamily member 1A','protein','serum ','not mention','ELISA ','IgAN(347)','N','N','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','ROC','0.808','univariate','N','not mention','ROC','worse\r',NULL,NULL),(2000098,'26177311','TNFR2','TRAF2','Q12933','TNF receptor-associated factor 2','protein','serum ','not mention','ELISA ','IgAN(347)','N','N','the decline of estimated glomerular filtration rate (eGFR; ! 30% decline compared to baseline).','N','ROC','0.714','univariate','N','not mention','ROC','worse\r',NULL,NULL),(2000099,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','baseline eGFR ','N','r','-0.347','univariate','N','＜0.001','Spearman correlation analysis ','worse\r',NULL,NULL),(2000100,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','baseline eGFR ','N','r','-0.291','multivariate','baseline proteinuria','＜0.001','Spearman correlation analysis ','worse\r',NULL,NULL),(2000101,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','baseline proteinuria ','N','r','0.461','univariate','N','＜0.001','Spearman correlation analysis ','worse\r',NULL,NULL),(2000102,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','2.68 (1.81–3.96)','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000103,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','1.84 (1.22–2.78)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP)','0.004','cox','worse\r',NULL,NULL),(2000104,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','1.98 (1.28–3.08)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups)','0.002','cox','worse\r',NULL,NULL),(2000105,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','1.74 (1.16–2.64)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups),prednisone and/or other immunosuppressive agents','0.008','cox','worse\r',NULL,NULL),(2000106,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','3rd:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','17.23(2.30–129.14)','univariate','N','0.006','cox','worse\r',NULL,NULL),(2000107,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','3rd:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','11.56(1.53–84.47)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP)','0.018','cox','worse\r',NULL,NULL),(2000108,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','3rd:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','11.49(1.52–86.93)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups)','0.018','cox','worse\r',NULL,NULL),(2000109,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','3rd:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','11.48 (1.52–86.93)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups),prednisone and/or other immunosuppressive agents','0.018','cox','worse\r',NULL,NULL),(2000110,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','4th:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','20.87(2.77–157.18)','univariate','N','0.003','cox','worse\r',NULL,NULL),(2000111,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','4th:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','12.56(1.64–96.25)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP)','0.015','cox','worse\r',NULL,NULL),(2000112,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','4th:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','10.71(1.29–88.63)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups)','0.014','cox','worse\r',NULL,NULL),(2000113,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','4th:1st','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','12.78(1.67–97.82)','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups),prednisone and/or other immunosuppressive agents','0.032','cox','worse\r',NULL,NULL),(2000114,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','34.5','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','9.13 (3.24–25.70) ','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000115,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','34.5','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','6.59(2.30–18.86) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP)','＜0.001','cox','worse\r',NULL,NULL),(2000116,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','34.5','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','6.62(2.31–18.95) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups)','＜0.001','cox','worse\r',NULL,NULL),(2000117,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','34.5','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','6.25 (2.18–17.90) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups),prednisone and/or other immunosuppressive agents','0.001','cox','worse\r',NULL,NULL),(2000118,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','13,33.7,96.0','3rd/4th:1st/2nd','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000119,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','34.5','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000120,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','28.7','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000121,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN(351)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','ROC','0.745 (0.681–0.809)','univariate','N','＜0.001','ROC','worse\r',NULL,NULL),(2000122,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','ROC','0.724(0.630–0.817)','univariate','N','0.002','ROC','worse\r',NULL,NULL),(2000123,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','2.21 (1.13–4.30) ','univariate','N','0.019','cox','worse\r',NULL,NULL),(2000124,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','2.21 (1.13–4.30) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP)','0.019','cox','worse\r',NULL,NULL),(2000125,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','2.21 (1.13–4.3) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups)','0.019','cox','worse\r',NULL,NULL),(2000126,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','2.21 (1.13–4.30) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups),prednisone and/or other immunosuppressive agents','0.019','cox','worse\r',NULL,NULL),(2000127,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR＜60 ml/min/1.73 m2] (71)','N','N','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','1.81(1.11–2.96) ','univariate','N','0.017','cox','worse\r',NULL,NULL),(2000128,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','28.7','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','12.75(1.69–96.24) ','univariate','N','0.014','cox','worse\r',NULL,NULL),(2000129,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','28.7','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','12.75(1.69–96.24) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP)','0.014','cox','worse\r',NULL,NULL),(2000130,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','28.7','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','12.75(1.69–96.24) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups)','0.014','cox','worse\r',NULL,NULL),(2000131,'26035554','Complement factor H (CFH) ','CFAH','P08603','Complement factor H','protein','urine','not mention','ELISA ','IgAN[with eGFR≥60 ml/min/1.73 m2] (280)','28.7','H:L','instances of end-stage renal disease (ESRD),≥50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels','N','HR','12.75(1.69–96.24) ','multivariate','eGFR, proteinuria, mean arterial blood pressure(MAP),histological grades(mild and severe lesion groups),prednisone and/or other immunosuppressive agents','0.014','cox','worse\r',NULL,NULL),(2000132,'22518072','IL-18','IL18','Q14116','Interleukin-18','protein','serum ','not mention','ELISA ','IgAN(76)','N','N','N','responsiveness to steroid therapy ','β','−0.003','multivariate','age, smoking and history, blood pressure, albumin, lipids, CRP, and hemoglobin at enrollment','0.01','Multivariate regression analysis ','worse\r',NULL,NULL),(2000133,'22518072','IL-18','IL18','Q14116','Interleukin-18','protein','serum ','not mention','ELISA ','IgAN(76)',' IL-18 levels at baseline:346.80 pg/mL','H:L','doubling of baseline serum creatinine,ESRD (permanent hemodialysis, peritoneal dialysis, or renal transplantation) ,death from any cause. Treatment outcome','N','Kaplan-Meier ','N','univariate','N','0.03','log-rank test ','worse\r',NULL,NULL),(2000134,'22518072','IL-18','IL18','Q14116','Interleukin-18','protein','serum ','not mention','ELISA ','IgAN(76)',' IL-18 levels at baseline:346.80 pg/mL','H:L','doubling of baseline serum creatinine,ESRD (permanent hemodialysis, peritoneal dialysis, or renal transplantation) ,death from any cause. Treatment outcome','N','β','1.98','multivariate','age, smoking and history, blood pressure, albumin, lipids, CRP, and hemoglobin at enrollment','0.001','cox','worse\r',NULL,NULL),(2000135,'23135864','KIM-1 ','HAVR1','Q96D42','Hepatitis A virus cellular receptor 1','protein','renal biopsies ','not mention','semi- quantitatively by counting the stained tubules per 100* power field','IgAN(69)','0 tubule( grade 0); 1–5 tubules(grade 1); 6–10 tubules(grade 2); more than 10 tubules(grade 3)','grade 3:grade 1/grade 2','a 50 % decline in eGFR or ESRD ','N','Kaplan-Meier ','N','univariate','N','0.003','log-rank test ','worse\r',NULL,NULL),(2000136,'23135864','KIM-1 ','HAVR1','Q96D42','Hepatitis A virus cellular receptor 1','protein','renal biopsies ','not mention','semi- quantitatively by counting the stained tubules per 100* power field','IgAN(69)','0 tubule( grade 0); 1–5 tubules(grade 1); 6–10 tubules(grade 2); more than 10 tubules(grade 3)','grade 3:grade 1/grade 2','a 50 % decline in eGFR or ESRD ','N','HR','3.194(1.042–9.788)','multivariate','proteinuria, eGFR at biopsy, age, sex ','0.042','cox','worse\r',NULL,NULL),(2000137,'25973081','mannose-binding lectin (MBL) ','MBL2','P11226','Mannose-binding protein C','protein','Renal biopsy specimens( tubulointerstitial)','not mention',' gel electrophoresis,matrix-assisted laser desorption/ionization time of  ight mass spectrometry,Immunohistochemical staining,ELISA','IgAN(131)','according to the stained degree of glomerulus.','positive:negative','ESRD','N','Kaplan-Meier ','N','univariate','N','not mention','log-rank test ','better\r',NULL,NULL),(2000138,'25995666','NGAL','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','serum ','not mention','ELISA ','IgAN(121)','N','N','N','baseline eGFR ','r','-0.225','univariate','N','0.015','Pearson or Spearman correlation coefficients','worse\r',NULL,NULL),(2000139,'25995666','NGAL','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','serum ','not mention','ELISA ','IgAN(121)','N','N','N','baseline urine protein/creatinine ratio(PCR)','r','0.201','univariate','N','0.03','Pearson or Spearman correlation coefficients','worse\r',NULL,NULL),(2000140,'25995666','NGAL','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','urine ','not mention','ELISA ','IgAN(121)','N','N','N','baseline eGFR ','r','-0.186','univariate','N','0.045','Pearson or Spearman correlation coefficients','worse\r',NULL,NULL),(2000141,'25995666','NGAL','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','urine ','not mention','ELISA ','IgAN(121)','N','N','N','baseline serum albumin ','r','-0.315','univariate','N','0.001','Pearson or Spearman correlation coefficients','worse\r',NULL,NULL),(2000142,'25816025','CXCL1 ','CXCL1','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','18.29 pg/mg','H:L','50% eGFR decline, ESRD or death(ESRD was defined as eGFR < 15 ml/min per 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis or renal transplantation))','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(2000143,'25816025','CXCL1 ','CXCL1','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','N','proteinuria ','r','0.155','univariate','N','0.001','Spearman’s correlation ','worse\r',NULL,NULL),(2000144,'25816025','CXCL1 ','CXCL3','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','N','SBP ','r','0.138','univariate','N','0.004','Spearman’s correlation ','worse\r',NULL,NULL),(2000145,'25816025','CXCL1 ','CXCL4','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','N','DBP ','r','0.114','univariate','N','0.019','Spearman’s correlation ','worse\r',NULL,NULL),(2000146,'25816025','CXCL1 ','CXCL5','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','N','tubular atrophy and interstitial fibrosis ','r','0.181','univariate','N','＜0.001','Spearman’s correlation ','worse\r',NULL,NULL),(2000147,'25816025','CXCL1 ','CXCL6','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','N','eGFR','r','-0.259','univariate','N','＜0.001','Spearman’s correlation ','worse\r',NULL,NULL),(2000148,'25816025','CXCL1 ','CXCL7','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','N','Initial proteinuria ','β','0.128(0.585, 4.220)','multivariate','gender, age, eGFR, systolic blood pressure, diastolic blood pressure and tubular atrophy and interstitial fibrosis','0.01','linear regression analyses','worse\r',NULL,NULL),(2000149,'25816025','CXCL1 ','CXCL8','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','50% eGFR decline, ESRD or death(ESRD was defined as eGFR < 15 ml/min per 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis or renal transplantation))','N','HR','2.047(1.487–2.816)','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000150,'25816025','CXCL1 ','CXCL9','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','50% eGFR decline, ESRD or death(ESRD was defined as eGFR < 15 ml/min per 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis or renal transplantation))','N','HR','1.748(1.222–2.499)','multivariate','gender, age, eGFR, systolic blood pressure, diastolic blood pressure and tubular atrophy and interstitial fibrosis','0.002','cox','worse\r',NULL,NULL),(2000151,'25816025','CXCL1 ','CXCL10','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','2.047 (1.487–2.816)','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000152,'25816025','CXCL1 ','CXCL11','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','2.171(1.572–2.998)','multivariate','sexual,age','＜0.001','cox','worse\r',NULL,NULL),(2000153,'25816025','CXCL1 ','CXCL12','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','1.737(1.221–2.471)','multivariate','sexual,age,estimate glomerular filtration rate (eGFR), natural log–transformed proteinuria, systolic pressure and tubular atrophy,interstitial fibrosis','0.002','cox','worse\r',NULL,NULL),(2000154,'25816025','CXCL1 ','CXCL13','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','N','N','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','1.748(1.222–2.499)','multivariate','sexual,age,estimate glomerular filtration rate (eGFR), natural log–transformed proteinuria, systolic pressure and tubular atrophy,interstitial fibrosis, steroid or other immunosuppressants use (yes or no)','0.002','cox','worse\r',NULL,NULL),(2000155,'25816025','CXCL1 ','CXCL14','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','18.29 pg/mg','H:L','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','4.624(2.309–9.260)','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(2000156,'25816025','CXCL1 ','CXCL15','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','18.29 pg/mg','H:L','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','5.023(2.492–10.124) ','multivariate','sexual,age','＜0.001','cox','worse\r',NULL,NULL),(2000157,'25816025','CXCL1 ','CXCL16','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','18.29 pg/mg','H:L','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','2.879(1.407–5.892) ','multivariate','sexual,age,estimate glomerular filtration rate (eGFR), natural log–transformed proteinuria, systolic pressure and tubular atrophy,interstitial fibrosis','0.004','cox','worse\r',NULL,NULL),(2000158,'25816025','CXCL1 ','CXCL17','P09341','Growth-regulated alpha protein','protein','urine ','not mention','ELISA ','IgAN(425)','18.29 pg/mg','H:L','50% decline of eGFR, end-stage renal disease, or death. ','N','HR','2.914(1.417–5.989) ','multivariate','sexual,age,estimate glomerular filtration rate (eGFR), natural log–transformed proteinuria, systolic pressure and tubular atrophy,interstitial fibrosis, steroid or other immunosuppressants use (yes or no)','0.004','cox','worse\r',NULL,NULL),(2000159,'23828164','URG11 ','VWCE','Q96DN2','von Willebrand factor C and EGF domain-containing protein','protein','Renal biopsy specimens(mesangial)','not mention','Immunohistochemistry,Image analysis(OLYMPUS (ShangHai) CX41-32C02 microscope, and pictures were taken with an OLYMPUS DSE330 camera)','IgAN(86)','N','N','N','eGFR ','r','−0.305 ','univariate','N','0.038','linear regression analyses','worse\r',NULL,NULL),(2000160,'23828164','URG11 ','VWCE','Q96DN2','von Willebrand factor C and EGF domain-containing protein','protein','Renal biopsy specimens(mesangial)','not mention','Immunohistochemistry,Image analysis(OLYMPUS (ShangHai) CX41-32C02 microscope, and pictures were taken with an OLYMPUS DSE330 camera)','IgAN(86)','N','N','N','Tubulointerstitial fibrosis ','r','0.35','univariate','N','0.023','linear regression analyses','worse\r',NULL,NULL),(2000161,'23828164','Twist ','TWST1','Q15672','Twist-related protein 1','protein','Renal biopsy specimens(mesangial)','tubular epithelial cells ','Immunohistochemistry,Image analysis(OLYMPUS (ShangHai) CX41-32C02 microscope, and pictures were taken with an OLYMPUS DSE330 camera)','IgAN(86)','25% of the tubular epithelial cells(＞:positive；≤:negative)','Positive:negative','a 100% increase in serum creatinine from baseline or the development of end-stage renal disease (ESRD). ','N','RR','4.250 (1.170-15.446) ','multivariate','Gender ,Age (≥35),Bp,Urinary protein/24 h (≥1.0 g),eGFR (<60 mL/min),Glomerulosclerosis (≥20%),Tubulointerstitial fibrosis (≥30%),URG11 positive,URG11/Twist','0.028','cox','worse\r',NULL,NULL),(2000162,'23611517','IL-1b','IL1B','P01584','Interleukin-1 beta','protein','urine ','not mention','a Bio-Plex human cytokine assay,sandwich ELISA  ','IgAN[responded and continued on the same treatment that is renin angiotensin aldosterone system inhibitors (RAASi) +  sh oils (FO)] (35)','0.04fg/mg cr','H:L','ESRD(hemodialysis or transplantation and/ or reduction of GFR ≤ 10 ml/min/1.73 m2)','N','Kaplan-Meier ','N','univariate','N','0.04','log-rank test ','worse\r',NULL,NULL),(2000163,'23611517','IL-6','IL6','P05231','Interleukin-6','protein','urine ','not mention','a Bio-Plex human cytokine assay,sandwich ELISA  ','IgAN[responded and continued on the same treatment that is renin angiotensin aldosterone system inhibitors (RAASi) +  sh oils (FO)] (35)','0.12fg/mg cr','H:L','ESRD(hemodialysis or transplantation and/ or reduction of GFR ≤ 10 ml/min/1.73 m2)','N','Kaplan-Meier ','N','univariate','N','0.05','log-rank test ','worse\r',NULL,NULL),(2000164,'23611517','IL-6','IL6','P05231','Interleukin-6','protein','urine ','not mention','a Bio-Plex human cytokine assay,sandwich ELISA  ','IgAN[did not responded to renin angiotensin aldosterone system inhibitors (RAASi) +  sh oils (FO) and steroids + azathio- pine were added] (18)','0.12fg/mg cr','H:L','ESRD(hemodialysis or transplantation and/ or reduction of GFR ≤ 10 ml/min/1.73 m2)','N','Kaplan-Meier ','N','univariate','N','0.01','log-rank test ','worse\r',NULL,NULL),(2000165,'23611517','IL-10','IL10','P22301','Interleukin-10','protein','urine ','not mention','a Bio-Plex human cytokine assay,sandwich ELISA  ','IgAN[responded and continued on the same treatment that is renin angiotensin aldosterone system inhibitors (RAASi) +  sh oils (FO)] (35)','0.144fg/mg cr','H:L','ESRD(hemodialysis or transplantation and/ or reduction of GFR ≤ 10 ml/min/1.73 m2)','N','Kaplan-Meier ','N','univariate','N','0.05','log-rank test ','worse\r',NULL,NULL),(2000166,'23611517','MCP-1 ','CCL2','P13500','C-C motif chemokine 2','protein','urine ','not mention','a Bio-Plex human cytokine assay,sandwich ELISA  ','IgAN[responded and continued on the same treatment that is renin angiotensin aldosterone system inhibitors (RAASi) +  sh oils (FO)] (35)','1.45fg/mg cr','H:L','ESRD(hemodialysis or transplantation and/ or reduction of GFR ≤ 10 ml/min/1.73 m2)','N','Kaplan-Meier ','N','univariate','N','0.05','log-rank test ','worse\r',NULL,NULL),(2000167,'22792353','C3','C3','P01024','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','90 mg/dl','H:L','ESRD ','N','Kaplan-Meier ','N','univariate','N','0.006','log-rank test ','better\r',NULL,NULL),(2000168,'22792353','C3','C3','P01024','Complement C3','protein','Renal biopsy (in the mesangial area)','not mention','immunofluorescence ','IgAN(343)','AU level＜5:0; 5≤AU level＜20:1+;  20≤AU level ＜40:2+; 40≤AU level:3+','2+/3+:0','ESRD ','N','Kaplan-Meier ','N','univariate','N','0.04','log-rank test ','worse\r',NULL,NULL),(2000169,'22792353','C3','C3','P01024','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','N','N','doubling of the baseline serum creatinine ','N','AUC','0.642','univariate','N','0.011','ROC','better\r',NULL,NULL),(2000170,'22792353','C3','C3','P01024','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','90 mg/dl','H:L','doubling of the baseline serum creatinine ','N','HR','0.96(0.93–0.98)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment','0.002','cox','better\r',NULL,NULL),(2000171,'22792353','C3','C3','P01024','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','N','N','doubling of the baseline serum creatinine ','N','HR','0.96(0.93–0.98)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment','0.002','cox','better\r',NULL,NULL),(2000172,'22792353','C3','C3','P01024','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','90 mg/dl','L:H','doubling of the baseline serum creatinine ','N','HR',' 3.59 (1.56–8.28)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment','0.003','cox','better\r',NULL,NULL),(2000173,'22792353','C3','C3','P01024','Complement C3','protein','Renal biopsy (in the mesangial area)','not mention','immunofluorescence ','IgAN(343)','AU level＜5:0; 5≤AU level＜20:1+;  20≤AU level ＜40:2+; 40≤AU level:3+','2+/3+:0','doubling of the baseline serum creatinine ','N','HR','14.24 (2.03–99.87)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment, Tubular atrophy/interstitial fibrosis','0.008','cox','worse\r',NULL,NULL),(2000174,'22792353','C3','C3','P01024','Complement C3','protein','Renal biopsy (in the mesangial area)','not mention','immunofluorescence ','IgAN(343)','AU level＜5:0; 5≤AU level＜20:1+;  20≤AU level ＜40:2+; 40≤AU level:3+','2+/3+:0','doubling of the baseline serum creatinine ','N','HR','8.76(1.39–55.2)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Tubular atrophy/interstitial fibrosis,serum C3 levels','0.021','cox','worse\r',NULL,NULL),(2000175,'22792353','C3','C3','P01024','Complement C3','protein','Renal biopsy (in the mesangial area)','not mention','immunofluorescence ','IgAN(343)','AU level＜5:0; 5≤AU level＜20:1+;  20≤AU level ＜40:2+; 40≤AU level:3+','2+/3+:0','doubling of the baseline serum creatinine ','N','HR',' 14.03 ( 1.86–105.77)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Tubular atrophy/interstitial fibrosis,serum C3 levels','0.01','cox','worse\r',NULL,NULL),(2000176,'22792353','C3','C3','P01024','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','N','N','doubling of the baseline serum creatinine ','N','HR','0.95(0.93–0.98)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Mesangial C3 deposition,Tubular atrophy/interstitial fibrosis','0.004','cox','better\r',NULL,NULL),(2000177,'22792353','C3','C3','P01024','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','90 mg/dl','L:H','doubling of the baseline serum creatinine ','N','HR',' 3.35 ( 1.41–7.99)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Mesangial C3 deposition,Tubular atrophy/interstitial fibrosis','0.006','cox','better\r',NULL,NULL),(2000178,'22792353','C3','C3','P01024','Complement C3','protein','Renal biopsy (in the mesangial area)','not mention','immunofluorescence ','IgAN(343)','AU level＜5:0; 5≤AU level＜20:1+;  20≤AU level ＜40:2+; 40≤AU level:3+','2+/3+:0','doubling of the baseline serum creatinine ','N','HR','10.17(1.33–77.9)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Tubular atrophy/interstitial fibrosis,Serum C3 levels,BMI, total cholesterol, serum albumin','0.026','cox','worse\r',NULL,NULL),(2000179,'22792353','C3','C3','P01024','Complement C3','protein','Renal biopsy (in the mesangial area)','not mention','immunofluorescence ','IgAN(343)','AU level＜5:0; 5≤AU level＜20:1+;  20≤AU level ＜40:2+; 40≤AU level:3+','2+/3+:0','doubling of the baseline serum creatinine ','N','HR','16.18 ( 1.89–138.36)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Tubular atrophy/interstitial fibrosis,Serum C3 levels,BMI, total cholesterol, serum albumin','0.011','cox','worse\r',NULL,NULL),(2000180,'22792353','C3','C3','P01024','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','N','N','doubling of the baseline serum creatinine ','N','HR','0.96( 0.93–0.99)','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Tubular atrophy/interstitial fibrosis,Mesangial C3 deposition,BMI, total cholesterol, serum albumin','0.019','cox','better\r',NULL,NULL),(2000181,'22792353','C3','C3','P01024','Complement C3','protein','Serum ','not mention','immunoturbidimetry (Cobas C501, Roche, Mannhein, Germany). ','IgAN(343)','90 mg/dl','L:H','doubling of the baseline serum creatinine ','N','HR',' 2.73  (  1.09–6.86 )','multivariate','age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment,Tubular atrophy/interstitial fibrosis,Mesangial C3 deposition,BMI, total cholesterol, serum albumin','0.032','cox','better\r',NULL,NULL),(2000182,'24851068','β2-microglobulin (β2-MG) ','B2MG','P61769','Beta-2-microglobulin','protein','urine ','not mention','Immunofluorescence','IgAN(51)','N','N','1) a rise in SCr > 50% above baseline measurements and 2) a rise in SCr > 30% and an absolute level > 1.5 mg/dL. ','N','HR',' 1.334 ( 1.080–1.647 )','univariate','N','0.008','cox','worse\r',NULL,NULL),(2000183,'25510296','CD147 ','BSG','P35613','Basigin','protein','Renal biopsy (in the renal tubules)','not mention','immunohistochemical staining using the avidin–biotin peroxidase complex method with an LSAB2 kit (Dako, Glostrup, Denmark) ','IgAN(?)','＜5 % staining:0; 5–25 %staining per visual field:1+;26–50 % immunostaining:2+; ＞50 % immunostaining:3+','2+/3+:0/1+','ESRD','N','Kaplan-Meier ','N','univariate','N','0','log-rank test ','worse\r',NULL,NULL),(2000184,'25510296','CD147 ','BSG','P35613','Basigin','protein','Renal biopsy (in the renal tubules)','not mention','immunohistochemical staining using the avidin–biotin peroxidase complex method with an LSAB2 kit (Dako, Glostrup, Denmark) ','IgAN(?)','＜5 % staining:0; 5–25 %staining per visual field:1+;26–50 % immunostaining:2+; ＞50 % immunostaining:3+','2+/3+:0/1+','ESRD','N','HR','8.731 (1.095–69.596)','univariate','N','0.041','cox','worse\r',NULL,NULL),(2000185,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','N','Initial creatinine (mg/dL)','r','0.336','univariate','N','0.001','Pearson correlation coe cient ','worse\r',NULL,NULL),(2000186,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','N','Initial eGFR','r','-0.397','univariate','N','＜0.001','Pearson correlation coe cient ','worse\r',NULL,NULL),(2000187,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','N','Initial protein-creatinine ratio (PCR)','r','0.288','univariate','N','0.006','Pearson correlation coe cient ','worse\r',NULL,NULL),(2000188,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','chronic kidney disease (CKD) stage 3 or above at the last follow-up ','N','HR','1.011 (1.004–1.017)','univariate','N','0.001','cox','worse\r',NULL,NULL),(2000189,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','chronic kidney disease (CKD) stage 3 or above at the last follow-up ','N','HR','1.009 (1.002–1.017)','multivariate','Age','0.012','cox','worse\r',NULL,NULL),(2000190,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','chronic kidney disease (CKD) stage 3 or above at the last follow-up ','N','HR','1.009 (1.001–1.018) ','multivariate','Age,Hypertension','0.029','cox','worse\r',NULL,NULL),(2000191,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','chronic kidney disease (CKD) stage 3 or above at the last follow-up ','N','HR','1.012 (1.003–1.022) ','multivariate','Age,Hypertension,Proteinuria (> 1 g/day)','0.013','cox','worse\r',NULL,NULL),(2000192,'25995665','Neutrophil gelatinase-associated lipocalin (NGAL) ','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','Plasma ','not mention','a commercial enzyme-linked immuno- sorbent assay kit (R&D Systems) ','IgAN(91)','N','N','chronic kidney disease (CKD) stage 3 or above at the last follow-up ','N','ROC','0.777','univariate','N','0.001','ROC','worse\r',NULL,NULL),(2000193,'26223295','Myeloid-related proteins 8','S10A8','P05109','Protein S100-A8','protein','Renal biopsy','not mention','real-time quantitative polymerase chain reaction','LN(54)','0.5 log','H:L','2-fold increase of the serum creatinine ','N','Kaplan-Meier ','N','univariate','N','0.008','log-rank test ','worse\r',NULL,NULL),(2000194,'26223295','Myeloid-related proteins 14','S10A9','P06702','Protein S100-A9','protein','Renal biopsy','not mention','real-time quantitative polymerase chain reaction','LN(54)','0.5 log','H:L','2-fold increase of the serum creatinine ','N','Kaplan-Meier ','N','univariate','N','0.002','log-rank test ','worse\r',NULL,NULL),(2000195,'25724035','COL1','COL1A1','P02452','collagen type I alpha 1 chain','mRNA','Renal biopsy','not mention','real-time multiplex quantitative polymerase chain reaction','LN[with GFR≥60 mL/min/1.73m2](31)','8-fold compared to controls without LN.','H:L',' renal failure, defined as a reduction of GFR by 50% (GFR50) or end-stage renal disease (ESRD) (GFR , 15 mL/min/1.73m2 or dialysis for more than 3 months).','N','HR','6.52(1.30 to 6.61)','univariate','N','0.01','cox','worse\r',NULL,NULL),(2000196,'25724035','COL1','COL1A1','P02452','collagen type I alpha 1 chain','mRNA','Renal biopsy','not mention','real-time multiplex quantitative polymerase chain reaction','LN[with GFR≥60 mL/min/1.73m2](31)','8-fold compared to controls without LN.','H:L',' renal failure, defined as a reduction of GFR by 50% (GFR50) or end-stage renal disease (ESRD) (GFR , 15 mL/min/1.73m2 or dialysis for more than 3 months).','N','HR','4.38(1.05 to 4.55)','multivariate','Extracellular matrix index,Glomerular filtration rate,TGFB1','0.04','cox','worse\r',NULL,NULL),(2000197,'25724035','TGFB1','TGFB1','P01137','transforming growth factor beta 1','mRNA','Renal biopsy','not mention','real-time multiplex quantitative polymerase chain reaction','LN[with GFR≥60 mL/min/1.73m2](31)','7-fold compared to controls without LN.','H:L',' renal failure, defined as a reduction of GFR by 50% (GFR50) or end-stage renal disease (ESRD) (GFR , 15 mL/min/1.73m2 or dialysis for more than 3 months).','N','HR','5.86(1.18 to 6.36)','univariate','N','0.02','cox','worse\r',NULL,NULL),(2000198,'25724035','COL1','COL1A1','P02452','collagen type I alpha 1 chain','mRNA','Renal biopsy','not mention','real-time multiplex quantitative polymerase chain reaction','LN[with GFR≥60 mL/min/1.73m2](31)','8-fold compared to controls without LN.','H:L',' renal failure, defined as a reduction of GFR by 50% (GFR50) or end-stage renal disease (ESRD) (GFR , 15 mL/min/1.73m2 or dialysis for more than 3 months).','N','Kaplan-Meier ','N','univariate','N','0.01','log-rank test ','worse\r',NULL,NULL),(2000199,'25724035','TGFB1','TGFB1','P01137','transforming growth factor beta 1','mRNA','Renal biopsy','not mention','real-time multiplex quantitative polymerase chain reaction','LN[with GFR≥60 mL/min/1.73m2](31)','7-fold compared to controls without LN.','H:L',' renal failure, defined as a reduction of GFR by 50% (GFR50) or end-stage renal disease (ESRD) (GFR , 15 mL/min/1.73m2 or dialysis for more than 3 months).','N','Kaplan-Meier ','N','univariate','N','0.02','log-rank test ','worse\r',NULL,NULL),(2000201,'24536044','connective tissue growth factor','CTGF','P29279','Connective tissue growth factor','protein','serum','not mention','enzyme-linked immunosorbent assay','LN(101)','normal range（didn\'t refer to Specific value）','H:L','doubling of serum creatinine','N','Kaplan-Meier ','N','univariate','N','0.0049','log-rank test ','worse\r',NULL,NULL),(2000202,'24536044','connective tissue growth factor','CTGF','P29279','Connective tissue growth factor','protein','serum','not mention','enzyme-linked immunosorbent assay','LN(101)','N','N','doubling of serum creatinine','N','HR','1.015(1.008 to 1.022)','univariate','N','<0.001','cox','worse\r',NULL,NULL),(30000133,'24262501','HLA-DQA1','HLA-DQA1','rs2187668','major histocompatibility complex, class II, DQ alpha 1','SNP(AA)','blood','not mention','TaqMan','IMN(89)','genotype ','AA/AG:GG','doubling serum creatinine ','N','Kaplan-Meier ','N','univariate ','N','<0.001 ','N','better\r',NULL,NULL),(2000206,'25411257','soluble uPAR','UPAR','Q03405','Urokinase plasminogen activator surface receptor','protein','plasma','not mention','ELISA','LN(202)','N','N','The primary end point was defined as death, and secondary end points were defined as end-stage renal disease or doubling of serum creatinine.','N','HR','6.326(1.466 to 27.298)','univariate','N','0.013','cox','worse\r',NULL,NULL),(2000207,'25411257','soluble uPAR','UPAR','Q03405','Urokinase plasminogen activator surface receptor','protein','plasma','not mention','ELISA','LN(202)','3443.4 pg/ml','H:L','The primary end point was defined as death, and secondary end points were defined as end-stage renal disease or doubling of serum creatinine.','N','Kaplan-Meier ','N','univariate','N','<0.001','log-rank test ','worse\r',NULL,NULL),(2000208,'25196784','Human neutrophil peptide 1-3','DEF1,DEF3','DEFA1,DEFA3,P59665,P59666','Neutrophil defensin 1,Neutrophil defensin 3 ','protein','serum','not mention','ELISA','LN(40)','N','N','proteinuria remission','N','HR','0.209(0.046 to 0.951)','multivariate','age, sex, initial renal function and the use of ACEI/ARB and immunosuppressive agents ','0.043','cox','worse\r',NULL,NULL),(2000209,'18308774','Uβ2m','B2MG','P61769','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN(57)','54 µg/mmol cr ','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >135 µmol/l','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(2000210,'18308774','Uβ2m','B2MG','P61769','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN(57)','40 µg/mmol cr','H:L','remission (proteinuria <2.0 g/day)','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(2000211,'18308774','Uβ2m','B2MG','P61769','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN(57)','54 µg/mmol cr','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >136 µmol/l','N','ROC','0.906','univariate','N','not mention','AUC','worse\r',NULL,NULL),(2000212,'18308774','Uβ2m','B2MG','P61769','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN(57)','40 µg/mmol cr ','H:L','remission (proteinuria <2.0 g/day)','N','ROC','0.861','univariate','N','not mention','AUC','worse\r',NULL,NULL),(2000213,'18308774','Uβ2m ','B2MG','P61769','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN(57)','N','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >139 µmol/l','N','RR','2.69（1.82–3.98）','multivariate','serum creatinine, serum albumin, proteinuria','P < 0.001','COX','worse\r',NULL,NULL),(2000214,'15563570','Uβ2m','B2MG','P61769','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN(57)','0.5  g/min','H:L','an increase of serum creatinine to values  1.5 mg/dl or an increase of serum creatinine  50%','N','Kaplan-Meier ','N','univariate','N','N','log-rank test ','worse\r',NULL,NULL),(2000215,'15563570','Uβ2m','B2MG','P61769','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN(57)','0.5  g/min','H:L','an increase of serum creatinine to values  1.5 mg/dl or an increase of serum creatinine  50%','N','ROC','0.947','univariate','N','not mention','AUC','worse\r',NULL,NULL),(2000216,'15563570','Uβ2m','B2MG','P61769','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN(57)','N','H:L','an increase of serum creatinine to values  1.5 mg/dl or an increase of serum creatinine  50%','N','RR','1.030(1.017-1.043)','multivariate','Serum creatinine,serum albumin,ECC,proteinuria,selectivity index,urinary excretion of albumin,beta2m, alpha1microglobulin,transferrin, IgG ','<0.001 ','COX','worse\r',NULL,NULL),(2000218,'25098821','cTNFR1','TNR1A','P19438','Tumor necrosis factor receptor superfamily member 1A','protein','serum','not mention','ELISA','IMN(113)',' based on cTNFRs levels tertiles','T3:T1/T2',' Renal progression was defined as a decrease in baseline eGFR by more than 31%.','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(2000219,'25098821','cTNFR1','TNR1A','P19438','Tumor necrosis factor receptor superfamily member 1A','protein','serum','not mention','ELISA','IMN(113)','based on cTNFRs levels tertiles','T3:T1/T2',' Renal progression was defined as a decrease in baseline eGFR by more than 32%.','N','HR',' 3.39（1.48– 7.78）','multivariate','age, sex, presence of hypertension, eGFR, proteinuria, pathologic stage, kind of treatment, and presence of remission','0.004','Cox ','worse\r',NULL,NULL),(2000221,'25098821','cTNFR2','TNR1B','P20333','Tumor necrosis factor receptor superfamily member 1B','protein','serum','not mention','ELISA','IMN(113)',' based on cTNFRs levels tertiles','T3:T1/T2',' Renal progression was defined as a decrease in baseline eGFR by more than 34%.','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(2000222,'25098821','cTNFR2','TNR1B','P20333','Tumor necrosis factor receptor superfamily member 1B','protein','serum','not mention','ELISA','IMN(113)','based on cTNFRs levels tertiles','T3:T1/T2',' Renal progression was defined as a decrease in baseline eGFR by more than 35%.','N','HR','3.29（1.43–7.54）','multivariate','age, sex, presence of hypertension, eGFR, proteinuria, pathologic stage, kind of treatment, presence of remission','0.005','Cox ','worse\r',NULL,NULL),(2000225,'26296473','mPLA2R1','PLA2R_MOUSE','Q62028','Secretory phospholipase A5 receptor ','protein','serum','not mention','ELISA','IMN(42)','605 RU/mL','H:L','a doubling of serum creatinine from baseline','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(2000226,'25313791','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(33)','20 U/ml','H:L',' development of nephrotic range proteinuria','N','HR','3.66（1.39-9.64）','multivariate','age, sex, high proteinuria','0.009','Cox ','worse\r',NULL,NULL),(2000227,'25313791','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(33)','20 U/ml','positive:negative',' development of nephrotic range proteinuria','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test','worse\r',NULL,NULL),(2000228,'24610926','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(128)','12.0','H:L','remission of proteinuria','N','HR','0.81(0.70-0.95)','multivariate','age, sex,proteinuria, serum creatinine, serum albumin, immunosuppressive treatment','0.008','Cox ','worse\r',NULL,NULL),(2000229,'25804280','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(81)',' titer 14–86 (lowest), 87–204 (middle), or ＞204(highest) RU/ml.','L:H','complete or partial remission ','N','Kaplan-Meier ','N','univariate','N','0.003','log-rank test ','worse\r',NULL,NULL),(2000230,'25804280','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(81)',' titer 14–86 (lowest), 87–204 (middle), or ＞204(highest) RU/ml.','L:H','complete or partial remission ','N','HR','4.198(1.919-9.185)','multivariate','sex,proteinuria, serum creatinine, anti-PLA2R antibody levels at baseline.','<0.001 ','Cox ','worse\r',NULL,NULL),(2000231,'25804280','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(81)',' titer 14–86 (lowest), 87–204 (middle), or ＞204(highest) RU/ml.','M:H','complete or partial remission ','N','HR','2.298(1.001-5.230)','multivariate','sex,proteinuria,serum creatinine,anti-PLA3R antibody levels at baseline.','0.048','Cox ','worse\r',NULL,NULL),(2000232,'25804280','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(81)',' titer 14–86 (lowest), 87–204 (middle), or ＞204(highest) RU/ml.','L:H','complete remission ','N','HR','3.410(1.108-10.491)','multivariate','sex,proteinuria,serum creatinine,anti-PLA4R antibody levels at baseline.','0.032','Cox ','worse\r',NULL,NULL),(2000233,'25804280','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(81)',' titer 14–86 (lowest), 87–204 (middle), or ＞204(highest) RU/ml.','M:H','complete remission ','N','HR','3.174(0.988-10.195)','multivariate','sex ,proteinuria,serum creatinine,anti-PLA5R antibody levels at baseline.','0.052','Cox ','worse\r',NULL,NULL),(2000234,'25804280','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(64)','Six-month depletion of anti-PLA2R autoantibodies','YES:NO','complete or partial remission ','N','HR','7.90(2.54-24.60)','multivariate','sex,proteinuria,serum creatinine,anti-PLA6R antibody levels at baseline.','<0.001 ','Cox ','better\r',NULL,NULL),(2000235,'25804280','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(64)','Six-month depletion of anti-PLA5R autoantibodies','YES:NO','complete remission ','N','HR','2.89(0.63-13.36)','multivariate','sex,proteinuria,serum creatinine,anti-PLA9R antibody levels at baseline.','<0.001 ','Cox ','better\r',NULL,NULL),(2000236,'24021909','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','western blot','IMN(91)','The presence of circulating anti-PLA2R','negative:positive','malignancies were detected','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(2000237,'23364522','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(82)',' tertiles','High:Mid:Low','doubling of serum creatinine','N','Kaplan-Meier ','N','multivariate','treatment','<0.001 ','log-rank test','worse\r',NULL,NULL),(2000238,'27058841','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN[sPLA2R positive](93)','89.67U/ml','H:L','the extent of proteinuria','N','OR','4.80(1.37-16.74)','multivariate','age,hypertension,Egfr,Alb,proteinuria,gPLA2R,gender,BMI,FBG,TC,immunosuppresion,sPLA2R','0.014','Multivariate logistic regression','worse\r',NULL,NULL),(2000239,'27058841','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN[sPLA2R positive](93)','89.67U/ml','H:L',' remission of proteinuria','N','HR','0.29(0.14-0.59)','multivariate','age,hypertension,Egfr,Alb,proteinuria,gPLA2R,gender,BMI,FBG,TC,sPLA3R','0.0007','Multivariate COX regression','worse\r',NULL,NULL),(2000240,'27058841','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(113)','20U/ml','positive：negative',' remission of proteinuria','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(2000241,'27058841','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN[sPLA2R positive](93)','median','H:L',' remission of proteinuria','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(2000246,'25953939','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','immunofluorescence assay','IMN(37)','0.048611111','H:L','achieving treatment-induced complete or partial remission ','N','Kaplan-Meier ','N','univariate','N','0.01','log-rank test ','worse\r',NULL,NULL),(2000247,'26344651','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(73)','antibody levels in the lowest tertile and seronegative patients ; H: high anti-PLA2R levels were defined as antibody levels in the highest tertiles','L:H','induced remission,relapse of proteinuria,ESRD,mortality;appearance  of  a  spontaneous remission, defined as induction of either a complete or partial remission (PR) without the use of immunosuppressive agents','N','HR','2.72 (1.22–6.08)','multivariate','age, male gender, rate of proteinuria, serum creatinine','0.02',' Cox ','better\r',NULL,NULL),(2000249,'25035272','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(33)','40 U/ml','negative：positive',' relapse, death, or start of additional immunosuppressive therapy)','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(2000250,'18403431','L-FABP','FABPL','P07148','Fatty acid-binding protein, liver','protein','urine','not mention','ELISA','IMN(40)','5.7 µg/mmol Cr ','H:L','Renal failure was defined as an increase in serum creatinine >25% from baseline with a serum creatinine >135 µmol/l or an increase >50% from baseline','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(2000251,'18403431','H-FABP','FABPH','P05413','Fatty acid-binding protein, heart','protein','urine','not mention','ELISA','IMN(40)','3.1 µg/mmol Cr','H:L','Renal failure was defined as an increase in serum creatinine >25% from baseline with a serum creatinine >135 µmol/l or an increase >50% from baseline','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(2000252,'22801951','β2-microglobulin','B2MG','P61769','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN(57)','0.5  g per min','H:L','Renal death was defined as an increase in serum creatinine to >133 µmol/l or an increase >50% ','N','Kaplan-Meier ','N','univariate','N','N','log-rank test ','worse\r',NULL,NULL),(2000253,'22801951','β2-microglobulin','B2MG','P61769','Beta-2-microglobulin','protein','urine','not mention','ELISA','IMN(104)','N','N','The end point of the study was progression of the disease, defined as an increase in serum creatinine concentration of >50%, or of >25% with an absolute concentration of >135 mmol/l.','N','ROC','0.80 (0.71–0.89)','univariate','N','N','AUC','worse\r',NULL,NULL),(2000254,'22801951','α1-microglobulin','AMBP','P02760','Protein AMBP','protein','urine','not mention','ELISA','IMN(104)','N','N','The end point of the study was progression of the disease, defined as an increase in serum creatinine concentration of >50%, or of >25% with an absolute concentration of >135 mmol/l.','N','ROC','0.79 (CI 0.71–0.88),','univariate','N','N','AUC','worse\r',NULL,NULL),(2000255,'15361701','CD68','CD68','P34810','Macrosialin (Gp110) (CD antigen CD68)','protein','renal tissue','not mention','immunohistochemical assays','IMN(30)','positive or negative','positive:negative','ESRF','N','HR','1.039','multivariate','FSGS,MCP-1,CD68-postive cell','0.0061','multivariate stepwise Cox hazard analysis','worse\r',NULL,NULL),(2000257,'18753796','NGAL','LCN2','P80188','Neutrophil gelatinase-associated lipocalin','protein','urine','not mention','ELISA','IMN(23)','350 ng/ml','H:L','appearance of a chronic severe decrease in GFR≥ 50% of baseline values','N','HR','3.36（1.26-8.95）','univariate','N','0.003','Cox ','worse\r',NULL,NULL),(2000260,'25267554','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(118)','N','H:L','an increase of serum creatinine by ≥25% and serum creatinine reaching ≥1.3 mg/dl.','N','HR','1.6（1.02-2.5）','multivariate','age, sex,total IgG PLA2R-Ab levels, IgG4 PLA2R-Ab levels, proteinuria,serum albumin, serum creatinine, time between renal biopsy and measurement of PLA2R-Ab levels, glomerular lesions according to the work by Ehrenreich and Churg, BP,use of immunosuppressive treatment','0.04','COX','worse\r',NULL,NULL),(2000261,'25267554','PLA2R','PLA2R','Q13018','Secretory phospholipase A2 receptor','protein','blood','not mention','ELISA','IMN(118)','tertile 1 levels=20–86 units/ml (low), tertile 2 levels=87–201 units/ml(medium), and tertile 3 levels $202 units/ml (high).','H:L','an increase of serum creatinine by ≥25% and serum creatinine reaching ≥1.3 mg/dl.','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(2000262,'25129203','nestin','NEST','P48681','Nestin','Protein','renal tissue','not mention','PAS','FSGS(38)','25%(the estimated percentage of glomerular nestin expression in the whole biopsy sample)','H:L','CKD2–5','N','Kaplan-Meier method，logistic regression','3.964','univariate','N','0.046','log-rank test ','better\r',NULL,NULL),(2000263,'16967287','HLA-DR3','HLA-DR3','Q29905','HLA-DR3 protein','DNA','blood','not mention','polymerase chain reaction sequence-specific oligonucleotide probing technique and the microlymphocytotoxicity test. ','FSGS(48)','yes or no ','positive:negative','remission (a reduction in rate of urinary protein excretion to less than 4 mg/h/m2 for three consecutive days)','N','Kaplan-Meier method，logistic regression','N','univariate','N','0.01','log-rank test ','better\r',NULL,NULL),(70000001,'11967037','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(160)','2.0 g/day ','H:L','ESRD（initiation of dialysis or a doubling in the SCr level after the time of diagnosis）','N','HR','3.671(2.19,6.16)','univariate','N','＜0.0001','cox','worse\r',NULL,NULL),(70000002,'12172761','Grade of proteinuria ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(79)','1.0 g/1.73 m2 per day,3.0 g/1.73 m2 per day','H:M:L','ESRD','N','HR','2.99(1.56–5.73)','multivariate','ACE genotype ','0.001','cox','worse\r',NULL,NULL),(70000003,'12897092','24-h urine protein excretion (UP0) ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(711)','0.5g/day ','H:L','ESRF','N','HR','1.13','multivariate','age0,gender male,CrCl0,MAP0,race','<0.001 ','cox','worse\r',NULL,NULL),(70000004,'12897092','24-h urine protein excretion (UP0) ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(711)','0.5g/day ','H:L','ESRF','N','HR','1.2','univariate','N','<0.001 ','cox','worse\r',NULL,NULL),(70000005,'12897092','24-h urine protein excretion (UP0) ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(711)','0.5g/day ','H:L','N','less negative slope CrCl ','β','-0.39','univariate','N','<0.001 ','linear','worse\r',NULL,NULL),(70000006,'12897092','24-h urine protein excretion (UP0) ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(711)','0.5g/day ','H:L','N','less negative slope CrCl ','β','-0.33','multivariate','age0,gender male,CrCl0,MAP0,race','<0.001 ','linear','worse\r',NULL,NULL),(70000007,'12897092','creatinine clearance (CrCl0) ','creatinine','','','clinical','other','not mention','calculated either by the classic 24h urine creatinine excretion and simultaneous serum creatinine or by the formula of Cockcroft and Gault ','IgAN(711)','75ml/min','H:L','ESRF','N','HR','0.96','univariate','N','<0.001 ','cox','better\r',NULL,NULL),(70000008,'12897092','creatinine clearance (CrCl0) ','creatinine','','','clinical','other','not mention','calculated either by the classic 24h urine creatinine excretion and simultaneous serum creatinine or by the formula of Cockcroft and Gault ','IgAN(711)','75ml/min','H:L','ESRF','N','HR','0.96','multivariate','age0,gender male,UP0,MAP0,race','<0.001 ','cox','better\r',NULL,NULL),(70000009,'12897092','creatinine clearance (CrCl0) ','creatinine','','','clinical','other','not mention','calculated either by the classic 24h urine creatinine excretion and simultaneous serum creatinine or by the formula of Cockcroft and Gault ','IgAN(711)','75ml/min','H:L','N','less negative slope CrCl ','β','0.18','univariate','N','<0.001 ','linear','better\r',NULL,NULL),(70000010,'12897092','creatinine clearance (CrCl0) ','creatinine','','','clinical','other','not mention','calculated either by the classic 24h urine creatinine excretion and simultaneous serum creatinine or by the formula of Cockcroft and Gault ','IgAN(711)','75ml/min','H:L','N','less negative slope CrCl ','β','0.11','multivariate','age0,gender male,UP0,MAP0,race','0.03','linear','better\r',NULL,NULL),(70000011,'11961402','duration of proteinuria ','proteinuria ','','','clinical','other','not mention','calculated either by the classic 24h urine creatinine excretion and simultaneous serum creatinine or by the formula of Cockcroft and Gault ','IgAN(57)','N','N','N','Ccr ','r','-0.354','univariate','N','0.0069. ','Parametric linear regression analysis ','worse\r',NULL,NULL),(70000012,'12164881','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(137)','2g/day','H:L','doubling of Scr or initiation of hemodialysis','N','HR','28.3(7.3-109.8)','multivariate','hypertention at renal biopsy,AGT C(-20)','<0.001 ','cox','worse\r',NULL,NULL),(70000013,'12566518','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(216)','the amount of Proteinuria','＞3000mg/day:＜1000mg/day','doubling the baseline serum creatinine ','N','HR','4.0(1.8-8.5)','univariate','N','0.0004','cox','worse\r',NULL,NULL),(70000014,'12566518','Creatinine ','creatinine','','','clinical','serum ','not mention','not mention','IgAN(216)','1.4 mg/dl ','H:L','doubling the baseline serum creatinine ','N','HR','3.6(1.9-5.8)','univariate','N','0.0015','cox','worse\r',NULL,NULL),(70000015,'12746403','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(271)','1.0g/day','H:L','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','HR','3.362(1.891-5.977)','multivariate','Hypertension,No ACEI/ARB administration,genotype of CYP11B2','<0.0001 ','cox','worse\r',NULL,NULL),(70000016,'12746403','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN[female](143)','1.0g/day','H:L','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','HR','2.505(1.203-5.217)','multivariate','Hypertension,No ACEI/ARB administration,genotype of CYP11B2','0.0141','cox','worse\r',NULL,NULL),(70000017,'12746403','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN[male](128)','1.0g/day','H:L','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','HR','4.768(1.664-13.666)','multivariate','Hypertension,No ACEI/ARB administration,genotype of CYP11B2','0.0036','cox','worse\r',NULL,NULL),(70000018,'12885793','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(276)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','3.40(1.91-6.05)','multivariate','hypertension,No ACEI/ARB administration,genotype of ADD1','<0.0001 ','cox','worse\r',NULL,NULL),(70000019,'12885793','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN[carrying the ACE II genotype](106)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','1.54(1.08-3.25)','multivariate','hypertension,No ACEI/ARB administration,genotype of ADD1','0.026','cox','worse\r',NULL,NULL),(70000020,'12885793','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN[carrying the ACE ID/DD genotype](170)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','5.08(1.90-13.57)','multivariate','hypertension,No ACEI/ARB administration,genotype of ADD1','0.0012','cox','worse\r',NULL,NULL),(70000021,'14616762','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(225)','1.0g/day','H:L','ESRD(when patients underwent first hemodialysis)','N','HR','3.004(1.655-5.454)','multivariate','hypertension at the time of renal biopsy ','0.0003','cox','worse\r',NULL,NULL),(70000022,'14684698','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(267)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','2.961(1.719-5.101)','univariate','N','＜0.0001','cox','worse\r',NULL,NULL),(70000023,'14684698','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(267)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','3.102(1.771-5.433)','multivariate','\"Hypertension,No administration',NULL,NULL,NULL,NULL,NULL),(70000024,'14684698','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN[with the AA genotype of ACE A2350G](87)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','2.620(1.209-5.680)','univariate','N','0.0147','cox','worse\r',NULL,NULL),(70000025,'14684698','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN[with the AG or GG genotype of ACE A2350G](180)','1.0g/day','H:L','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','3.307(1.412-7.743)','univariate','N','0.0059','cox','worse\r',NULL,NULL),(70000026,'15609695','IgA/C3 ratio','IgA/C3','','','clinical','blood','not mention','measure serum IgA and C3 using a turbidimetric immunoassay and then calculate','IgAN(86)','4.5','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','＜0.05','log-rank test ','worse\r',NULL,NULL),(70000027,'16105038','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN[whose serum creatinine concentrations were normal at the time of renal biopsy](142)','1.0g/day','H:L','100% increase in serum creatinine from baseline ','N','RR','4.20(1.14–15.56)','multivariate','Gender,Age,Serum creatinine,Hypertension,Glomerulosclerosis ,Mesangial proliferation,Area of fibrosis,a-smooth muscle actin+ area,Fibroblast-specific protein 1+ cells','0.032','cox','worse\r',NULL,NULL),(70000028,'16175941','protein ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(181)','according to urinary protein excretion: ','isolated hematuria:hema- turia with proteinuria < 1 g/24 hours: hema- turia with proteinuria > 1 g/2','N','Cumulative risk of persistent hematuria and/or proteinuria ','Kaplan-Meier ','N','univariate','N','＜0.05','log-rank test ','worse\r',NULL,NULL),(70000029,'17943082','EGF/MCP-1 ratio','EGF/MCP-1','','','clinical','urine','not mention','sandwich-ELISA','IgAN(132)','tertile','1st:2nd:3rd','ESRD and/or doubling of sCr.','N','Kaplan-Meier ','N','univariate','N','0.0001','log-rank test ','better\r',NULL,NULL),(70000030,'17943082','EGF/MCP-1 ratio','EGF/MCP-1','','','clinical','urine','not mention','sandwich-ELISA','IgAN(132)','N','N','ESRD and/or doubling of sCr.','N','HR','0.93 (0.90–0.96)','univariate','N','＜0.0001','cox','better\r',NULL,NULL),(70000031,'17943082','EGF/MCP-1 ratio','EGF/MCP-1','','','clinical','urine','not mention','sandwich-ELISA','IgAN(132)','N','N','ESRD and/or doubling of sCr.','N','HR','0.94 (0.91–0.98)','multivariate','eCrCl,uPr,hypertension,and histologic grade','0.002','cox','better\r',NULL,NULL),(70000032,'17943082','EGF/MCP-1 ratio','EGF/MCP-1','','','clinical','urine','not mention','sandwich-ELISA','IgAN(132)','N','N','ESRD and/or doubling of sCr.','N','ROC','0.91 (95% CI: 0.84–0.95)',' ','','','','\r',NULL,NULL),(70000033,'18334740','mast cells','mast cells','','','clinical','renal biopsy （Interstitial）','not mention','morphometry ','IgAN(62)','N','N','N','serum creatinine at the time of biopsy ','r','0.295','univariate','N','0.0201','Spearman’s correlation coefficient ','worse\r',NULL,NULL),(70000034,'18334740','mast cells','mast cells','','','clinical','renal biopsy （Interstitial）','not mention','morphometry ','IgAN(62)','N','N','N','serum creatinine at the end of follow-up ','r','0.323','univariate','N','0.0116','Spearman’s correlation coefficient ','worse\r',NULL,NULL),(70000035,'18334740','mast cells','mast cells','','','clinical','renal biopsy （Interstitial）','not mention','morphometry ','IgAN(62)','N','N','N','clinical outcome of IgAN ','r','0.337','univariate','N','0.0077','Spearman’s correlation coefficient ','worse\r',NULL,NULL),(70000036,'18334740','mast cells','mast cells','','','clinical','renal biopsy （Interstitial）','not mention','morphometry ','IgAN(62)','3.5 cells/mm2','H:L',' ESRD requiring dialysis or transplant','N','Kaplan-Meier ','N','univariate','N','＜0.01','log-rank test ','worse\r',NULL,NULL),(70000037,'21490589','index of chronic damage (ICD) ','index of chronic damage (ICD) ','','','clinical','','','','IgAN(93)','10%,30%','H:M:L','ESRD','N','Kaplan-Meier ','N','univariate','N','0.0001','log-rank test ','worse\r',NULL,NULL),(70000038,'21490589','urinary albumin–creatinine ratio (ACR) ','proteinuria/creatinine','','','clinical','','','','IgAN(93)','100300','H:M:L','ESRD','N','Kaplan-Meier ','N','univariate','N','0.0001','log-rank test ','worse\r',NULL,NULL),(70000039,'23391320','uric acid ','uric acid ','','','clinical','serum ','not mention','a standard enzymatic determination of uric acid levels using the Hitachi 7170 autoana- lyzer','IgAN[with eGFR≥60 ml/min/1.73 m2] (291)','420 μmol/l in males and 357 μmol/l in females ','H:L','ESRD','N','OR','4.17(2.13 – 13.72)','univariate','N','not mention','logistic regression ','worse\r',NULL,NULL),(70000040,'23391320','uric acid ','uric acid ','','','clinical','serum ','not mention','a standard enzymatic determination of uric acid levels using the Hitachi 7170 autoana- lyzer','IgAN[with eGFR≥60 ml/min/1.73 m2] (291)','420 μmol/l in males and 357 μmol/l in females ','H:L','ESRD','N','OR','3.15(1.68 – 10.79)','multivariate','age, gender, obese, smoke, hypertension, diabetes, ACEi/ARB, and corticosteroid treatment.','not mention','logistic regression ','worse\r',NULL,NULL),(70000041,'23391320','uric acid ','uric acid ','','','clinical','serum ','not mention','a standard enzymatic determination of uric acid levels using the Hitachi 7170 autoana- lyzer','IgAN[with eGFR＜60 ml/min/1.73 m2] (57)','420 μmol/l in males and 357 μmol/l in females ','H:L','ESRD','N','OR','2.75(1.62 – 8.35)','univariate','N','not mention','logistic regression ','worse\r',NULL,NULL),(70000042,'23391320','uric acid ','uric acid ','','','clinical','serum ','not mention','a standard enzymatic determination of uric acid levels using the Hitachi 7170 autoana- lyzer','IgAN[with eGFR＜60 ml/min/1.73 m2] (57)','420 μmol/l in males and 357 μmol/l in females ','H:L','ESRD','N','OR','1.46(1.20 – 6.59)','multivariate','age, gender, obese, smoke, hypertension, diabetes, ACEi/ARB, and corticosteroid treatment.','not mention','logistic regression ','worse\r',NULL,NULL),(70000043,'23391320','uric acid ','uric acid ','','','clinical','serum ','not mention','a standard enzymatic determination of uric acid levels using the Hitachi 7170 autoana- lyzer','IgAN[with eGFR≥60 ml/min/1.73 m2] (291)','420 μmol/l in males and 357 μmol/l in females ','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','not mention','log-rank test ','worse\r',NULL,NULL),(70000044,'23391320','uric acid ','uric acid ','','','clinical','serum ','not mention','a standard enzymatic determination of uric acid levels using the Hitachi 7170 autoana- lyzer','IgAN[with eGFR＜60 ml/min/1.73 m2] (57)','420 μmol/l in males and 357 μmol/l in females ','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','not mention','log-rank test ','worse\r',NULL,NULL),(70000045,'26894025','uric acid ','uric acid ','','','clinical','serum ','not mention','not mention','IgAN[follow-up for ≥1y,having complete laboratory data] (145)','serum uric acid level Z7.3 mg/dL in men and Z5.3 mg/dL in women, ','H:L','erum creatinine elevation above 1.2 mg/dL or over 20% elevation from baseline ','N','Kaplan-Meier ','N','univariate','N','＜0.0001','log-rank test ','worse\r',NULL,NULL),(70000046,'25011573','averaged serum albumin (ALB)','averaged serum albumin','','','clinical','serum ','not mention','not mention','IgAN(369)','39g/L (ALB at month 6)','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','Kaplan-Meier ','N','univariate','N','0.001','log-rank test ','better\r',NULL,NULL),(70000047,'25011573','time-averaged serum albumin (TA-ALB) ','averaged serum albumin','','','clinical','serum ','not mention','not mention','IgAN(369)','38g/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','better\r',NULL,NULL),(70000048,'25011573','SCr','creatinine','','','clinical','serum ','not mention','not mention','IgAN(369)','120umol/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','Kaplan-Meier ','N','univariate','N','0.002','log-rank test ','worse\r',NULL,NULL),(70000049,'25011573','SCr ','creatinine','','','clinical','serum ','not mention','not mention','IgAN(369)','120umol/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','Kaplan-Meier ','N','univariate','N','0.002','log-rank test ','worse\r',NULL,NULL),(70000050,'25011573','SCr ','creatinine','','','clinical','serum ','not mention','not mention','IgAN(369)','120umol/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','Kaplan-Meier ','N','univariate','N','0.002','log-rank test ','worse\r',NULL,NULL),(70000051,'25011573','the time-averaged creatinine (TA-SCr) ','creatinine','','','clinical','serum ','not mention','not mention','IgAN(369)','120umol/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(70000052,'25011573','time-averaged serum albumin (TA-ALB) ','creatinine','','','clinical','serum ','not mention','not mention','IgAN(369)','38g/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','HR','0.8(0.70-0.93)','univariate','N','0.002','cox','better\r',NULL,NULL),(70000053,'25011573','the time-averaged creatinine (TA-SCr) ','creatinine','','','clinical','serum ','not mention','not mention','IgAN(369)','120umol/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','HR','1.02(1.01-1.03)','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(70000054,'25011573','time-averaged serum albumin (TA-ALB) ','creatinine','','','clinical','serum ','not mention','not mention','IgAN(369)','38g/L','H:L','The primary outcome was a doubling of the baseline serum creatinine (SCr); secondary outcomes included ESRD and death. ','N','HR','0.86(0.75-0.98)','multivariate','ALB(at baseline, at month 3,at month 6),TA-ALB,Scr(at baseline, at month 3,at month 6),TA-Scr,BUN(at baseline, at month 3,at month 6),TA-BUN,eGRF(at baseline, at month 3,at month 6),TA-eGFR,UPE,TA-UPE','0.002','cox','better\r',NULL,NULL),(70000055,'15171553','Creatinine ','creatinine','','','clinical','serum ','not mention','not mention','IgAN(495)','133umol/L','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(70000056,'15171553','Creatinine ','creatinine','','','clinical','serum ','not mention','not mention','IgAN(495)','133umol/L','H:L','ESRD','N','HR','1.49(1.54-38.90)','multivariate','hypertension','0.01','cox','worse\r',NULL,NULL),(70000057,'15171553','24h proteinuria','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(495)','3g','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(70000058,'15458457','Urinary protein excretion ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(120)','N','N','N','∆Ccr ','r','0.71','univariate','N','<0.0001 ','linear','worse\r',NULL,NULL),(70000059,'15458457','advanced oxidation protein prod- ucts (AOPP)','proteinuria ','','','clinical','plasma ','not mention','using the semiautomated method previously devised in our laboratory (measured by spectrophotometry on a microplate reader (Model MR 5000; Dynatech, Paris, France), and are calibrated with chloramine-T','IgAN(120)','N','N','N','∆Ccr ','r','0.53','univariate','N','<0.0001 ','linear','worse\r',NULL,NULL),(70000060,'15458457','Urinary protein excretion ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(120)','1g/day','H:L','halving of baseline creatinine clearance ','N','HR','16.41 (3.97–67.84) ','univariate','N','0.00001','cox','worse\r',NULL,NULL),(70000061,'15458457','advanced oxidation protein prod- ucts (AOPP ','proteinuria ','','','clinical','plasma ','not mention','using the semiautomated method previously devised in our laboratory (measured by spectrophotometry on a microplate reader (Model MR 5000; Dynatech, Paris, France), and are calibrated with chloramine-T','IgAN(120)','40umol/L ','H:L','halving of baseline creatinine clearance ','N','HR','1.42 (1.28–1.58) ','univariate','N','0.00001','cox','worse\r',NULL,NULL),(70000062,'15458457','Urinary protein excretion ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(120)','1g/day','H:L','halving of baseline creatinine clearance ','N','HR','7.78 (1.81–33.4) ','multivariate','Ccr,AOPP ','0.0057','cox','worse\r',NULL,NULL),(70000063,'15458457','advanced oxidation protein prod- ucts (AOPP ','proteinuria ','','','clinical','plasma ','not mention','using the semiautomated method previously devised in our laboratory (measured by spectrophotometry on a microplate reader (Model MR 5000; Dynatech, Paris, France), and are calibrated with chloramine-T','IgAN(120)','40umol/L ','H:L','halving of baseline creatinine clearance ','N','HR','1.11 (1.02–1.21) ','multivariate','Ccr ,Proteinuria ≥1 g/day yes','0.0305','cox','worse\r',NULL,NULL),(70000064,'15458457','Urinary protein excretion ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(120)','1g/day','H:L','halving of baseline creatinine clearance ','N','HR','23.7 (5.35–104.8) ','multivariate','Hypertension,Angiotensin II inhibitors,AOPP ','0.0001','cox','worse\r',NULL,NULL),(70000065,'15458457','advanced oxidation protein prod- ucts (AOPP ','proteinuria ','','','clinical','plasma ','not mention','using the semiautomated method previously devised in our laboratory (measured by spectrophotometry on a microplate reader (Model MR 5000; Dynatech, Paris, France), and are calibrated with chloramine-T','IgAN(120)','40umol/L ','H:L','halving of baseline creatinine clearance ','N','HR','1.09 (1.00–1.18) ','multivariate','Hypertension,Angiotensin II inhibitors,Proteinuria ≥ 1g/day','0.042','cox','worse\r',NULL,NULL),(70000066,'15458457','Urinary protein excretion ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(120)','1g/day','H:L','halving of baseline creatinine clearance ','N','Kaplan-Meier ','N','univariate','N','< 0.00001','log-rank test ','worse\r',NULL,NULL),(70000067,'15458457','advanced oxidation protein prod- ucts (AOPP ','proteinuria ','','','clinical','plasma ','not mention','using the semiautomated method previously devised in our laboratory (measured by spectrophotometry on a microplate reader (Model MR 5000; Dynatech, Paris, France), and are calibrated with chloramine-T','IgAN(120)','40umol/L ','H:L','halving of baseline creatinine clearance ','N','Kaplan-Meier ','N','univariate','N','< 0.0001 ','log-rank test ','worse\r',NULL,NULL),(70000068,'16221102','proteinuria ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN[ followed on average for 27 months after diagnosis and the creatinine clearance estimated by the Modification of Diet in Renal Disease formula was <85 mL/min] (229)','3.5g/day','H:L','ESRD','N','OR','3.456 (1.777–6.723) ','multivariate','Creatinine clearance,Hypertension,Sclerosed glomeruli,Interstitial fibrosis,Constant','0','logistic regression ','worse\r',NULL,NULL),(70000069,'16221102','proteinuria ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN[ followed on average for 27 months after diagnosis ] (347)','3.5g/day','H:L','ESRD','N','HR','1.962 (1.191–3.231) ','multivariate','Hypertension,Sclerosed glomeruli,Interstitial fibrosis','0.008','Cox ','worse\r',NULL,NULL),(70000070,'24408121','Baseline proteinuria','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(703)','N','N','end stage kidney failure or eGFR halving ','N','HR ','1.13 (1.07-1.18) ','univariate','N','＜0.001 ','Cox ','worse\r',NULL,NULL),(70000071,'24408121','Proteinuria at month 6','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(703)','N','N','end stage kidney failure or eGFR halving ','N','HR ','1.85 (1.64-2.09) ','univariate','N','＜0.001 ','Cox ','worse\r',NULL,NULL),(70000072,'24408121','Proteinuria at month 6','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(703)','N','N','end stage kidney failure or eGFR halving ','N','HR ','1.53 (1.27-1.84) ','multivariate','Age,Sex ,Haas classification,Baseline eGFR,Baseline proteinuria,Baseline SBP,SBP at month 6 ,Immunosuppressive therapy ,Uric acid','＜0.001 ','Cox ','worse\r',NULL,NULL),(70000073,'24408121','TA(time average) proteinuria ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(703)','N','N','N','GFR ','Regression Coefficients','-0.21(\'-0.26 to\' -0.17)','univariate','N','＜0.001 ','linear regression ','worse\r',NULL,NULL),(70000074,'24408121','TA(time average) proteinuria ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(703)','N','N','N','GFR ','Regression Coefficients','-0.21(\'-0.25 to\' -0.16)','multivariate','Age,Sex,Haas classification,Baseline eGFR ,Baseline proteinuria,TA proteinuria,Baseline MAP ,TA MAP,Immunosuppressive therapy ,Uric acid ','＜0.001 ','linear regression ','worse\r',NULL,NULL),(70000075,'24824243','homocysteine ','homocysteine','','','clinical','serum ','not mention','Roche MODULAR automatic biochemistry analyzer ','IgAN(108)','with hyperhomocysteinemia  or not','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','0.005','log-rank test ','worse\r',NULL,NULL),(70000076,'24824243','homocysteine ','homocysteine','','','clinical','serum ','not mention','Roche MODULAR automatic biochemistry analyzer ','IgAN(108)','with hyperhomocysteinemia  or not','H:L','ESRD','N','HR','4.71 (1.45-15.31) ','univariate','N','0.01','log-rank test ','worse\r',NULL,NULL),(70000077,'25003873','Time-averaged proteinuria (TA-P) ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(500)','0.3,0.99','H:L','50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. ','N','Kaplan-Meier ','N','univariate','N','＜0.001 ','log-rank test ','worse\r',NULL,NULL),(70000078,'25003873','Time-averaged proteinuria (TA-P) ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(500)','＜0.3:L;0.3 to 0.99:M;1.0 to 2.99:L;≥3.0:HH','H/HH:L','50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. ','N','Kaplan-Meier ','N','univariate','N','＜0.001 ','log-rank test ','worse\r',NULL,NULL),(70000079,'25003873','Time-averaged proteinuria (TA-P) ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(500)','＜0.3:L;0.3 to 0.99:M;1.0 to 2.99:L;≥3.0:HH','H:L','50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. ','N','HR','47.28 (6.38-350.15)','multivariate','Age,GFR,TA_MAP,Hypertension','＜0.001 ','Cox ','worse\r',NULL,NULL),(70000080,'25003873','Time-averaged proteinuria (TA-P) ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(500)','＜0.3:L;0.3 to 0.99:M;1.0 to 2.99:L;≥3.0:HH','HH:L','50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. ','N','HR','406.35 (49.30-3349.18)','multivariate','Age,GFR,TA_MAP,Hypertension','＜0.001 ','Cox ','worse\r',NULL,NULL),(70000081,'25003873','Time-averaged proteinuria (TA-P) ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(500)','＜0.3:L;0.3 to 0.99:M;1.0 to 2.99:L;≥3.0:HH','H:L','50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. ','N','HR','26.59 (3.48-203.34)','multivariate','Age,GFR,TA_MAP,Hypertension,Pathologic findings','0.002','Cox ','worse\r',NULL,NULL),(70000082,'25003873','Time-averaged proteinuria (TA-P) ','proteinuria ','','','clinical','urine','not mention','not mention','IgAN(500)','＜0.3:L;0.3 to 0.99:M;1.0 to 2.99:L;≥3.0:HH','HH:L','50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR. ','N','HR','288.86 (34.03-2451.86) ','multivariate','Age,GFR,TA_MAP,Hypertension,Pathologic findings','＜0.001 ','Cox ','worse\r',NULL,NULL),(70000083,'25355499','uric acid ','uric acid ','','','clinical','blood','not mention','not mention','IgAN[with CKD stage G3a ] (103)','＞7.0 mg/dL for males and ＞6.0 mg/dL for females at the time of renal biopsy:H;uric acid level ≤6.9 mg/dL for males and ≤5.9 mg/dL for females:N','H:N','ESRD, defined as requiring dialysis or renal transplantation ','N','Kaplan-Meier ','N','univariate','N','0.0205','log-rank test ','worse\r',NULL,NULL),(70000084,'25355499','uric acid ','uric acid ','','','clinical','blood','not mention','not mention','IgAN[with CKD stage G3a ] (103)','N','N','ESRD, defined as requiring dialysis or renal transplantation ','N','HR','1.40(1.11–1.76)','univariate','N','0.0042','Cox ','worse\r',NULL,NULL),(70000085,'25355499','uric acid ','uric acid ','','','clinical','blood','not mention','not mention','IgAN[with CKD stage G3a ] (103)','N','N','ESRD, defined as requiring dialysis or renal transplantation ','N','HR','1.36(1.07–1.72)','multivariate','Male,Age,BMI,MAP,eGFR,Serum albumin,T-Cho,T-G,U-Prot,U-RBC,IgA/C3,Oxford classification ','0.011','Cox ','worse\r',NULL,NULL),(70000086,'25700934','bilirubin ','bilirubin ','','','clinical','serum ','not mention','not mention','IgAN(694)','N','N','ESRD(initiation of renal replacement therapy, in- cluding hemodialysis, peritoneal dialysis and kidney transplantation)','N','HR','1.37 (1.22–1.53) ','multivariate','Age,sex','＜0.001 ','Cox ','worse\r',NULL,NULL),(70000087,'25700934','bilirubin ','bilirubin ','','','clinical','serum ','not mention','not mention','IgAN(694)','N','N','ESRD(initiation of renal replacement therapy, in- cluding hemodialysis, peritoneal dialysis and kidney transplantation)','N','HR','1.18 (1.04–1.33) ','multivariate','age, sex and clinical parameters (serum albumin, urinary protein excretion, estimated glomerular filtration rate) and pathological parameters (mesangial hypercellularity score, segmental glomerulosclerosis, tubular atrophy/interstitial fibrosis)','0.001','Cox ','worse\r',NULL,NULL),(70000088,'26825903','Antineutrophil Cytoplasmic Antibody','Anti-neutrophil cytoplasmic antibodies','','','protein','Renal biopsy','not mention','indirect immunofluorescence assay','LN(154)','with orwithout','positive:negative',' primary end point was defined as death, and the secondary end point was defined as end-stage renal disease (ESRD) or the doubling of SCr. The combined end point was defined as a composite outcome of death, ESRD or the doubling of SCr. ','N','Kaplan-Meier ','6.59','univariate','N','0.01','log-rank test ','worse\r',NULL,NULL),(70000089,'26825903','Antineutrophil Cytoplasmic Antibody','Anti-neutrophil cytoplasmic antibodies','','','protein','Renal biopsy','not mention','indirect immunofluorescence assay','LN(154)','with orwithout','positive:negative',' primary end point was defined as death, and the secondary end point was defined as end-stage renal disease (ESRD) or the doubling of SCr. The combined end point was defined as a composite outcome of death, ESRD or the doubling of SCr. ','N','HR','3.25 (1.24 to 8.55)','univariate','N','0.02','cox','worse\r',NULL,NULL),(70000090,'26825903','Antineutrophil Cytoplasmic Antibody','Anti-neutrophil cytoplasmic antibodies','','','protein','Renal biopsy','not mention','indirect immunofluorescence assay','LN(154)','with orwithout','positive:negative',' primary end point was defined as death, and the secondary end point was defined as end-stage renal disease (ESRD) or the doubling of SCr. The combined end point was defined as a composite outcome of death, ESRD or the doubling of SCr. ','N','HR','3.37 (1.13 to 10.09)','multivariate','Age,Sex,eGFR,24-h proteinuria,Albumin,NLR,Anti-nucleosome antibody,Anti-histone antibody,antimitochondrial antibody M2,Anti-cardiolipin antibody,Crescent formation,Fibrinoid necrosis,Glomerulosclerosis','0.03','cox','worse\r',NULL,NULL),(70000091,'26704903','anti-CRP antibodies ','CRP antibodies','','','protein','Renal biopsy','not mention','in-house ELISA','LN[newly diagnosed LN patients and finish ] (24)','with orwithout','positive:negative','the time to response','N','Kaplan-Meier ','N','univariate','N','0.037','log-rank test ','worse\r',NULL,NULL),(70000092,'22904352','IgG autoantibody ','IgG','','','protein','serum ','not mention','ELISA ','IgAN(97)','1.33 OD','H:L','dialysis or death ','N','Kaplan-Meier ','N','univariate','N','0.007','log-rank test ','worse\r',NULL,NULL),(70000093,'22904352','IgA autoantibody ','IgA','','','protein','serum ','not mention','ELISA ','IgAN(97)','N','N','dialysis or death ','N','RR','1.22(1.02–1.44)','univariate','N','0.03','cox','worse\r',NULL,NULL),(70000094,'22904352','IgG autoantibody ','IgG','','','protein','serum ','not mention','ELISA ','IgAN(97)','N','N','dialysis or death ','N','RR','2.77(1.59–4.81)','univariate','N','0.0003','cox','worse\r',NULL,NULL),(70000095,'22752397','IgG ','IgG','','','protein','biopsied glomerular tissue (in the glomerular mesangial area)','not mention','immunofluorescence techniques ','IgAN(57)','IgA with or without IgG','IgA-IgG:IgA ','complete remission (CR) ','N','Kaplan-Meier ','N','univariate','N','0.012','log-rank test ','worse\r',NULL,NULL),(70000096,'22752397','IgG ','IgG','','','protein','biopsied glomerular tissue (in the glomerular mesangial area)','not mention','immunofluorescence techniques ','IgAN(57)','IgA with or without IgG','IgA-IgG:IgA ','complete remission (CR) ','N','HR','0.35(0.14–0.82)','univariate','N','0.014','cox','worse\r',NULL,NULL),(70000097,'22752397','IgG ','IgG','','','protein','biopsied glomerular tissue (in the glomerular mesangial area)','not mention','immunofluorescence techniques ','IgAN(57)','IgA with or without IgG','IgA-IgG:IgA ','complete remission (CR) ','N','HR','0.31(0.12–0.77)','multivariate','Age,Female gender,Duration from onset ,History of hypertension ,Proteinuria,eGFR,Histological grade ,Use of RASI,Underwent ST','0.014','cox','worse\r',NULL,NULL),(70000098,'25539484','complement 4 d','C4d','','','protein','serum ','not mention','measured by a turbidimetric method using a commercial kit in commercial equipment (Beckman Coulter IMMAGE, Fullerton, CA) following the instructions from the manufac- turer. ','IgAN(512)','16mg/dL','H:L','the serum creatinine increased 1.5 times from baseline.','N','Kaplan-Meier ','N','univariate','N','0.05','log-rank test ','worse\r',NULL,NULL),(70000099,'25539484','complement 4 d','C4d','','','protein','serum ','not mention','measured by a turbidimetric method using a commercial kit in commercial equipment (Beckman Coulter IMMAGE, Fullerton, CA) following the instructions from the manufac- turer. ','IgAN(512)','16mg/dL','H:L','the serum creatinine increased 1.5 times from baseline.','N','HR','9.69 (1.90–49.48) ','multivariate','age, MAP, eGFR, 24h proteinuria, serum C3 level(binary variable, low C3 or not), serum C4 level (binary variable, low C4 or not), treatment (ACEI/ARB, steroid and/or immunosupressor) and pathological parameters based on Oxford IgAN classification including endocapillary hypercellularity, mesangial hypercellularity, interstitial fibrosis/ tubular atrophy, segmental glomerulosclerosis, crescents. ','0.03','cox','worse\r',NULL,NULL),(70000100,'25031752','complement 4 d','C4d','','','protein','Renal biopsy specimens(glomerular)','not mention','immunohistochemical staining ','IgAN(33)','75% of the glomeruli were positive for C4d(＞:positive；＜:negative)','Positive:negative','ESRD(chronic repetitive dialysis)','N','Kaplan-Meier ','N','univariate','N','0.0072','log-rank test ','worse\r',NULL,NULL),(70000101,'25031752','complement 4 d','C4d','','','protein','Renal biopsy specimens(glomerular)','not mention','immunohistochemical staining ','IgAN(33)','75% of the glomeruli were positive for C4d(＞:positive；＜:negative)','Positive:negative','ESRD(chronic repetitive dialysis)','N','OR','11.083','univariate','N','0.006','cox','worse\r',NULL,NULL),(70000102,'25031752','complement 4 d','C4d','','','protein','Renal biopsy specimens(glomerular)','not mention','immunohistochemical staining ','IgAN(33)','75% of the glomeruli were positive for C4d(＞:positive；＜:negative)','Positive:negative','ESRD(chronic repetitive dialysis)','N','OR','15.022','multivariate','Age,Gender,Serum creatinine,eGFR,Hypertension,Proteinuria,Glomerulosclerosis,Mesangial hypercellularity,Interstisiel  brosis (%)','0.027','cox','worse\r',NULL,NULL),(70000103,'24578331','complement 4 d','C4d','','','protein','Renal biopsy specimens(mesangial)','not mention','immunohistochemical staining using a polyclonal antibody ','IgAN(283)','25% of the nonsclerotic glomeruli were positive for C4d(＞:positive；≤:negative)','Positive:negative','ESRD(onset of chronic dialysis or renal transplantation)','N','Kaplan-Meier ','N','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(70000104,'24578331','complement 4 d','C4d','','','protein','Renal biopsy specimens(mesangial)','not mention','immunohistochemical staining using a polyclonal antibody ','IgAN(283)','25% of the nonsclerotic glomeruli were positive for C4d(＞:positive；≤:negative)','Positive:negative','ESRD(onset of chronic dialysis or renal transplantation)','N','HR','4.65 (2.63-8.22) ','univariate','N','＜0.001','cox','worse\r',NULL,NULL),(70000105,'24578331','complement 4 d','C4d','','','protein','Renal biopsy specimens(mesangial)','not mention','immunohistochemical staining using a polyclonal antibody ','IgAN(283)','25% of the nonsclerotic glomeruli were positive for C4d(＞:positive；≤:negative)','Positive:negative','ESRD(onset of chronic dialysis or renal transplantation)','N','HR','2.45 (1.30-4.64) ','multivariate','Proteinuria,eGFR,Oxford classification','＜0.001','cox','worse\r',NULL,NULL),(70000106,'18842673','C4d','C4d','','','protein','renal biopsy （Mesangial deposition）','not mention','inmunohistochemical staining ','IgAN(59)','degree of the Glomerular expression of α-SMA:>75% of the glomeruli were positive for C4d(positive) or ≤75% of the glomeruli were positive for C4d(negative) ','positive:negative','ESRD','N','Kaplan-Meier ','N','univariate','N','0.0005','log-rank test ','worse\r',NULL,NULL),(70000107,'20194446','anti-C1q antibody','C1q antibody','','','protein','serum','not mention','enzyme-linked immunosorbent assay (ELISA) kits ','LN(73)',' L:Patients with marked decrease of anti-C1q antibody levels (the extent of reduction exceeding 50% or being negative) at the end of the third month after treatment. H:Patients with persistent high levels or increased titers of anti-C1q antibody after treatment for 3 months.','H:L','disappearance of proteinuria','N','Kaplan-Meier ','N','univariate','N','0.002','log-rank test ','worse\r',NULL,NULL),(70000108,'20194446','anti-C1q antibody','C1q antibody','','','protein','serum','not mention','enzyme-linked immunosorbent assay (ELISA) kits ','LN(73)','N','N','disappearance of proteinuria','N','HR','0.229(0.103 to 0.513)','multivariate','ody levels at the end of the third month after treatment, and cyclophosphamide therapy ','<0.001','cox','worse\r',NULL,NULL),(70000109,'23458172','Decreased eGFR at biopsy ','Decreased eGFR','','','other','blood','not mention','calculated using a modified MDRD formula for Chinese patients','IMN(217)',' 60 ml/min','decreased  eGFR：normal eGFR','N','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(70000110,'23458172','Decreased eGFR at biopsy ','Decreased eGFR','','','other','blood','not mention','calculated using a modified MDRD formula for Chinese patients','IMN(217)','N','N','N','N','HR','7.70（2.00-29.62）','multivariate','\"age, Hypertension,Proteinuria, Decreased eGFR,Elevated u-NAG, Elevated u-RBP,Existence of arteriole,pathological changes',NULL,NULL,NULL,NULL,NULL),(70000111,'23458172','chronic tubulointerstitial lesion','chronic tubulointerstitial lesion','','','other','renal biopsy ','not mention','grade of chronic tubulointerstitial lesions in cortex (classified according to the area of tubular at-rophy and the percentage of interstitial fibro-sis  as  Grade  1,  no  cortical  tubulointerstitia','IMN(217)','N','N','N','N','HR','2.90(1.37 – 6.16)','multivariate','\"age, Hypertension,Proteinuria, Decreased eGFR,Elevated u-NAG, Elevated u-RBP,Existence of arteriole,pathological changes,',NULL,NULL,NULL,NULL,NULL),(70000112,'25492250','IgG4','','','','protein','renal biopsy ','not mention','Immunohistological staining','PLA2R-related IMN(16)','the presence of dominant IgG4 deposition','Y:N','incomplete remission type I, that is, mean daily proteinuria of 0.3–1.0 g/gCre with normal serum albumin levels (more than 3.0 g/dL)','N','Kaplan-Meier ','N','univariate','N','0.032','log-rank test ','worse\r',NULL,NULL),(70000113,'25492250','IgG4','','','','protein','renal biopsy ','not mention','Immunohistological staining','IMN(22)','the presence of dominant IgG4 deposition','Y:N','incomplete remission type I, that is, mean daily proteinuria of 0.3–1.0 g/gCre with normal serum albumin levels (more than 3.0 g/dL)','N','HR','0.02(0.00-0.91)','multivariate','age, sex, eGFR, relevance to PLA2R, IgG4 dominancy, treatment,uPCR,Enrenreich-Churg stage','0.044','Cox ','worse\r',NULL,NULL),(70000114,'25492250','therapy','N','','','clinical','N','N','N','IMN(22)','therapy','Immunosuppressive therapy: supportive therapy','incomplete remission type I, that is, mean daily proteinuria of 0.3–1.0 g/gCre with normal serum albumin levels (more than 3.0 g/dL)','N','HR','7.58(1.20-47.6)','multivariate','age, sex, eGFR, relevance to PLA2R, IgG4 dominancy, treatment,uPCR,Enrenreich-Churg stage','0.03','Cox ','better\r',NULL,NULL),(70000117,'24886340','FE IgG','','','','clinical','urine','not mention','immunoturbidimetry ','IMN(84)','0.02','H:L','progression to end stage kidney failure or kidney function (eGFR)decline ≥ 50% of baseline','N','HR','20.84 (2.8 to 156.8) ','multivariate','age, kidney function, blood pressure, proteinuria, and treatment with ACEi/ARB,immunosuppression drug','0.003',' Cox ','worse\r',NULL,NULL),(70000118,'24886340','FE IgG','','','','clinical','urine','not mention','immunoturbidimetry ','IMN(84)','0.02','H:L','progression to end stage kidney failure or kidney function (eGFR)decline ≥ 50% of baseline','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(70000119,'24886340','FE IgG','','','','clinical','urine','not mention','immunoturbidimetry ','NS-IMN(343)','0.02','H:L','complete or partial remission of NS (proteinuria < 0.2 or < 2.0 g/day, respectively)','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(70000120,'15327418','remission','','','','clinical','other','not mention',' A PR was defined by a proteinuria value <3.5 g/day plus a 50% reduction from its peak value','IMN(343)','N','NR:PR:CR','Renal failure was defined as a CrCl ≤15 mL/min at last follow-up, the start of dialysis, or a renal transplantation','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','better\r',NULL,NULL),(70000121,'15327418','partial remission','','','','clinical','other','not mention',' A PR was defined by a proteinuria value <3.5 g/day plus a 50% reduction from its peak value','IMN(343)','N','','Renal failure was defined as a CrCl ≤15 mL/min at last follow-up, the start of dialysis, or a renal transplantation','N','HR','0.08 (0.03–0.19)','multivariate','CrCl and proteinuria on set,follow-up MAP ,ACEi or ARB therapy','<0.001 ','Cox ','better\r',NULL,NULL),(70000123,'22995635','Maximal 24-h  proteinuria','','','','clinical','','','','IMN(60)','7.2g','H:L','≥50% permanent decrease in estimated glomerular filtration rate or  death','N','HR','1.127(1.011-1.053)','multivariate','cholesterol,albumin,eGFR,injury score,glomerular membrane thickness,glomerulopathy index,nephroangiosclerosis grade','0.008','COX','worse\r',NULL,NULL),(70000124,'22995635','interstitial fibrosis and tubular atrophy(%)','','','','clinical','','','','IMN(60)','0.18','H:L','≥50% permanent decrease in estimated glomerular filtration rate or  death','N','HR','1.029(1.007-1.051)','multivariate','cholesterol,albumin,eGFR,injury score,glomerular membrane thickness,glomerulopathy index,nephroangiosclerosis grade','0.01','COX','worse\r',NULL,NULL),(70000125,'22995635','interstitial fibrosis and tubular atrophy(%)','','','','clinical','','','','IMN(60)','0.18','H:L','≥50% permanent decrease in estimated glomerular filtration rate or  death','N','ROC','0.872','univariate','N','＜0.0001（The calculated sensitivity and specificity were respectively 91.67% and 77.08%)','AUC','worse\r',NULL,NULL),(70000126,'22995635','interstitial fibrosis and tubular atrophy(%)','','','','clinical','','','','IMN(60)','0.18','H:L','≥50% permanent decrease in estimated glomerular filtration rate or  death','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(70000127,'18308774','Uβ-NAG','Uβ-NAG','','','enzyme','urine','not mention','colourimetric assay','IMN(57)','2.64 U/mmol cr','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >137 µmol/l','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(70000128,'18308774','Uβ-NAG','Uβ-NAG','','','enzyme','urine','not mention','colourimetric assay','IMN(57)','2.50 U/mmol cr','H:L','remission (proteinuria <2.0 g/day)','N','Kaplan-Meier ','N','univariate','N','0.002','log-rank test ','worse\r',NULL,NULL),(70000129,'18308774','Uβ-NAG','Uβ-NAG','','','enzyme','urine','not mention','colourimetric assay','IMN(57)','2.64 U/mmol cr','H:L','an increase in serum creatinine by >50% from baseline or a serum creatinine >138 µmol/l','N','ROC','0.870','univariate','N','not mention','AUC','worse\r',NULL,NULL),(70000130,'18308774','Uβ-NAG','Uβ-NAG','','','enzyme','urine','not mention','colourimetric assay','IMN(57)','2.50 U/mmol cr ','H:L','remission (proteinuria <2.0 g/day)','N','ROC','0.851','univariate','N','not mention','AUC','worse\r',NULL,NULL),(70000131,'26893829','age','','','','clinical','','','','IMN(73)','60 years','H:L','A 30% decrease in eGFR or entry of ESRD within 2 years','N','OR','3.471','multivariate','age，tubulointerstitial injury area，BUN,SCr，eGFR','0.025','COX','worse\r',NULL,NULL),(70000132,'26893829','serum albumin','','','','clinical','','','','IMN(73)','25g/L','L:H','A 30% decrease in eGFR or entry of ESRD within 2 years','N','OR','3.195','multivariate','Alb，tubulointerstitial injury area，BUN,SCr，eGFR','0.034','COX','worse\r',NULL,NULL),(70000133,'26893829','tubulointerstitial injury area','','','','clinical','','','','IMN(73)','0.25','H:L','A 30% decrease in eGFR or entry of ESRD within 2 years','N','OR','6.724','multivariate','Alb，age，BUN,SCr，eGFR','0.044','COX','worse\r',NULL,NULL),(70000134,'26893829','age','','','','clinical','','','','IMN(73)','60 years','H:L','A 30% decrease in eGFR or entry of ESRD within 2 years','N','Kaplan-Meier ','N','univariate','N','0.004','log-rank test ','worse\r',NULL,NULL),(70000135,'26893829','serum albumin','','','','clinical','','','','IMN(73)','25g/L','L:H','A 30% decrease in eGFR or entry of ESRD within 2 years','N','Kaplan-Meier ','N','univariate','N','0.024','log-rank test ','worse\r',NULL,NULL),(70000136,'26893829','tubulointerstitial injury area','','','','clinical','','','','IMN(73)','0.25','H:L','A 30% decrease in eGFR or entry of ESRD within 2 years','N','Kaplan-Meier ','N','univariate','N','0.001','log-rank test ','worse\r',NULL,NULL),(70000137,'18495745','initial Cr','','','','clinical','','','','IMN(104)','','','ESRF','','HR','3.74(2.11-6.62)','univariate ','N','<0.001 ','COX','worse\r',NULL,NULL),(70000138,'18495745','remission of proteinuria','','','','clinical','','','','IMN(104)','','','ESRF','','HR','0.39(0.21-0.72)','univariate ','N','0.002','COX','better\r',NULL,NULL),(70000139,'18495745','age at biopsy','','','','clinical','','','','IMN(104)','','','death','','HR','1.1(1.02-1.19)','univariate ','N','0.008','COX','worse\r',NULL,NULL),(70000140,'11961401','urRBP','','','','clinical','urine','not mention','not mention','GN(149)','1.0mg/l ','H:L','doubling of serum creatinine level','N','Kaplan-Meier ','N','univariate','N','0','log-rank test ','worse\r',NULL,NULL),(70000141,'12401843','NAG excretion','','','','clinical','urine','not mention','For the determination of NAG in the second morning urine samples, a colourimetric assay was performed using 3-cresolsulfonphthaleyn-N-acetyl-b-Dglucosaminide which is hydrolysed by NAG with the releas','IMN(36)','18U/g urinary Cr','H:L','ESRD or doubling of sCr','N','\"Kaplan–',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(70000142,'12401843','NAG excretion','','','','clinical','urine','not mention','For the determination of NAG in the second morning urine samples, a colourimetric assay was performed using 3-cresolsulfonphthaleyn-N-acetyl-b-Dglucosaminide which is hydrolysed by NAG with the releas','FSGS(20)','24 U/g urinary Cr','H:L','ESRD or doubling of sCr','N','\"Kaplan–',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(70000143,'12552493','FE IgG','','','','clinical','urine','not mention','immunoglobulin G (IgG),and  1-microglobulin ( 1m) were measured in secondmorning urine samples by means of an immunonephelometric ethod on a BNA nephelometer (Behring, Milan, Italy) using rabbit serum','FSGS[with NS](50)','0.140g/d','H:L','ESRF','N','Kaplan-Meier method，logistic regression','N','univariate','N','0','log-rank test ','worse\r',NULL,NULL),(70000144,'17969486','FE β2m','','','','clinical','urine','not mention','immunonephelometry ','FSGS[untreated patients](9)','0.01','H:L','not mention','N','ROC','0.571','univariate','N','＜0.05','log-rank test ','worse\r',NULL,NULL),(70000145,'15563570','UIgG','UIgG','','','protein','urine','not mention','immunonephelometry','IMN(58)','250 mg/24 h','H:L','an increase of serum creatinine to values  1.5 mg/dl or an increase of serum creatinine  51%','N','Kaplan-Meier ','N','univariate','N','N','log-rank test ','worse\r',NULL,NULL),(70000146,'15563570','UIgG','UIgG','','','protein','urine','not mention','immunonephelometry','IMN(58)','250 mg/24 h','H:L','an increase of serum creatinine to values  1.5 mg/dl or an increase of serum creatinine  51%','N','ROC','N','univariate','N','The calculated sensitivity and specificity were respectively 88% and 88% for UIgG','AUC','worse\r',NULL,NULL),(30000001,'11967037','uteroglobin','SCGB1A1','uteroglobin G38A polymorphism','secretoglobin family 1A member 1','SNP (GG)','blood','not mention','PCR-RFLP ','IgAN[with hypertension at the time of renal biopsy](97)','genotype  with or without the A allele','GG：AG/AA','ESRD（initiation of dialysis or a doubling in the SCr level after the time of diagnosis）','N','Kaplan-Meier ','N','multivariate','hypertension','0.038','log-rank test ','worse\r',NULL,NULL),(30000002,'11967037','uteroglobin','SCGB1A1','uteroglobin G38A polymorphism','secretoglobin family 1A member 1','SNP (GG)','blood','not mention','PCR-RFLP ','IgAN[with a proteinuria level of more than 2 g/day at the time of renal biopsy](78)','genotype  with or without the A allele','GG：AG/AA','ESRD（initiation of dialysis or a doubling in the SCr level after the time of diagnosis）','N','Kaplan-Meier ','N','multivariate','proteinuria level ','0.014','log-rank test ','worse\r',NULL,NULL),(30000003,'12005241','IgH','IGH','VNTR allele of the hs1,2 enhancer of the α1 gene of the IgH locus :hs1,2 enhancer of the α1 gene of ','immunoglobulin heavy locus','VNTR (Allele B positive)','blood','not mention','PCR-SSP','IgAN(125)','genotype Allele B negative or positive','positive：negative','aggravation（initiation of chronic renal failure or transplantation）','N','Kaplan-Meier ','N','univariate ','N','0.04','log-rank test ','worse\r',NULL,NULL),(30000004,'12172761','ACE','ACE','rs1799752,Angiotensin-converting enzyme (ACE) I/D polymorphism ','angiotensin I converting enzyme','insert/deletion (D)','blood','not mention','PCR','IgAN(79)','genotype ','D：II','ESRD ','N','HR','2.37（1.08–5.21）','multivariate','Grade of proteinuria ','0.031','cox','worse\r',NULL,NULL),(30000005,'12172761','ACE','ACE','Angiotensin-converting enzyme (ACE) I/D polymorphism ','angiotensin I converting enzyme','insert/deletion (DD)','blood','not mention','PCR','IgAN(79)','','DD:ID/II','','N','RR','4.74','','','','','worse\r',NULL,NULL),(30000006,'12164881','Angiotensinogen(AGT)','AGT','A(-20)C polymorphism of the Angiotensinogen gene','angiotensinogen','SNP (C(-20))','blood','not mention','PCR','IgAN(137)','genotype  with or without the C allele','AC/CC:AA','doubling of Scr or initiation of hemodialysis','N','Kaplan-Meier ','N','univariate ','N','0.008','log-rank test ','worse\r',NULL,NULL),(30000007,'12164881','Angiotensinogen(AGT)','AGT','the M235T polymorphism of the Angiotensinogen gene','angiotensinogen','SNP (TT)','blood','not mention','PCR','IgAN(137)','genotype  with or without the M allele','TT:MM/MT','doubling of Scr or initiation of hemodialysis','N','Kaplan-Meier ','N','univariate ','N','0.02','log-rank test ','worse\r',NULL,NULL),(30000008,'12164881','Angiotensinogen(AGT)','AGT','A(-20)C polymorphism of the Angiotensinogen gene','angiotensinogen','SNP (C(-20))','blood','not mention','PCR','IgAN(137)','genotype  with or without the C allele','AC/CC:AA','doubling of Scr or initiation of hemodialysis','N','HR','3.6(1.5-8.7)','multivariate','urinary protein,hypertention at renal biopsy','0.004','cox','worse\r',NULL,NULL),(30000009,'12484505','SA','ACSM3','SA genotype (Genetic Polymorphism in the SA Gene )','acyl-CoA synthetase medium-chain family member 3 ','SNP (A1)','blood','not mention','PCR-RFLP ','IgAN(274)','genotype  with or without the A2 allele','A1A1:A1A2/A2A2','ESRD（initiation of dialysis or a doubling in the SCr level after the time of diagnosis）','N','Kaplan-Meier ','N','univariate ','N','0.0748','log-rank test ','worse\r',NULL,NULL),(30000010,'12566518','CD14 ','CD14','CD14 gene –159C polymorphism ','CD14 molecule','SNP (CC)','blood','not mention','PCR-RFLP ','IgAN(216)','genotype ','CC:TC/TT','doubling the baseline serum creatinine ','N','Kaplan-Meier ','N','univariate ','N','0.03','log-rank test ','worse\r',NULL,NULL),(30000011,'12566518','CD14 ','CD14','CD14 gene –159C polymorphism ','CD14 molecule','SNP (CC)','blood','not mention','PCR-RFLP ','IgAN[with CD14 genetype of CC or TT](106)','genotype ','CC:TT','doubling the baseline serum creatinine ','N','HR','3.2(1.2-8.8)','univariate ','N','0.025','cox','worse\r',NULL,NULL),(30000012,'12746403','aldosterone synthase (CYP11B2)','CYP11B2','CYP11B2 C-344T polymorphism ','cytochrome P450 family 11 subfamily B member 2','SNP (CC)','blood','not mention','PCR-RFLP ','IgAN(271)','genotype ','CC:CT/TT','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','0.0225','log-rank test ','worse\r',NULL,NULL),(30000013,'12746403','aldosterone synthase (CYP11B2)','CYP11B2','CYP11B2 C-344T polymorphism ','cytochrome P450 family 11 subfamily B member 2','SNP (CC)','blood','not mention','PCR-RFLP ','IgAN(271)','genotype ','CC:CT/TT','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','HR','2.099(1.098-4.013)','univariate ','N','0.0249','cox','worse\r',NULL,NULL),(30000014,'12746403','aldosterone synthase (CYP11B2)','CYP11B2','CYP11B2 C-344T polymorphism ','cytochrome P450 family 11 subfamily B member 2','SNP (CC)','blood','not mention','PCR-RFLP ','IgAN[female](143)','genotype ','CC:CT/TT','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','HR','4.284(1.686-10.881)','multivariate','Hypertension,No ACEI/ARB administration,urinary protein','0.0022','cox','worse\r',NULL,NULL),(30000015,'12746403','aldosterone synthase (CYP11B2)','CYP11B2','CYP11B2 C-344T polymorphism ','cytochrome P450 family 11 subfamily B member 2','SNP (CC)','blood','not mention','PCR-RFLP ','IgAN[female](143)','genotype ','CC:CT/TT','the sCr level was double that at the time of diagnosis, or when patients underwent their first renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','0.0002','log-rank test ','worse\r',NULL,NULL),(30000016,'12885793','ADD1 ','ADD1','ADD1 G460W polymorphisms ','adducin 1','SNP (WW)','blood','not mention','allele-specific oligonucleotide hybridization after PCR amplification. ','IgAN[carrying the ACE II genotype](106)','genotype ','WW:GW/GG','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','Kaplan-Meier ','N','univariate ','N','0.0138','log-rank test ','worse\r',NULL,NULL),(30000017,'12885793','ADD1 ','ADD1','ADD1 G460W polymorphisms ','adducin 1','SNP (WW)','blood','not mention','allele-specific oligonucleotide hybridization after PCR amplification. ','IgAN[carrying the ACE II genotype](106)','genotype ','WW:GW/GG','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','3.65(1.63-8.20)','multivariate','hypertension,No ACEI/ARB administration,urinary protein excretion','0.0016','cox','worse\r',NULL,NULL),(30000018,'14616762','Peroxisome proliferator-activated receptor γ (PPARγ) ','PPARG','PPARG C161T polymorphism','peroxisome proliferator activated receptor gamma','SNP (T)','blood','not mention','PCR-RFLP ','IgAN[without hypertension](106)','genotype ','CT/TT:CC','ESRD(when patients underwent first hemodialysis)','N','Kaplan-Meier ','N','univariate ','N','0.024','log-rank test ','better\r',NULL,NULL),(30000019,'14684698','ACE ','ACE','ACE A2350Gpolymorphism ','angiotensin I converting enzyme','SNP (AA)','blood','not mention','PCR','IgAN[who did receive treatment with ACE inhibitor or ARB](114)','genotype ','AA:AG/GG','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','Kaplan-Meier ','N','univariate ','N','0.0332','log-rank test ','worse\r',NULL,NULL),(30000020,'14684698','ACE ','ACE','ACE A2350Gpolymorphism ','angiotensin I converting enzyme','SNP (AA)','blood','not mention','PCR','IgAN(267)','genotype ','AA:AG/GG','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','1.599(1.033-2.475)','univariate ','N','0.0352','cox','worse\r',NULL,NULL),(30000021,'14684698','ACE ','ACE','ACE A2350Gpolymorphism ','angiotensin I converting enzyme','SNP (AA)','blood','not mention','PCR','IgAN(267)','genotype ','AA:AG/GG','PRD (the date when the sCr level was double that at the time of diagnosis or when patients underwent their first renal replacement therapy.)','N','HR','1.794(1.112-2.894)','multivariate','\"Urinary protein excretion,Hypertension,No administration',NULL,NULL,NULL,NULL,NULL),(30000022,'14990020','uteroglobin ','SCGB1A1','UteroglobinG38A polymorphism','secretoglobin family 1A member 1','SNP (AA)','blood','not mention','PCR-RFLP ','IgAN(300)','genotype ','AA:AG/GG','PRD','N','OR','2.37(1.12-5.01)','univariate ','N','＜0.01','chi-square test ','worse\r',NULL,NULL),(30000023,'15031629','angiotensinogen','AGT','angiotensinogen gene M235T polymorphism ','angiotensinogen','SNP (MM)','blood','not mention','PCR','IgAN(107)','genotype ','MM:MT/TT','end-stage renal disease or doubling of the initial serum creatinine ','N','Kaplan-Meier ','N','univariate ','N','＜0.05','log-rank test ','better\r',NULL,NULL),(30000024,'15730046','TGF-β1','TGFB1','TGF-β1 C-509T polymorphism:at the promoter region ','TGFB1','SNP (TT)','blood','not mention','PCR-RFLP ','IgAN(108)','genotype ','TT:CC/CT','ESRD','N','Kaplan-Meier ','N','univariate ','N','0.042','log-rank test ','worse\r',NULL,NULL),(30000025,'16029633','MUC20','MUC20','MUC20 VNTR polymorphism','mucin 20, cell surface associated','VNTR  (SL/LL)','blood','not mention','PCR','IgAN[followed up for 1-7 years](113)','genotype ','SL/LL:SS','ESRD','N','OR','7.29(1.68-31.60)','univariate ','N','0.008','cox','worse\r',NULL,NULL),(30000026,'16362156','Monocyte chemoattractant protein (MCP)-1 ','CCL2','MCP-1 A-2518G gene polymorphism','C-C motif chemokine ligand 2','SNP (AA)','peripheral leukocytes ','not mention','PCR','IgAN(277)','genotype ','AA:AG:GG','ESRD','N','Kaplan-Meier ','N','univariate ','N','0.0029','log-rank test ','worse\r',NULL,NULL),(30000027,'16362156','Monocyte chemoattractant protein (MCP)-1 ','CCL2','MCP-1 A-2518G gene polymorphism','C-C motif chemokine ligand 2','SNP (AA)','peripheral leukocytes ','not mention','PCR','IgAN(277)','genotype ','AA:AG/GG','ESRD','N','Kaplan-Meier ','N','univariate ','N','0.0006','log-rank test ','worse\r',NULL,NULL),(30000028,'16362156','Monocyte chemoattractant protein (MCP)-1 ','CCL2','MCP-1 A-2518G gene polymorphism','C-C motif chemokine ligand 2','SNP (AA)','peripheral leukocytes ','not mention','PCR','IgAN(277)','genotype ','AA:AG:GG','doubling of serum creatinine ','N','Kaplan-Meier ','N','univariate ','N','0.01','log-rank test ','worse\r',NULL,NULL),(30000029,'16362156','Monocyte chemoattractant protein (MCP)-1 ','CCL2','MCP-1 A-2518G gene polymorphism','C-C motif chemokine ligand 2','SNP (AA)','peripheral leukocytes ','not mention','PCR','IgAN(277)','genotype ','AA:AG/GG','doubling of serum creatinine ','N','Kaplan-Meier ','N','univariate ','N','0.0024','log-rank test ','worse\r',NULL,NULL),(30000030,'16362156','Monocyte chemoattractant protein (MCP)-1 ','CCL2','MCP-1 A-2518G gene polymorphism','C-C motif chemokine ligand 2','SNP (AA)','peripheral leukocytes ','not mention','PCR','IgAN(277)','genotype ','AA:AG/GG','ESRD','N','HR','2.058(1.092-3.876)','multivariate','Sex,Age at onset,Urinary protein excretion at biopsy,Glomerular filtration rate < 60ml/min,Presence of hypertension,Absence of ACEI/ARB administration','0.026','cox','worse\r',NULL,NULL),(30000031,'16395252','The chemokine (CK) receptor 5 (CCR5) ','CCR5','d32–CCR5 polymorphism ','C-C motif chemokine receptor 5','SNP (d32 )','blood','not mention','PCR,garose gel (Nusieve) stained','IgAN(318)','CCR5 polymorphism.','d32d32 /d32nl :nlnl ','renal/patient death event or censore （primary endpoint）','N','Kaplan-Meier ','N','univariate ','N','0.002','log-rank test ','worse\r',NULL,NULL),(30000032,'16395252','The chemokine (CK) receptor 5 (CCR5) ','CCR5','d32–CCR5 polymorphism ','C-C motif chemokine receptor 5','SNP (d32 )','blood','not mention','PCR,garose gel (Nusieve) stained','IgAN(318)','CCR5 polymorphism.','d32d32 /d32nl :nlnl ','CRF (＜60 ml/ min)event or censored（secondary endpoint）','N','Kaplan-Meier ','N','univariate ','N','0.03','log-rank test ','worse\r',NULL,NULL),(30000033,'16395252','The chemokine (CK) receptor 5 (CCR5) ','CCR5','d32–CCR5 polymorphism ','C-C motif chemokine receptor 5','SNP (nl)','blood','not mention','PCR,garose gel (Nusieve) stained','IgAN(318)','CCR5 polymorphism.','nlnl:d32d32 /d32nl ','ESRF ','N','HR','0.31 (0.15–0.65)','multivariate','Proteinuria/RB1,GOS1,CRF/RB1,Hypertension/RB1,Age at onset,Overweight/obesity:,Gender','0.002','cox','better\r',NULL,NULL),(30000034,'16395252','The chemokine (CK) receptor 5 (CCR5) ','CCR5','d32–CCR5 polymorphism ','C-C motif chemokine receptor 5','SNP (nl)','blood','not mention','PCR,garose gel (Nusieve) stained','IgAN(318)','CCR5 polymorphism.','nlnl:d32d32 /d32nl ','CRF (o60 ml/min) ','N','HR','0.57 (0.35–0.95)','multivariate','Proteinuria/RB1,GOS1,CRF/RB1,Hypertension/RB1,Age at onset,Overweight/obesity:,Gender','0.03','cox','better\r',NULL,NULL),(30000035,'16508246','MUC20 ','MUC20','MUC20 VNTR polymorphism','mucin 20, cell surface associated','VNTR  (SL/LL)','peripheral white blood cells of the whole blood samples ','not mention','PCR,1.5% agarose gel electrophoresis,sequencing','IgAN[followed up for 60.6±22.4 years](113)','genotype ','SL/LL:SS','ESRD or doubling of the initial serum creatinine ','N','Kaplan-Meier ','N','univariate ','N',' ＜0.001','log-rank test ','worse\r',NULL,NULL),(30000036,'16508246','MUC20 ','MUC20','MUC20 VNTR polymorphism','mucin 20, cell surface associated','VNTR  (SL/LL)','peripheral white blood cells of the whole blood samples ','not mention','PCR,1.5% agarose gel electrophoresis,sequencing','IgAN[followed up for 60.6±22.4 years](113)','genotype ','SL/LL:SS','ESRD or doubling of the initial serum creatinine ','N','OR','20.9(2.6–168.1)','multivariate','hypertension,chronic kidney disease stage,glomerular pathological scores ','0.004','cox','worse\r',NULL,NULL),(30000037,'16526314','Vascular endothelial growth factor (VEGF) ','VEGFA','VEGF-2578 genotype. ','vascular endothelial growth factor A','SNP (CC)','blood','not mention','PCR, electrophoresed through a 2% agarose gel.','IgAN(195)','genotype ','CC:CA/AA','kidney survival as measured by the time interval from renal biopsy to end-stage renal disease or the requirement of renal replacement therapy.','N','Kaplan-Meier ','N','univariate ','N','0.023','log-rank test ','worse\r',NULL,NULL),(30000038,'17338426',' Clara cell secretory protein (CC16)','SCGB1A1','CC16 G38A polymorphism','secretoglobin family 1A member 1 ','SNP (AA)','blood','not mention','PCR-RFLP ','IgAN(267)','genotype ','AA:AG:GG','doubling of serum creatinine (Scr) level or progression to end- stage renal disease requiring renal replace- ment therapy ','N','Kaplan-Meier ','N','univariate ','N','0.043','log-rank test ','worse\r',NULL,NULL),(30000039,'17338426',' Clara cell secretory protein (CC16)','SCGB1A1','CC16 G38A polymorphism','secretoglobin family 1A member 1 ','SNP (AA)','blood','not mention','PCR-RFLP ','IgAN(267)','genotype ','AA:AG/GG','doubling of serum creatinine (Scr) level or progression to end- stage renal disease requiring renal replace- ment therapy ','N','HR','2.344(1.185–4.638)','multivariate','Presence of hypertension,Initial creatinine (per 1 mg/dl),Proteinuria* (3 3.0 g/day)','0.014','cox','worse\r',NULL,NULL),(30000040,'18793525','Megsin','SERPINB7','Megsin C2093T polymorphism','serpin family B member 7','SNP (CC)','blood','not mention','Taqman assay,PCR,DNA sequencing','IgAN(260)','genotype ','CC:CT/TT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','0.027','log-rank test ','better\r',NULL,NULL),(30000041,'18793525','Megsin','SERPINB7','Megsin C2180T polymorphism','serpin family B member 7','SNP (TT)','blood','not mention','Taqman assay,PCR,DNA sequencing','IgAN(260)','genotype ','TT:CC/CT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','0.025','log-rank test ','better\r',NULL,NULL),(30000042,'18793525','Megsin','SERPINB7','Megsin C2093T-C2180T haplotype:3\'UTR','serpin family B member 7','haplotype (TC)','blood','not mention','Taqman assay,PCR,DNA sequencing,PHASE PROGRAME','IgAN(260)','genotype ','TC:CT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','0.028','log-rank test ','worse\r',NULL,NULL),(30000043,'18793525','Megsin','SERPINB7','Megsin C2093T polymorphism','serpin family B member 7','SNP (TT)','blood','not mention','Taqman assay,PCR,DNA sequencing','IgAN(260)','genotype ','TT:CC/CT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','HR','3.52(1.69–7.34)','multivariate','prensence of hypertension,proteinuria(＞3.0g/day),initial creatine(per 1mg/dl)','0.001','cox','worse\r',NULL,NULL),(30000044,'18793525','Megsin','SERPINB7','Megsin C2093T polymorphism','serpin family B member 7','SNP (CT)','blood','not mention','Taqman assay,PCR,DNA sequencing','IgAN(260)','genotype ','CT:CC/TT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','HR','2.15(1.30–3.57)','multivariate','prensence of hypertension,proteinuria(＞3.0g/day),initial creatine(per 1mg/dl)','0.003','cox','worse\r',NULL,NULL),(30000045,'18793525','Megsin','SERPINB7','Megsin C2180T polymorphism','serpin family B member 7','SNP (CC)','blood','not mention','Taqman assay,PCR,DNA sequencing','IgAN(260)','genotype ','CC:CT/TT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','HR','4.05(1.93–8.51)','multivariate','prensence of hypertension,proteinuria(＞3.0g/day),initial creatine(per 1mg/dl)','0','cox','worse\r',NULL,NULL),(30000046,'18793525','Megsin','SERPINB7','Megsin C2180T polymorphism','serpin family B member 7','SNP (CT)','blood','not mention','Taqman assay,PCR,DNA sequencing','IgAN(260)','genotype ','CT:CC/TT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','HR','2.35(1.40–3.97)','multivariate','prensence of hypertension,proteinuria(＞3.0g/day),initial creatine(per 1mg/dl)','0.001','cox','worse\r',NULL,NULL),(30000047,'18793525','Megsin','SERPINB7','Megsin C2093T-C2180T haplotype:3\'UTR','serpin family B member 7','haplotype (TC)','blood','not mention','Taqman assay,PCR,DNA sequencing,PHASE PROGRAME','IgAN(260)','genotype ','TC:CT','doubling of the initial Sc or progression to ESRD requiring renal replacement therapy ','N','HR','2.010(1.438–2.808)','multivariate','prensence of hypertension,proteinuria(＞3.0g/day),initial creatine(per 1mg/dl)','0','cox','worse\r',NULL,NULL),(30000048,'19194560','Angiotensin II type 2 receptor (AT2R) ','AGTR2','Angiotensin II Type 2 Receptor Gene A1818T Polymorphism:intron 2 ','angiotensin II receptor type 2','SNP (T)','blood','not mention','PCR-RFLP,DNA sequecing','IgAN(480)','with or without T','with:without','an increase of serum creatinine level by more than 50% of baseline value or initiation of renal replacement therapy for the end stage renal diseas ','N','Kaplan-Meier ','N','univariate ','N','0.0236','log-rank test ','better\r',NULL,NULL),(30000049,'19194560','Angiotensin II type 2 receptor (AT2R) ','AGTR2','Angiotensin II Type 2 Receptor Gene A1818T Polymorphism:intron 2 ','angiotensin II receptor type 2','SNP (T)','blood','not mention','PCR-RFLP,DNA sequecing','IgAN(480)','with or without T','with:without','an increase of serum creatinine level by more than 50% of baseline value or initiation of renal replacement therapy for the end stage renal diseas ','N','Exp (B) ','0.309(0.111–0.862)','univariate ','N','0.025','cox','better\r',NULL,NULL),(30000050,'19194560','Angiotensin II type 2 receptor (AT2R) ','AGTR2','Angiotensin II Type 2 Receptor Gene A1818T Polymorphism:intron 2 ','angiotensin II receptor type 2','SNP (T)','blood','not mention','PCR-RFLP,DNA sequecing','IgAN(480)','with or without T','with:without','an increase of serum creatinine level by more than 50% of baseline value or initiation of renal replacement therapy for the end stage renal diseas ','N','Exp (B) ','0.221(0.052–0.940)','multivariate','age, sex, serum creatinine level, the degree of proteinuria ','0.041','cox','better\r',NULL,NULL),(30000051,'27450519','not mention','','rs 2856717 ','','SNP (CC)','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN[followed up for 44.49±19.94 years](315)','genotype ','CC:TT/TC','a doubling of serum creatinine levels compared to the levels measured at renal biopsy, a need for renal replacement therapy or death','N','Kaplan-Meier ','N','univariate ','N','0.046','log-rank test ','better\r',NULL,NULL),(30000052,'27450519','not mention','','rs 2856717 ','','SNP (TT/TC)','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN[followed up for 44.49±19.94 years](315)','genotype ','TT/TC:CC','eGFR decline≥50% ','N','RR','1.8(1.78–3.46)','multivariate','age,hypertension,GFR ≤ 60 mL/min','0.01','cox','worse\r',NULL,NULL),(30000053,'19729965','angiotensinogen (AGT)','AGT','AGT M235T','angiotensinogen','SNP (TT)','blood','not mention','TaqMan PCR, DNA sequencing','IgAN[male](130)','genotype ','TT:MM/MT',' doubling of Cr or progression to ESRD ','N','Kaplan-Meier ','N','univariate ','N','0.01','log-rank test ','worse\r',NULL,NULL),(30000054,'19729965','angiotensinogen (AGT)','AGT','AGT M235T','angiotensinogen','SNP (TT)','blood','not mention','TaqMan PCR, DNA sequencing','IgAN[male](130)','genotype ','TT:MM/MT',' doubling of Cr or progression to ESRD ','N','HR','5.704(1.578–20.618)','multivariate','age at diagnosis, hypertension, serum creatinine and urinary protein excretion at renal biopsy','0.008','cox','worse\r',NULL,NULL),(30000055,'19967654','TGF-β1','TGFB1','TGF-β1 T869C (COD 10) ','TGFB1','SNP (CC)','blood','not mention','PCR, electrophoresed through an agarose gel.','IgAN(105)','genotype ','CC:TT/TC','ESRD or creatinine doubling','N','Kaplan-Meier ','7.81','univariate ','N','0.009','log-rank test ','better\r',NULL,NULL),(30000056,'19967654','TGF-β1','TGFB1','TGF-β1 T869C (COD 10) ','TGFB1','SNP (CT/TT)','blood','not mention','PCR, electrophoresed through an agarose gel.','IgAN(105)','genotype ','TT/TC:CC','ESRD or creatinine doubling','N','OR','19.5(1.6-131.9)','multivariate','Sex (male),Age,SCr (≥1.4 in males, ≥1.2 in females),UProt (<1 g/24 hours),Hypertension,ACE-Is /ARBs','0.018','cox','worse\r',NULL,NULL),(30000057,'21429967','epoxide hydrolase (EPHX2)','EPHX2','rs751141 (R287Q; G＞A) ','epoxide hydrolase 2','SNP (AA/AG)','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','genotype ','AA/AG:GG','ESRD requiring renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','＜0.001','log-rank test ','better\r',NULL,NULL),(30000058,'21429967','epoxide hydrolase (EPHX2)','EPHX2','rs751141 (R287Q; G＞A) ','epoxide hydrolase 2','SNP (AA/AG)','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN[eGFR＞60](257)','genotype ','AA/AG:GG','ESRD requiring renal replacement therapy ','N','Kaplan-Meier ','N','univariate ','N','0.024','log-rank test ','better\r',NULL,NULL),(30000059,'21429967','epoxide hydrolase (EPHX2)','EPHX2','rs751141 (R287Q; G＞A) ','epoxide hydrolase 2','SNP (GG)','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','genotype ','GG:AA/AG','ESRD requiring renal replacement therapy ','N','HR','2.10(1.35–3.25)','univariate ','N','0.001','cox','worse\r',NULL,NULL),(30000060,'21429967','epoxide hydrolase (EPHX2)','EPHX2','rs751141 (R287Q; G＞A) ','epoxide hydrolase 2','SNP (GG)','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','genotype ','GG:AA/AG','ESRD requiring renal replacement therapy ','N','HR','2.07(1.33–3.21)','multivariate','age,gender','0.001','cox','worse\r',NULL,NULL),(30000061,'21429967','epoxide hydrolase (EPHX2)','EPHX2','rs751141 (R287Q; G＞A) ','epoxide hydrolase 2','SNP (GG)','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','genotype ','GG:AA/AG','ESRD requiring renal replacement therapy ','N','HR','2.02(1.29–3.17)','multivariate','age, gender, hypertension, diabetes mellitus','0.002','cox','worse\r',NULL,NULL),(30000062,'21429967','epoxide hydrolase (EPHX2)','EPHX2','rs751141 (R287Q; G＞A) ','epoxide hydrolase 2','SNP (GG)','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','genotype ','GG:AA/AG','ESRD requiring renal replacement therapy ','N','HR','1.83(1.13–2.96)','multivariate','age, gender, hypertension, diabetes mellitus, initial proteinuria','0.014','cox','worse\r',NULL,NULL),(30000063,'21429967','epoxide hydrolase (EPHX2)','EPHX2','rs751141 (R287Q; G＞A) ','epoxide hydrolase 2','SNP (GG)','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN[eGFR＞60](257)','genotype ','GG:AA/AG','ESRD requiring renal replacement therapy ','N','HR','2.45(1.14–5.24)','multivariate','age, gender, Initial eGFR,Initial proteinuria,hypertension,diabetes mellitus','0.021','cox','better\r',NULL,NULL),(30000064,'23147162','Klotho ','KL','Klotho G395A','klotho','SNP (GG)','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(973)','genotype ','GG:AA/AG','ESRD','N','Kaplan-Meier ','N','univariate ','N','0.04','log-rank test ','better\r',NULL,NULL),(30000065,'25973081','mannose-binding lectin (MBL) ','MBL2','SNP in condon 54 of exon region of MBL gene:in condon 54 of exon region','mannose binding lectin 2','SNP (mutant)','peripheral venous blood ','not mention','semi-nest- ed ampli cation,capillary electrophoresis sequencing,','IgAN(131)','genotype ','mutant:wild','ESRD','N','Kaplan-Meier ','N','univariate ','N','0.005','log-rank test ','worse\r',NULL,NULL),(30000066,'25973081','mannose-binding lectin (MBL) ','MBL2','SNP in condon 54 of exon region of MBL gene:in condon 54 of exon region','mannose binding lectin 2','SNP (mutant)','peripheral venous blood ','not mention','semi-nest- ed ampli cation,capillary electrophoresis sequencing,','IgAN(131)','genotype ','mutant:wild','ESRD','N','β','2.46','multivariate','initial Scr,DBP,TID','0.033','log-rank test ','worse\r',NULL,NULL),(30000067,'15610230','Chemokine receptor 5 (CCR5) ','CCR5','CCR5 delta 32','C-C motif chemokine receptor 5 (gene/pseudogene)','genotype (mutant)','blood','not mention','PCR,automatic DNA sequencing and showed re- sults identical to the gel electrophoresis analysis ','IgAN[with available demographic and clinical follow-up data](190)','genotype ','mutant:wild','ESRD','N','Kaplan-Meier ','N','univariate ','N','< 0.001 ','log-rank test ','better\r',NULL,NULL),(30000068,'15610230','Chemokine receptor 5 (CCR5) ','CCR5','CCR5 delta 32','C-C motif chemokine receptor 5 (gene/pseudogene)','genotype (mutant)','blood','not mention','PCR,automatic DNA sequencing and showed re- sults identical to the gel electrophoresis analysis ','IgAN[with available demographic and clinical follow-up data](190)','genotype ','mutant:wild','ESRD','N','HR','0.29 (0.13–0.62) ','univariate ','N','0.001','cox','better\r',NULL,NULL),(30000069,'15610230','Chemokine receptor 5 (CCR5) ','CCR5','CCR5 delta 32','C-C motif chemokine receptor 5 (gene/pseudogene)','genotype (mutant)','blood','not mention','PCR,automatic DNA sequencing and showed re- sults identical to the gel electrophoresis analysis ','IgAN[with available demographic and clinical follow-up data](190)','genotype ','mutant:wild','ESRD','N','HR','0.23 (0.09–0.57) ','multivariate','Serum creatinine,Proteinuria >1 g/24 hours,Hypertension,Gender,Age','0.002','cox','better\r',NULL,NULL),(30000070,'19420105','GPIa ','ITGA2','GPIa C807T ','integrin subunit alpha 2','SNP (TT)','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','TT:CC/CT','a 50% increase of serum creatinine level and slope of eGFR) ','N','Kaplan-Meier ','N','univariate ','N','0.0005','log-rank test ','worse\r',NULL,NULL),(30000071,'19420105','GPIa ','ITGA2','GPIa C807T ','integrin subunit alpha 2','SNP (TT)','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','TT:CC/CT','a 50% increase of serum creatinine level and slope of eGFR) ','N','Kaplan-Meier ','N','multivariate','adjusted for multiple comparisons by the method of Bonferroni. ','0.0174','log-rank test ','worse\r',NULL,NULL),(30000072,'19420105','ICAM-1 ','ICAM1','ICAM-1 A1548G (K469E) ','intercellular adhesion molecule 1','SNP (GG)','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','GG:AA/AG','a 50% increase of serum creatinine level and slope of eGFR) ','N','Kaplan-Meier ','N','univariate ','N','0.0013','log-rank test ','worse\r',NULL,NULL),(30000073,'19420105','ICAM-1 ','ICAM1','ICAM-1 A1548G (K469E) ','intercellular adhesion molecule 1','SNP (GG)','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','GG:AA/AG','a 50% increase of serum creatinine level and slope of eGFR) ','N','Kaplan-Meier ','N','multivariate','adjusted for multiple comparisons by the method of Bonferroni. ','0.043','log-rank test ','worse\r',NULL,NULL),(30000074,'19420105','ACE ','ACE','ACE I/D ','angiotensin I converting enzyme','SNP (DD )','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','DD:ID/II','a 50% increase of serum creatinine level and slope of eGFR) ','N','Kaplan-Meier ','N','univariate ','N','0.0177','log-rank test ','worse\r',NULL,NULL),(30000075,'19420105','PGC-1α','PPARGC1A','PGC-1 G1564A (G482S) ','PPARG coactivator 1 alpha','SNP (GG)','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','GG:AA/AG','a 50% increase of serum creatinine level and slope of eGFR) ','N','Kaplan-Meier ','N','univariate ','N','0.0193','log-rank test ','worse\r',NULL,NULL),(30000076,'19420105','GPIa ','ITGA2','GPIa C807T ','integrin subunit alpha 2','SNP (TT)','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','TT:CC','a 50% increase of serum creatinine level and slope of eGFR) ','N','HR','2.29 (1.32–3.99) ','univariate ','N','0.003','cox','worse\r',NULL,NULL),(30000077,'19420105','GPIa ','ITGA2','GPIa C807T ','integrin subunit alpha 2','SNP (TT)','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','TT:CC','a 50% increase of serum creatinine level and slope of eGFR) ','N','HR','2.05 (1.13–3.71) ','multivariate','baseline clinical characteristics (facility, age, gender, body mass index, use of antihypertensives, eGFR and urine protein), therapeutic interventions within 1 year of diagnosis (use of RAAS blockers and corticosteroid/immunosuppressants) ,genotypes of ICAM-1 A1548G (1548AA, AG and GG).','0.018','cox','worse\r',NULL,NULL),(30000078,'19420105','ICAM-1 ','ICAM1','ICAM-1 A1548G ','intercellular adhesion molecule 1','SNP (GG)','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','GG:AA','a 50% increase of serum creatinine level and slope of eGFR) ','N','HR','2.25 (1.29–3.92) ','univariate ','N','0.004','cox','worse\r',NULL,NULL),(30000079,'19420105','ICAM-1 ','ICAM1','ICAM-1 A1548G ','intercellular adhesion molecule 1','SNP (GG)','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','GG:AA','a 50% increase of serum creatinine level and slope of eGFR) ','N','HR','2.55 (1.40–4.65) ','univariate ','baseline clinical characteristics (facility, age, gender, body mass index, use of antihypertensives, eGFR and urine protein), therapeutic interventions within 1 year of diagnosis (use of RAAS blockers and corticosteroid/immunosuppressants) ,genotypes of GPIa C807T (807CC, CT and CT) ','0.002','cox','worse\r',NULL,NULL),(30000080,'19420105','GPIa ','ITGA2','GPIa C807T ','integrin subunit alpha 2','SNP (TT)','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','TT:CC','N','slope of eGFR ','β-coeff icient ','−1.98 ','multivariate','baseline clinical characteristics (facility, age, gender, body mass index, systolic blood pressure, use of antihypertensives, eGFR and urine protein), therapeutic interventions within 1 year of diagnosis (use of RAAS blockers and corticosteroid/immunosuppressants) and genotypes of ICAM-1 A1548G (1548AA, AG and GG).','0.031','linear regression model ','worse\r',NULL,NULL),(30000081,'19420105','ICAM-1 ','ICAM1','ICAM-1 A1548G ','intercellular adhesion molecule 1','SNP (GG)','Venous blood ','not mention','a fluorescence- or colorimetry-based allele-specific DNA primer probe assay system (Toyobo Gene Analysis) as described in detail by Yamada et al ','IgAN(320)','genotype ','GG:AA','N','slope of eGFR ','β-coeff icient ','−2.21 ','multivariate','baseline clinical characteristics (facility, age, gender, body mass index, systolic blood pressure, use of antihypertensives, eGFR and urine protein), therapeutic interventions within 1 year of diagnosis (use of RAAS blockers and corticosteroid/immunosuppressants) and genotypes of GPIa C807T (807CC, CT and CT) ','0.016','linear regression model ','worse\r',NULL,NULL),(30000082,'21150220','CMA ','CMA1','rs1800875 ','chymase 1','SNP (AA/AG )','blood','not mention','TaqMan PCR method,DNA sequencing','IgAN(261)','genotype ','AA/AG:GG','doubling of baseline serum creatinine (Cr) concentration or the development of ESRD requiring renal replacement therapy. ','N','Kaplan-Meier ','N','univariate ','N','0.04','log-rank test ','worse\r',NULL,NULL),(30000083,'21150220','CMA ','CMA1','rs1800876 ','chymase 1','SNP (CC/CT)','blood','not mention','TaqMan PCR method,DNA sequencing','IgAN(261)','genotype ','CC/CT:TT','doubling of baseline serum creatinine (Cr) concentration or the development of ESRD requiring renal replacement therapy. ','N','Kaplan-Meier ','N','univariate ','N','0.035','log-rank test ','worse\r',NULL,NULL),(30000084,'21150220','CMA ','CMA1','rs1800875 ','chymase 1','SNP (AA/AG )','blood','not mention','TaqMan PCR method,DNA sequencing','IgAN(261)','genotype ','AA/AG:GG','doubling of baseline serum creatinine (Cr) concentration or the development of ESRD requiring renal replacement therapy. ','N','HR','2.351 (1.414–3.908) ','multivariate','hypertension, higher glomerular grades, advanced tubulointerstitial lesions, a urinary pro- tein excretion of more than 1.5 g/day, an elevated baseline,serum Cr level','0.001','cox','worse\r',NULL,NULL),(30000085,'21245129','MYH9 ','MYH9','rs11089788 ','myosin heavy chain 9','SNP (AA/AC)','blood ','not mention','TaqMan assay or a restriction fragment length polymorphism assay ','IgAN[regularly followed and the mean follow-up duration was 31.3±17.7 months](384)','genotype ','AA/AC:CC','ESRD','N','HR','3.95(1.23–12.63)','multivariate','time-average proteinuria,serum creatinine,Haas','0.021','cox','worse\r',NULL,NULL),(30000086,'24452035','ACE ','ACE','ACE insertion/deletion polymorphism (rs1799752) ','angiotensin I converting enzyme','SNP (DD )','blood','not mention','PCR','IgAN(237)','genotype ','DD:ID/II','50% increase in serum creatinine level ','N','HR','1.97 (1.15-3.40) ','multivariate','facility ','0.014','cox','worse\r',NULL,NULL),(30000087,'24452035','ACE ','ACE','ACE insertion/deletion polymorphism (rs1799752) ','angiotensin I converting enzyme','SNP (DD )','blood','not mention','PCR','IgAN(237)','genotype ','DD:ID/II','50% increase in serum creatinine level ','N','HR','1.86 (1.03, 3.33) ','multivariate','facility, clinical characteristics at kidney biopsy (age, gender, smoking status, hyperten- sion, eGFR, urinary protein, and urinary occult blood); ACE I/D and therapeutic interventions within one year of kidney biopsy (RAS blockade and use of immunosuppressants) ','0.038','cox','worse\r',NULL,NULL),(30000088,'27358498','DEFA1A3','DEFA1A3','DEFA1A3 CNV','defensin alpha 1 and alpha 3, variable copy number locus','CNV','blood','not mention',' PRT-based methods ','IgAN[had follow-up information with a median follow-up time of 4.5 years](382)',' the quintile of their GS values','Q1:Q2:Q3:Q4:Q5','ESRD or doubling of serum creat- inine after diagnosis','N','Kaplan-Meier ','N','univariate ','N','0.0008','log-rank test ','better\r',NULL,NULL),(30000089,'27358498','DEFA1A3','DEFA1A3','DEFA1A3 CNV','defensin alpha 1 and alpha 3, variable copy number locus','CNV','blood','not mention',' PRT-based methods ','IgAN[had follow-up information with a median follow-up time of 4.5 years](382)','N','N ','ESRD or doubling of serum creat- inine after diagnosis','N','HR','0.78 (0.66–0.92)','univariate ','N','0.004','cox','better\r',NULL,NULL),(30000090,'27358498','DEFA1A3','DEFA1A3','DEFA1A3 CNV','defensin alpha 1 and alpha 3, variable copy number locus','CNV','blood','not mention',' PRT-based methods ','IgAN[had follow-up information with a median follow-up time of 4.5 years](382)','N','N ','ESRD or doubling of serum creat- inine after diagnosis','N','HR','0.79 (0.66–0.95)','multivariate','age, gender, proteinuria, hypertension, and serum creatinine at biopsy','0.012','cox','better\r',NULL,NULL),(30000091,'27358498','DEFA1A3','DEFA1A3','DEFA1A3 CNV','defensin alpha 1 and alpha 3, variable copy number locus','CNV','blood','not mention',' PRT-based methods ','IgAN[had follow-up information with a median follow-up time of 4.5 years](382)',' the quintile of their GS values','Q1:Q5','ESRD or doubling of serum creat- inine after diagnosis','N','HR','5.60 (1.84–17.05)','univariate ','N','0.002','cox','better\r',NULL,NULL),(30000092,'27358498','DEFA1A3','DEFA1A3','DEFA1A3 CNV','defensin alpha 1 and alpha 3, variable copy number locus','CNV','blood','not mention',' PRT-based methods ','IgAN[had follow-up information with a median follow-up time of 4.5 years](382)',' the quintile of their GS values','Q1:Q5','ESRD or doubling of serum creat- inine after diagnosis','N','HR','3.69 (1.16–11.82)','multivariate','age, gender, proteinuria, hypertension, and serum creatinine at biopsy','0.028','cox','better\r',NULL,NULL),(30000093,'26045217','NCX1','SLC8A1','rs11893826','solute carrier family 8 member A1','genotype (AA/AG)','blood','not mention','5′ nuclease allelic discrimination assays, with allele- speci c MGB probes','LN(55)','genotype ','AA/AG:GG','relapse during follow-up','N','Kaplan-Meier ','16.082','multivariate','therapeutic regimen used at induction',' < 0.001','log-rank test ','worse\r',NULL,NULL),(30000094,'26045217','NCX1','SLC8A1','rs434082','solute carrier family 8 member A1','genotype (GG)','blood','not mention','5′ nuclease allelic discrimination assays, with allele- speci c MGB probes','LN(55)','genotype ','GG:AA/AG','sustained CR','N','Kaplan-Meier ','3.92','multivariate','the presence of hypertension ;the therapeutic regimen chosen at induction','0.048','log-rank test ','better\r',NULL,NULL),(30000095,'24658608','MYH9 ','MYH9','E1 haplotype','myosin heavy chain 9','genotype (GCCT)','blood','not mention','PCR','LN(196)','genotype ','GCCT:no-GCCT','doubling of serum creatinine (DC) or end stage renal disease (ESRD)','N','Kaplan-Meier ','N','univariate ','N','0.02','log-rank test ','worse\r',NULL,NULL),(30000096,'24658608','MYH9 ','MYH9','E1 haplotype','myosin heavy chain 9','genotype (GCCT)','blood','not mention','PCR','LN(196)','genotype ','GCCT:no-GCCT','doubling of serum creatinine (DC) or end stage renal disease (ESRD)','N','HR','1.8 (1.1–2.9)','univariate ','N','0.02','cox','worse\r',NULL,NULL),(30000097,'24658608','MYH9 ','MYH9','E1 haplotype','myosin heavy chain 9','genotype (GCCT)','blood','not mention','PCR','LN(196)','genotype ','GCCT:no-GCCT','doubling of serum creatinine (DC) or end stage renal disease (ESRD)','N','HR','2.0 (1.2–3.4)','multivariate','MDRD, hypertension ,african autossomal ancestry','0.01','cox','worse\r',NULL,NULL),(30000098,'24658608','MYH9 ','MYH9','rs3752462','myosin heavy chain 9','genotype (TC/TT)','blood','not mention','PCR','LN(196)','genotype ','TC/TT:CC','doubling of serum creatinine (DC) or end stage renal disease (ESRD)','N','HR','2.89 (1.31–6.36)','univariate ','N','0.008','cox','worse\r',NULL,NULL),(30000099,'24658608','MYH9 ','MYH9','rs3752462','myosin heavy chain 9','genotype (TC/TT)','blood','not mention','PCR','LN(196)','genotype ','TC/TT:CC','doubling of serum creatinine (DC) or end stage renal disease (ESRD)','N','HR','3.72 (1.47–9.38)','multivariate','MDRD, hypertension ,african autossomal ancestry','0.005','cox','worse\r',NULL,NULL),(30000100,'14767013','ACE','ACE','ACE I/D（The 287 bp insertion/deletion (I/D) polymorphism in intron 16 of the ACE gene）','angiotensin I converting enzyme','SNP (DD+ID/aa+ab)','blood','not mention','PCR-RFLP ','IMN(117)','genotype ','DD+ID/aa+ab: II/bb','s-Cr doubled and RDT','N','Kaplan-Meier ','N','univariate ','N','0.028','log-rank test ','worse\r',NULL,NULL),(30000101,'14767013','AII receptor 1','AGTR1','AT1R 1166A/C (The A/C transversion at base 1166 in the 3’untranslated region of the AT1R gene)','angiotensin II receptor type 1','SNP ','blood','not mention','PCR-RFLP ','IMN(118)','genotype ','','s-Cr doubled and RDT','N','Kaplan-Meier ','N','univariate ','N','','','\r',NULL,NULL),(30000102,'14767013','AGT','AGT','AGT M235T(The C/T transition in exon 2 of the AGT gene)','angiotensinogen ','SNP (TT+MT/aa+ab)','blood','not mention','PCR-RFLP ','IMN(119)','genotype ','TT+MT/aa+ab:MM/bb','s-Cr doubled and RDT','N','Kaplan-Meier ','N','univariate ','N','0.024','log-rank test ','worse\r',NULL,NULL),(30000103,'14767013','NOS','NOS3','ecNOS4b/a(The 27 bp variable number of tandem repeats polymorphism in intron 4 of the ecNOS gene)','nitric oxide synthase 3','SNP ','blood','not mention','PCR-RFLP ','IMN(120)','genotype ','','s-Cr doubled and RDT','N','Kaplan-Meier ','N','univariate ','N','','','\r',NULL,NULL),(30000104,'20937089','PLA2R1 ','PLA2R1','rs35771982/rs6757188','phospholipase A2 receptor 1','SNP ','blood','not mention','TaqMan,PCR-RFLP ','IMN(129)','genotype ','G:C','N','N','OR','1.900 (1.209–2.987)','univariate ','N','0.005','unconditional logistic regression','worse\r',NULL,NULL),(30000105,'20937089','PLA2R1 ','PLA2R1','rs6757188','phospholipase A2 receptor 1','SNP ','blood','not mention','TaqMan,PCR-RFLP ','IMN(129)','rs6757188 （T）+rs35771982 （G）','N','N','N','OR','1.647 (1.140–2.379)','univariate ','N','0.004','unconditional logistic regression','worse\r',NULL,NULL),(30000106,'20937089','PLA2R1 ','PLA2R1','rs6757188','phospholipase A2 receptor 1','SNP ','blood','not mention','TaqMan,PCR-RFLP ','IMN(129)','rs6757188 （T）+rs35771982 （C）','','N','N','OR','0.581 (0.368–0.919)','univariate ','N','0.004','unconditional logistic regression','better\r',NULL,NULL),(30000110,'24262501','PLA2R1 ','PLA2R1','rs4664308','phospholipase A2 receptor 1','SNP ','blood','not mention','TaqMan','IMN(89)','genotype ','GG/AG:AA','N','N','OR','2(1.23,3.23)','univariate ','N','0.005','N','worse\r',NULL,NULL),(30000111,'24262501','HLA-DQA1','HLA-DQA1','rs2187668','major histocompatibility complex, class II, DQ alpha 1','SNP ','blood','not mention','TaqMan','IMN(89)','genotype ','AA/AG:GG','N','N','OR','3.7(2.256.08)','univariate ','N','<0.001 ','N','worse\r',NULL,NULL),(30000112,'24262501','HLA-DQA1','HLA-DQA1','rs2187668','major histocompatibility complex, class II, DQ alpha 1','SNP ','blood','not mention','TaqMan','IMN(89)','genotype ','GG:AA/AG','doubling of serum creatinine','N','Kaplan-Meier ','N','univariate ','N','0.05','log-rank test ','worse\r',NULL,NULL),(30000114,'23964786','TLR9','TLR9',' rs352139 ','toll like receptor 9','SNP','blood','not mention','TaqMan','IMN(91)','genotype ','AA:GA/GG','developing MGN','N','OR','1.55 (1.02–2.35)','univariate ','N','0.04','logistic regression','worse\r',NULL,NULL),(30000115,'23964786','TLR9','TLR9','rs352140','toll like receptor 9','SNP','blood','not mention','TaqMan','IMN(91)','genotype ','GG:GA/AA','developing MGN','N','OR','1.57 (1.03–2.39)','univariate ','N','0.034','logistic regression','worse\r',NULL,NULL),(30000122,'15200436','IL-10','IL-10','G-1082A','Interleukin 10','SNP (GG)','\"Whole blood',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(30000123,'15200436','IL-10','IL-10','G-1082A','Interleukin 10','SNP (GG)','\"Whole blood',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(30000124,'21777344','CYP11B2','CYP11B2','C-344T','Cytochrome P450 Family 11 Subfamily B Member 2 ','SNP (TT)','whole blood samples','not mention','PCR','FSGS(81)','genotype ','TT:CC/CT','stage V of chronic kidney disease','N','Kaplan–Meier method','N','univariate ','N','0.027','log-rank test (Mantel-Cox)','better\r',NULL,NULL),(30000125,'21997394','APOL1','APOL1','G1,G2','Apolipoprotein L1','SNP (G1G1)','whole blood samples','not mention','TaqMan assays ','FSGS(92)','genotype ','G1G1:G1G2/G2G2','ESRD','N','Kaplan-Meier','N','univariate ','N','＜0.01','log-rank test (Mantel-Cox)','worse\r',NULL,NULL),(30000126,'25573908','APOL1','APOL1','G1,G2','Apolipoprotein L1','SNP (G1,G2)','whole blood samples','not mention','Taqman assay','FSGS(138)','genotype ','G1G1:G1G2/G2G2','ESRD','N','Kaplan-Meier','N','univariate ','N','0.002','log-rank test (Mantel-Cox)','worse\r',NULL,NULL),(30000127,'19546528','ACE ,eNOS','ACE,NOS3','Angiotensin-converting enzyme (ACE) I/D polymorphism ,eNOS G894T Gene Variants','angiotensin I converting enzyme,nitric oxide synthase 3','SNP (DD,GG)','blood','not mention','PCR,electrophoresed through an agarose gel.','IgAN(64)','genotype(ACE I/D + eNOS G894T)','(DD+GG):other','30% decrease of creatinine clearance ','N','HR','8.4(2.45–29.10)','multivariate','Baseline MAP','0.001','cox','worse\r',NULL,NULL),(30000128,'19546528','ACE ,eNOS','ACE,NOS3','Angiotensin-converting enzyme (ACE) I/D polymorphism ,eNOS G894T Gene Variants','angiotensin I converting enzyme,nitric oxide synthase 3','SNP (DD,GG)','blood','not mention','PCR,electrophoresed through an agarose gel.','IgAN(64)','genotype(ACE I/D + eNOS G894T)','(DD+GG):other','30% decrease of creatinine clearance ','N','HR','5.9(1.98–17.76)','univariate ','N','0.001','cox','worse\r',NULL,NULL),(30000129,'21429967','epoxide hydrolase (EPHX2)','EPHX2','rs751141 (R287Q; G＞A) ,rs1042032 ','epoxide hydrolase 2','SNP (A,G)','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','haplotype (rs751141+ rs1042032 )  ','other:(GG+AA)','ESRD requiring renal replacement therapy ','N','HR','0.45 (0.29–0.71)','univariate ','N','＜0.001','cox','better\r',NULL,NULL),(30000130,'21429967','epoxide hydrolase (EPHX2)','EPHX2','rs751141 (R287Q; G＞A) ,rs1042032 ','epoxide hydrolase 2','SNP (A,G)','blood','not mention','TaqMan allelic discrimination assay,PCR,','IgAN(401)','haplotype (rs751141+ rs1042032 )  ','other:(GG+AA)','ESRD requiring renal replacement therapy ','N','HR','0.45 (0.29–0.71)','multivariate','age,gender ','＜0.001','cox','better\r',NULL,NULL),(30000131,'19357720','C1GALT1,ST6GALNAC2  ','C1GALT1,ST6GALNAC2','YATIG, YAGDA, YATDG,OTHERS,ADG ,OTHERS','core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1,ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2','SNP','blood','not mention','PCR, sequence','IgAN(401)','haplotype (rs751141+ rs1042032 )  ','other:(GG+AA)','ESRD requiring renal replacement therapy ','N','HR','0.52 (0.32–0.84)','multivariate','age, gender, hypertension, diabetes mellitus, initial proteinuria','0.001','cox','better\r',NULL,NULL),(30000132,'12911556','angiotensinogen gene (AGT) ','AGT','AGT A(-20)C,AGT M235T:in the 5 upstream region of the core promoter in the AGT gene,exon 2 ','angiotensinogen','SNP','','','','IgAN[with follow-up data were recruited for renal survival analysis](119)','haplotype (C1GALT1 ※ ST6GALNAC2 )  ','ATDG (C1GALT1) * ADG (ST6GALNAC2) :ATIG (C1GALT1) * Others (ST6GALNAC2)/ATIG (C1GALT1) * ADG (ST6GAL','ESRD','N','Kaplan-Meier ','N','univariate ','N','0.022','log-rank test ','worse\r',NULL,NULL),(40000001,'24811838','uwGRS9 ','Calculating formula','','','Calculating formula','serum ','not mention','was the simple counts of the total number of risk alleles rather than weighting by the effect of each SNP, as the current data available may be insufficient to provide stable estimates for each effect','IgAN(1194)','16','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','0.00791','log-rank test ','worse\r',NULL,NULL),(40000002,'24811838','uwGRS9 ','Calculating formula','','','Calculating formula','serum ','not mention','was the simple counts of the total number of risk alleles rather than weighting by the effect of each SNP, as the current data available may be insufficient to provide stable estimates for each effect','IgAN(1194)','16','H:L','ESRD','N','RR','2.52(1.29-4.91)','univariate','N','0.00668','cox','worse\r',NULL,NULL),(40000003,'16523423','clinical prognostic index (CPI) ','Calculating formula','','','Calculating formula','','','','IgAN[from Modena](237)','scores 0-2:L; scores 3-5:H','H:L','ESRD','N','Kaplan-Meier ','41.04','univariate','N','＜0.001','log-rank test ','worse\r',NULL,NULL),(40000004,'16523423','clinical prognostic index (CPI) ','Calculating formula','','','Calculating formula','','','','IgAN[from Verona](73)','scores 0-2:L; scores 3-5:H','H:L','ESRD','N','Kaplan-Meier ','7.22','univariate','N','0.007','log-rank test ','worse\r',NULL,NULL),(40000006,'22595828','MDRD6 risk score  rst 6 months','','','','Calculating formula','','','','IMN(104)','0.1,0.3','H:M:L','defined progression as a rise in serum creatinine of more than 50%, a rise in serum creatinine of more than 25% and an absolute level higher than 135 mmol/L, or the need for immunosuppressive therapy because of severe nephrotic syndrome as judged by the treating physician','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(40000007,'22995635','injury score','','','','Calculating formula','','','','IMN(60)','0.322','H:L','≥50% permanent decrease in estimated glomerular filtration rate or  death','N','ROC','0.829','univariate','N','＜0.0001（The calculated sensitivity and specificity were respectively 91.67% and 75%)','AUC','worse\r',NULL,NULL),(40000008,'22995635','injury score','','','','Calculating formula','','','','IMN(60)','0.322','H:L','≥50% permanent decrease in estimated glomerular filtration rate or  death','N','Kaplan-Meier ','N','univariate','N','<0.001 ','log-rank test ','worse\r',NULL,NULL),(50000001,'17913589','IgA1','IgA1','','Alpha 2, 6 sialic acid (SA) of serum IgA1 ','Epigenetic inheritance','serum','not mention','sandwich-ELISA','IgAN(127)','0.78','L:H','ESRD','N','Kaplan–Meier','N','univariate ','N','0.0008','log-rank test ','worse\r',NULL,NULL),(50000002,'17913589','IgA1','IgA1','','Alpha 2, 6 sialic acid (SA) of serum IgA1 ','Epigenetic inheritance','serum','not mention','sandwich-ELISA','IgAN(127)','0.78,1.02','L:M:H','ESRD','N','Kaplan–Meier','N','univariate ','N','0.0032','log-rank test ','worse\r',NULL,NULL),(50000003,'17913589','IgA1','IgA1','','Alpha 2, 6 sialic acid (SA) of serum IgA1 ','Epigenetic inheritance','serum','not mention','sandwich-ELISA','IgAN(127)','0.78','L:H','ESRD','N','HR','3.7(1.54-8.90)','univariate ','N','0.004','cox','worse\r',NULL,NULL),(50000004,'22673888','IgA1','IgA1','','galactose-deficient IgA1 ','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','4th:3rd:2nd:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','Kaplan–Meier','N','univariate ','N','0.004','log-rank test ','worse\r',NULL,NULL),(50000005,'22673888','IgA1','IgA1','','galactose-deficient IgA1 ','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','3rd:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','4.03(1.36–11.96)','univariate ','N','0.012','cox','worse\r',NULL,NULL),(50000006,'22673888','IgA1','IgA1','','galactose-deficient IgA1 (Gd-IgA1)','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','3rd:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','3.74 (1.28–10.93)','multivariate','eGFR, proteinuria and hypertension (yes or no)','0.016','cox','worse\r',NULL,NULL),(50000007,'22673888','IgA1','IgA1','','galactose-deficient IgA1 (Gd-IgA1)','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','3rd:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','3.72 (1.27–10.89)','multivariate','eGFR, proteinuria and hypertension (yes or no),histological grading (mild and severe lesion group)','0.016','cox','worse\r',NULL,NULL),(50000008,'22673888','IgA1','IgA1','','galactose-deficient IgA1 (Gd-IgA1)','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','3rd:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','3.86 (1.33–11.33)','multivariate','eGFR, proteinuria and hypertension (yes or no),histological grading (mild and severe lesion group),steroid use (yes or no)','0.013','cox','worse\r',NULL,NULL),(50000009,'22673888','IgA1','IgA1','','galactose-deficient IgA1 (Gd-IgA1)','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','4th:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','6.76 (2.23–20.19) 0.001','univariate ','N','0.001','cox','worse\r',NULL,NULL),(50000010,'22673888','IgA1','IgA1','','galactose-deficient IgA1 (Gd-IgA1)','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','4th:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','5.18 (1.75–15.34)','multivariate','eGFR, proteinuria and hypertension (yes or no)','0.003','cox','worse\r',NULL,NULL),(50000011,'22673888','IgA1','IgA1','','galactose-deficient IgA1 (Gd-IgA1)','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','4th:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','5.29 (1.78–15.73)','multivariate','eGFR, proteinuria and hypertension (yes or no),histological grading (mild and severe lesion group)','0.003','cox','worse\r',NULL,NULL),(50000012,'22673888','IgA1','IgA1','','galactose-deficient IgA1 (Gd-IgA1)','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','quartile(236.5,312.5,407.8 )','4th:1st','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','4.76 (1.61–14.09)','multivariate','eGFR, proteinuria and hypertension (yes or no),histological grading (mild and severe lesion group),steroid use (yes or no)','0.005','cox','worse\r',NULL,NULL),(50000013,'22673888','IgA1','IgA1','','galactose-deficient IgA1 (Gd-IgA1)','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','N','N','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','2.07 (1.53–2.78) ','univariate ','N','0.00000168','cox','worse\r',NULL,NULL),(50000014,'22673888','IgA1','IgA1','','galactose-deficient IgA1 (Gd-IgA1)','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','N','N','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','1.51 (1.16–1.97) ','multivariate','eGFR, proteinuria and hypertension (yes or no)','0.002','cox','worse\r',NULL,NULL),(50000015,'22673888','IgA1','IgA1','','galactose-deficient IgA1 (Gd-IgA1)','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','N','N','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','1.50 (1.15–1.96) ','multivariate','eGFR, proteinuria and hypertension (yes or no),histological grading (mild and severe lesion group)','0.003','cox','worse\r',NULL,NULL),(50000016,'22673888','IgA1','IgA1','','galactose-deficient IgA1 (Gd-IgA1)','Epigenetic inheritance','serum','not mention','lectin-based ELISA','IgAN(275)','N','N','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','1.44 (1.11–1.88)','multivariate','eGFR, proteinuria and hypertension (yes or no),histological grading (mild and severe lesion group),steroid use (yes or no)','0.006','cox','worse\r',NULL,NULL),(50000017,'22673888','Gd-IgA1,IgA1 ','Gd-IgA1,IgA1 ','','','Epigenetic inheritance','serum','','','IgAN(275)','N','N','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','1.42(1.15-2.12)','univariate ','N','0.021','cox','worse\r',NULL,NULL),(50000018,'22673888','Gd-IgA1,IgA','Gd-IgA1,IgA','','','Epigenetic inheritance','serum','','','IgAN(275)','N','N','50% decline in eGFR from the time of diagnosis ESRD or death, whichever occurred first(ESRD was defined as eGFR < 15 ml/min/ 1.73 m2 or need for renal replacement therapy (such as hemodialysis, peritoneal dialysis, or renal transplantation))','N','HR','1.56(1.05–1.92)','univariate ','N','0.005','cox','worse\r',NULL,NULL),(30000134,'14767013','ACE,NOS','ACE,NOS3','ACE I/D（The 287 bp insertion/deletion (I/D) polymorphism in intron 16 of the ACE gene,ecNOS4b/a(The ','angiotensin I converting enzyme,nitric oxide synthase 3','SNP(II,bb)','blood','not mention','PCR-RFLP ','','genotype ','II+bb:IM/MM+aa/ab','s-Cr doubled and RDT','N','Kaplan-Meier ','N','univariate ','N','0.028','log-rank test ','better\r',NULL,NULL),(30000135,'14767013','ACE,NOS','ACE,NOS3','ACE I/D（The 287 bp insertion/deletion (I/D) polymorphism in intron 16 of the ACE gene,ecNOS4b/a(The ','angiotensin I converting enzyme,nitric oxide synthase 3','SNP(bb,MM)','blood','not mention','PCR-RFLP ','IMN(117)','genotype ','bb+MM:ab/aa+II/IM','s-Cr doubled and RDT','N','Kaplan-Meier ','N','univariate ','N','0.024','log-rank test ','better\r',NULL,NULL),(30000136,'24262501','HLA-DQA1,PLA2R1 ','HLA-DQA1,PLA2R1','rs2187668,rs4664308','major histocompatibility complex, class II, DQ alpha 1,phospholipase A2 receptor 1','SNP(AG/AA,AA)','blood','not mention','TaqMan','IMN(89)','genotype ','AA/AG+AA:GG+GG/AG','response to immunosuppressive therapy','N','OR','0.12 (0.02–0.72)','univariate ','N','0.02','not mention','better\r',NULL,NULL),(30000137,'24262501','HLA-DQA1,PLA2R1 ','HLA-DQA1,PLA2R1','rs2187668,rs4664308','major histocompatibility complex, class II, DQ alpha 1,phospholipase A2 receptor 1','SNP(AG/AA,AA)','blood','not mention','TaqMan','IMN(89)','genotype ','AA/AG+AA:GG+GG/AG','response to immunosuppressive therapy','N','OR','0.08 (0.01–0.58)','multivariate','proteinuria at diagnosis','0.01','not mention','better\r',NULL,NULL),(2000200,'24711435','Neutrophil gelatinase-associated lipocalin ','NGAL','P80188','Neutrophil gelatinase-associated lipocalin','protein','serum','not mention','enzyme-linked immu- nosorbent assay','LN(45)','444 ng/mL','H:L','ESRD','N','Kaplan-Meier ','N','univariate','N','0.0001','log-rank test ','worse\r',NULL,NULL),(2000203,'19295501','vascular endothelial growth factor','VEGFA','P15692','vascular endothelial growth factor A ','mRNA','Renal biopsy','not mention','real-time PCR','LN(35)',' 0.63 log copies','H:L','doubling serum creatinine','N','Kaplan-Meier ','11.49','univariate','N','<0.001','log-rank test ','better\r',NULL,NULL),(2000204,'19295501','vascular endothelial growth factor','VEGFA','P15692','vascular endothelial growth factor A ','mRNA','Renal biopsy','not mention','real-time PCR','LN(35)',' 0.63 log copies','H:L','end-stage renal disease (ESRD)','N','Kaplan-Meier ','11.43','univariate','N','<0.001','log-rank test ','better\r',NULL,NULL),(2000205,'19295501','vascular endothelial growth factor','VEGFA','P15692','vascular endothelial growth factor A ','mRNA','Renal biopsy','not mention','real-time PCR','LN(35)',' 0.63 log copies','H:L','doubling serum creatinine or end-stage renal disease (ESRD)','N','Kaplan-Meier ','12.89','univariate','N','<0.001','log-rank test ','better',NULL,NULL),(80000001,'24135218','25 (OH) vitamin D','','','25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system','biochemical','serum','','experiment','T2DM(103)','25 OH vitamin D deficiency 15 ng/ml to those with 25 OH vitamin D levels 15 ng/ml','L:H','>50% increase in serum creatinine concentration, ESRD, or death','2-3 stage','Time-to-event curves','HR,2.88 (1.84 to 7.67)','multivariate','','0.03','Cox','better','early',''),(80000002,'17699284','risk score','','','Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study','score','serum,urine','','experiment','T2DM(1513)','quartile1:<3.0 quartile2:3.0 to 4.0 quartile3:4.0 to 5.1  quartile4:>5.1','1:04','ESRD','','Kaplan-Meier curve','HR,0.02 (0.01 to 0.04)','multivariate','','0.0001','Cox','worse','','(1.96xlog[urinary albumin:creatinine ratio])-(0.78 serum albumin [g/dl])+(1.28 serum creatinine [mg/'),(80000003,'17699284','risk score','','','Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study','score','serum,urine','','experiment','T2DM(1513)','quartile1:<3.0 quartile2:3.0 to 4.0 quartile3:4.0 to 5.1  quartile4:>5.1','2:04','ESRD','','Kaplan-Meier curve','HR,0.07 (0.05 to 0.10)','multivariate','','0.0001','Cox','worse','','(1.96xlog[urinary albumin:creatinine ratio])-(0.78 serum albumin [g/dl])+(1.28 serum creatinine [mg/'),(80000004,'17699284','risk score','','','Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study','score','serum,urine','','experiment','T2DM(1513)','quartile1:<3.0 quartile2:3.0 to 4.0 quartile3:4.0 to 5.1  quartile4:>5.1','3:04','ESRD','','Kaplan-Meier curve','HR,0.27 (0.21 to 0.35)','multivariate','','0.0001','Cox','worse','','(1.96xlog[urinary albumin:creatinine ratio])-(0.78 serum albumin [g/dl])+(1.28 serum creatinine [mg/'),(80000005,'26801478','ITFA score','','','Prognostic Value of Tubulointerstitial Lesions, Urinary N-Acetyl-beta-d-Glucosaminidase, and Urinary beta2-Microglobulin in Patients with Type 2 Diabetes and Biopsy-Proven Diabetic Nephropathy','score','renal tissue','','experiment','T2DM(149)','Score 0,Score 1,Score 2,Score 3,Score 4','Score 0:Score 1','a decline in eGFR of 鈮?0% from baseline or commencement of dialysis for ESRD','','cumulative incidences','HR,0.05 (0.01 to 0.39)','multivariate','','','Cox','worse','','the extent of interstitial fibrosis and tubular atrophy (IFTA) score'),(80000006,'26801478','ITFA score','','','Prognostic Value of Tubulointerstitial Lesions, Urinary N-Acetyl-beta-d-Glucosaminidase, and Urinary beta2-Microglobulin in Patients with Type 2 Diabetes and Biopsy-Proven Diabetic Nephropathy','score','renal tissue','','experiment','T2DM(149)','Score 0,Score 1,Score 2,Score 3,Score 4','Score 2:Score 1','a decline in eGFR of 鈮?0% from baseline or commencement of dialysis for ESRD','','cumulative incidences','HR,1.59 (0.82 to 3.08)','multivariate','','','Cox','worse','','the extent of interstitial fibrosis and tubular atrophy (IFTA) score'),(80000007,'26801478','ITFA score','','','Prognostic Value of Tubulointerstitial Lesions, Urinary N-Acetyl-beta-d-Glucosaminidase, and Urinary beta2-Microglobulin in Patients with Type 2 Diabetes and Biopsy-Proven Diabetic Nephropathy','score','renal tissue','','experiment','T2DM(149)','Score 0,Score 1,Score 2,Score 3,Score 4','Score 3:Score 1','a decline in eGFR of 鈮?0% from baseline or commencement of dialysis for ESRD','','cumulative incidences','HR,3.82 (1.74 to 8.39)','multivariate','','','Cox','worse','','the extent of interstitial fibrosis and tubular atrophy (IFTA) score'),(80000008,'26801478','ITFA score','','','Prognostic Value of Tubulointerstitial Lesions, Urinary N-Acetyl-beta-d-Glucosaminidase, and Urinary beta2-Microglobulin in Patients with Type 2 Diabetes and Biopsy-Proven Diabetic Nephropathy','score','renal tissue','','experiment','T2DM(149)','Score 0,Score 1,Score 2,Score 3,Score 4','Per Score:Score 1','a decline in eGFR of 鈮?0% from baseline or commencement of dialysis for ESRD','','cumulative incidences','HR,2.31 (1.56 to 3.43)','multivariate','','','Cox','worse','','the extent of interstitial fibrosis and tubular atrophy (IFTA) score'),(80000009,'20966122','FGF-23','FGF23','Q9GZV9','FGF-23 as a predictor of renal outcome in diabetic nephropathy','protein','serum','','experiment','T2DM(56)','FGF-23 values of  70 pg/ml','','death, doubling of serum creatinine, and/or dialysis need','proteinuria above 500 mg/d','','HR,1.09 (1.01 to 1.16)','multivariate','','0.02','Cox','worse','middle,advanced',''),(80000010,'20966122','FGF-23','FGF23','Q9GZV9','FGF-23 as a predictor of renal outcome in diabetic nephropathy','protein','serum','','experiment','T2DM(56)','FGF-23 values of  70 pg/ml','H:L','death, doubling of serum creatinine, and/or dialysis need','proteinuria above 500 mg/d','Kaplan-Meier curve','','univariate','','<0.001','log rank','worse','middle,advanced',''),(80000011,'17914031','SOD1 ','SOD1','','Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,2.62 (1.64 to 4.18)','multivariate','','','Cox','worse','','rs17880135\r'),(80000012,'17914031','SOD1 ','SOD1','','Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,2.62 (1.64 to 4.18)','multivariate','','','Cox','worse','','rs9974610\r'),(80000013,'17914031','CASP3','CASP3','','Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,1.62 (1.20 to 2.17)','multivariate','','','Cox','worse','','rs2705897\r'),(80000014,'17914031','TRPC6','TRPC6','','Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,2(1.29 to 3.08)','multivariate','','','Cox','worse','','rs3824935\r'),(80000015,'17914031','TGFBR2','TGFBR2','','Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,0.4(0.22 to 0.71)','multivariate','','','Cox','better','','rs2276768\r'),(80000016,'17914031','HPSE','HPSE','','Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,1.61(1.19 to 2.19)','multivariate','','','Cox','worse','','rs4693614\r'),(80000017,'17914031','CYP11B2','CYP11B2','','Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,1.89(1.25 to 2.88)','multivariate','','','Cox','worse','','rs7844961\r'),(80000018,'17914031','COX5A','COX5A','','Multiple superoxide dismutase 1/splicing factor serine alanine 16 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications G','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,1.59(1.17 to 2.16)','multivariate','','','Cox','worse','','rs8042694\r'),(80000019,'17914031','NPHS1','NPHS1','','Multiple superoxide dismutase 1/splicing factor serine alanine 17 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,0.61(0.44 to 0.85)','multivariate','','','Cox','better','','rs3814995\r'),(80000020,'17914031','ATP5G3','ATP5G3','','Multiple superoxide dismutase 1/splicing factor serine alanine 18 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,2.39(1.33 to 4.29)','multivariate','','','Cox','worse','','rs10497435\r'),(80000021,'17914031','FLT4','FLT4','','Multiple superoxide dismutase 1/splicing factor serine alanine 19 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,1.66(1.17 to 2.37)','multivariate','','','Cox','worse','','rs307806\r'),(80000022,'17914031','FLT4','FLT4','','Multiple superoxide dismutase 1/splicing factor serine alanine 20 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,1.95(1.23 to 3.10)','multivariate','','','Cox','worse','','rs2279622\r'),(80000023,'17914031','UQCRC1','UQCRC1','','Multiple superoxide dismutase 1/splicing factor serine alanine 21 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,2.63(1.34 to 5.16)','multivariate','','','Cox','worse','','rs11715496\r'),(80000024,'17914031','BDKRB2','BDKRB2','','Multiple superoxide dismutase 1/splicing factor serine alanine 22 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,0.57(0.39 to 0.85)','multivariate','','','Cox','better','','rs4900312\r'),(80000025,'17914031','LIPC','LIPC','','Multiple superoxide dismutase 1/splicing factor serine alanine 23 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,0.65(0.47 to 0.88)','multivariate','','','Cox','better','','rs1968685\r'),(80000026,'17914031','PARP1','PARP1','','Multiple superoxide dismutase 1/splicing factor serine alanine 24 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,1.6(1.14 to 2.24)','multivariate','','','Cox','worse','','rs2027440\r'),(80000027,'17914031','PARP1','PARP1','','Multiple superoxide dismutase 1/splicing factor serine alanine 25 variants are associated with the development and progression of diabetic nephropathy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Genetics study','gene','serum','','microarray','T2DM(1362)','','','the time to AER >300 mg/24 h (>208 ?g/min) with prior persistent microalbuminuria or ESRD','','','HR,1.6(1.14 to 2.24)','multivariate','','','Cox','worse','','rs3219065\r'),(80000028,'19411615','uric acid','','','Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study','biochemical','urine','','experiment','T1DM(263)','uric acid >249 μmol/l to patients with uric acid <249 μmol/l','','persistent macroalbuminuria (urinary albumin excretion rate>300 mg/24 h in at least two of three consecutive samples)','','','HR,1.92(1.49 to 2.47)','multivariate','','0.04','Cox','worse','',''),(80000029,'19411615','uric acid','','','Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study','biochemical','urine','','experiment','T1DM(263)','uric acid >249 μmol/l to patients with uric acid <249 μmol/l','H:L','persistent macroalbuminuria (urinary albumin excretion rate>300 mg/24 h in at least two of three consecutive samples)','','cumulative incidences','','univariate','','<0.001','log rank','worse','',''),(80000030,'19651819','A1C','HbA1c','','A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes','protein','serum','','experiment','T1DM(2107)','1st:7.9±1.2,2nd:8.3±1.2,3rd:8.6±1.3,4th:9.2±1.9%','1:2:3:4','any increase in albuminuria level or progression to ESRD','','Kaplan-Meier curve','HR,2.37(1.04 to 5.39)','multivariate','','<0.001','Cox','worse','',''),(80000031,'23223350','L-FABP','FABP1','P07148','Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy','protein','urine','','experiment','T2DM(618)','highest tertile:≤5.0mg/g Cr, middle tertile 5.0–9.5 mg/g Cr,lowest tertile>9.5 mg/g Cr','H:L','the incidence of a 50% decline in estimated glomerular filtration rate (eGFR)','serum creatinine .0 mg/dL and without overt proteinuria','','HR,2.43 (1.14 to 5.16)','multivariate','','','Cox','worse','early,middle',''),(80000032,'23223350','L-FABP','FABP1','P07148','Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy','protein','urine','','experiment','T2DM(618)','highest tertile:≤5.0mg/g Cr, middle tertile 5.0–9.5 mg/g Cr,lowest tertile>9.5 mg/g Cr','H:L','progression to an eGFR <30 mL/min/1.73 m( 2), and the annual decline rate in eGFR','serum creatinine 鈮?.0 mg/dL and without overt proteinuria','','HR,3.53 (1.15 to 10.88)','multivariate','','','Cox','worse','early,middle',''),(80000033,'23223350','L-FABP','FABP1','P07148','Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy','protein','urine','','experiment','T2DM(618)','highest tertile:≤5.0mg/g Cr, middle tertile 5.0–9.5 mg/g Cr,lowest tertile>9.5 mg/g Cr','','renal and cardiovascular composites (hemodialysis, myocardial infarction, angina pectoris, stroke, cerebral hemorrhage, and peripheral vascular disease)','serum creatinine 鈮?.0 mg/dL and without overt proteinuria','cumulative incidences','','','','<0.001','log rank','worse','early,middle\r',NULL),(80000034,'24879837','sTNFaR1','TNFRSF1A','P19438','Added value of soluble tumor necrosis factor-alpha receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes','protein','serum','','experiment','T1DM(429)','','','an albumin excretion rate >=200 mg/min or >=300 mg/day in at least two out of three consecutive overnight or 24-h urine samples','','cumulative incidences','','multivariate','','','Cox','worse\r',NULL,NULL),(80000035,'21273494','L-FABP','FABP1','P07148','Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients','protein','urine','','experiment','T2DM(140)','urinary L-FABP of 8.4 mg/g creatinine','','progressive albuminuria, end-stage renal disease, or induction of hemodialysis','','','HR,7.285 (2.425 to 21.884)','multivariate','','0','Cox','worse','',''),(80000036,'22851596','cystatin C','CST3','P01034','Serum concentration of cystatin C and risk of end-stage renal disease in diabetes','protein','serum','','experiment','T1DM,T2DM(Joslin T1D (364),FinnDiane T1D(399),Joslin T2D(402))','','','ESRD or death unrelated to ESRD','1-3 stage','','HR,2.3 (1.8 to 3.1)','multivariate','','','Cox','worse','early',''),(80000037,'18344285','CTGF','CTGF','P29279','Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy','protein','plasma','','experiment','T1DM(198)','CTGF of 413 pmol/l','H:L','ESRD','persistent albuminuria ( 300 mg/day) in at least two of three consecutive 24-h urine collections,diabetic retinopathy, and no other kidney or renal tract disease ','cumulative incidences','','univariate','','<0.001','log rank','worse','middle,advanced',''),(80000038,'18344285','CTGF','CTGF','P29279','Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy','protein','plasma','','experiment','T1DM(198)','','','ESRD','persistent albuminuria ( 300 mg/day) in at least two of three consecutive 24-h urine collections,diabetic retinopathy, and no other kidney or renal tract disease ','','HR,1.62 (1.05 to 2.50)','multivariate','','0.03','Cox','worse','middle,advanced',''),(80000039,'20185732','LFABP','FABP1','P07148','Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients','protein','urine','','experiment','T1DM(165)','u-LFABP of 10.9 (pg/ml)/(mg/dl creatinine)','','macroalbuminuria','normoalbuminuric ','','HR,2.6 (1.2 to 5.4)','','','','Cox','worse','early',''),(80000040,'25510400','HbA1c','HbA1c','','Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden)','protein','serum','','experiment','T1DM(451)','1:HbA1c <=7.6%(60 mmol/mol),2:7.7–8.6% (61–70 mmol/mol),3:8.6–9.5% (71–80 mmol/mol), 4:>9.5% (80 mmol/mol)','4:01','persistent macroalbuminuria','','cumulative incidences','','','','<0.001','log rank','worse','',''),(80000041,'25510400','HbA1c','HbA1c','','Impact of HbA1c, followed from onset of type 1 diabetes, on the development of severe retinopathy and nephropathy: the VISS Study (Vascular Diabetic Complications in Southeast Sweden)','protein','serum','','experiment','T1DM(451)','1:HbA1c <=7.6%(60 mmol/mol),2:7.7–8.6% (61–70 mmol/mol),3:8.6–9.5% (71–80 mmol/mol), 4:>9.5% (80 mmol/mol)','3:01','persistent macroalbuminuria','','cumulative incidences','','','','0.008','log rank','worse','',''),(80000042,'25720601','ADP','ADIPOQ','Q15848','Urinary adiponectin is an independent predictor of progression to end-stage renal disease in patients with type 1 diabetes and diabetic nephropathy','protein','urine','','experiment','T1DM(macroalbuminuria(320))','','','ESRD','macroalbuminuria','','HR,1.37 (1.07 to 1.75)','multivariate','','','Cox','worse','advanced',''),(80000043,'17630266','A1C','HbA1c','','Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex','protein','serum','','experiment','T1DM(27805)','A1C level of 7.5%.','H:L','macroalbuminuria','','Time-to-event curves','','univariate','','<0.001','log rank','worse','',''),(80000044,'22498805','Mg','','','Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease','biochemical','serum','','experiment','T2DM(T2DM(144))','serum Mg level of 1.8 mg/dL','L:H','ESRD','','cumulative event-free survival for the primary outcome','HR,2.12 (1.28 to 2.52)','multivariate','','','Cox','better','',''),(80000045,'18716049','ALR2','AKR1B1','P15121','Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1,074 type 2 diabetic patients','gene','serum','',' LI-COR DN','T2DM(1074)','','','new onset of estimated glomerular filtration rate  60 ml/min per 1.72 m2 or hospitalizations with dialysis or death due to renal disease','','','HR,1.53 (1.14 to 2.05)','multivariate','','0.005','Cox','worse\r',NULL,NULL),(80000046,'18716049','ALR2','AKR1B1','P15122','Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1,074 type 2 diabetic patients','gene','serum','',' LI-COR DN','T2DM(1074)','','','new onset of estimated glomerular filtration rate  60 ml/min per 1.72 m2 or hospitalizations with dialysis or death due to renal disease','','','HR,1.54 (1.15 to 2.07)','multivariate','','0.004','Cox','worse\r',NULL,NULL),(80000047,'18716049','ALR2','AKR1B1','P15123','Aldose reductase genotypes and cardiorenal complications: an 8-year prospective analysis of 1,074 type 2 diabetic patients','gene','serum','',' LI-COR DN','T2DM(1074)','z-2+&T+;z-2+ or T+;z-2-&T-','z-2+&T+:z-2+ or T+:z-2-&T-','new onset of estimated glomerular filtration rate  60 ml/min per 1.72 m2 or hospitalizations with dialysis or death due to renal disease','','cumulative incidences','','','','0.003','log rank','worse\r',NULL,NULL),(80000048,'26124993','ceruloplasmin','CP','P00450','Serum Ceruloplasmin Level as a Predictor for the Progression of Diabetic Nephropathy in Korean Men with Type 2 Diabetes Mellitus','protein','serum','','experiment','T2DM(643)','Q1 (<=219 mg/L);Q2 (220?249 mg/L);Q3 (>=250 mg/L)','Q3:Q2:Q1','transition in albuminuria class and/or a greater than 2-fold increase of serum creatinine at follow-up compared with the baseline value.','','cumulative incidences','HR,3.32 (1.28 to 8.61)','multivariate','','0.002','Cox','worse','',''),(80000049,'23863910','copeptin','AVP','P01185','Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.','protein','plasma','','experiment','T2DM(microalbuminuria(2373))','plasma copeptin:Men:T1(0.9–5.8),T2(5.9–10.0),T3(10.1–143)pmol/L','T3:T2:T1','doubling of serum creatinine or development of end-stage renal disease','microalbuminuria or macroalbuminuria without renal failure at baseline. ','event-free curves','HR,4.69 (2.43 to 9.05)','multivariate','','<0.001','Cox','worse','early',''),(80000050,'23863910','copeptin','AVP','P01185','Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria.','protein','plasma','','experiment','T2DM(macroalbuminuria(729))','plasma copeptin:Men:T1(0.9–5.8),T2(5.9–10.0),T3(10.1–143)pmol/L','T3:T2:T1','doubling of serum creatinine or development of end-stage renal disease','microalbuminuria or macroalbuminuria without renal failure at baseline. ','event-free curves','HR,5.14 (1.98 to 6.06)','multivariate','','<0.001','Cox','worse','early',''),(80000051,'22078636','IgM','IGHM','P01871','Urine IgM-excretion as a prognostic marker for progression of type 2 diabetic nephropathy','protein','urine','','experiment','T2DM(106)','urine IgM of 0.015 mg/mmol','H:L','CV death or ESRD','','event-free curves','HR,3.6 (2.1 to 6.0)','univariate','','<0.001','Cox','worse','',''),(80000052,'22078636','IgM','IGHM','P01871','Urine IgM-excretion as a prognostic marker for progression of type 2 diabetic nephropathy','protein','urine','','experiment','T2DM(106)','urine IgM of 0.015 mg/mmol','','ESRD','','','HR,4.44 (2.15 to 9.14)','univariate','','<0.001','Cox','worse','',''),(80000053,'20396997','MBL','MBL2','P11226','Association between mannose-binding lectin, high-sensitivity C-reactive protein and the progression of diabetic nephropathy in type 1 diabetes','protein','serum','','experiment','T1DM(macroalbuminuria(318))','serum MBL levels of 1,864 ?g/l in men and 1,643 ?g/l in women. ','H:L','ESRD','','cumulative incidences','HR,1.88 (1.06 to 3.32)','multivariate','','0.03','Cox','worse','',''),(80000054,'18719882','osteoprotegerin','TNFRSF11B','P11226','Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy','protein','plasma','','experiment','T1DM(397)','first quartile:<=2.40,second quartile:2.41–2.97,third quartile:2.98–3.83,fourth quartileP:>=3.84 μg/ml','fourth:third:second:first','ESRD','overt diabetic nephropathy','cumulative incidences','HR,4.32 (1.45 to 12.87)','multivariate','','0.009','Cox','worse','advanced',''),(80000055,'18719882','osteoprotegerin','TNFRSF11B','O00300','Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy','protein','plasma','','experiment','T1DM(397)','first quartile:<=2.40,second quartile:2.41–2.97,third quartile:2.98–3.83,fourth quartileP:>=3.84 μg/ml','fourth:third:second:first','ESRD','overt diabetic nephropathy','cumulative incidences','HR,3.94 (1.36 to 11.38)','multivariate','','0.011','Cox','worse','advanced',''),(80000056,'24057136','CAT','CAT','P04040','Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes','gene','plasma','','KASP','T1DM(SURGENE(340))','','GG: GA/AA','new cases of microalbuminuria or progression to a more severe stage of nephropathy','','event-free curves','HR,1.82 (1.13 to 2.81) ','multivariate','','0.01','Cox','worse','','rs7947841'),(80000057,'24057136','CAT','CAT','P04040','Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 2 diabetes','gene','plasma','','KASP','T1DM(SURGENE(340))','','GG: GA/AA','ESRD','','event-free curves','','','','<0.001','log rank','worse','','rs7947841'),(80000058,'24057136','CAT','CAT','P04040','Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 3 diabetes','gene','plasma','','KASP','T1DM(GENEDIAB(444))','','GG: GA/AA','ESRD','','','HR, 2.11 (1.23 to 3.61)','multivariate','','0.008','Cox','worse','','rs7947841'),(80000059,'24057136','CAT','CAT','P04040','Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 3 diabetes','gene','plasma','','KASP','T1DM(GENEDIAB(444))','','','ESRD','','','HR, 2.80 (1.31 to 5.98)','multivariate','','0.009','Cox','worse','','rs2420388'),(80000060,'19816673','HbA1c','HbA1c','','Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes','protein','serum','','experiment','T1DM(2304)','HbA1c (%) of 8.7+-1.4','','macroalbuminuria','','','HR, 1.28 (1.09 to 1.50)','univariate','','0.003','Cox','worse','',''),(80000061,'19816673','Male sex','','','Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes','clinical','','','experiment','T1DM(2304)','','','macroalbuminuria','','','HR, 2.50 (1.22 to 5.09) ','univariate','','0.01','Cox','worse','',''),(80000062,'19816673','triacylglycerol','','','Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes','biochemical','serum','','experiment','T1DM(2304)','Triacylglycerol of 1.05 (0.80–1.47)mmol/l','','macroalbuminuria','','','HR, 2.69 (1.53 to 4.71)','univariate','','0.001','Cox','worse','','Loge triacylglycerol'),(80000063,'19816673','SBP','','','Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes','clinical','','','experiment','T1DM(2304)','SBP of 141+-19mmHg','','ESRD','','','HR, 1.02 (1.01 to 1.04)','univariate','','<0.001','Cox','worse','',''),(80000064,'19816673','BMI ','','','Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes','clinical','','','experiment','T1DM(2304)','BMI of 26.1+-3.8kg/m2','','ESRD','','','HR, 0.92 (0.86 to 0.98) ','univariate','','0.007','Cox','better','',''),(80000065,'19816673','triacylglycerol','','','Lipid abnormalities predict progression of renal disease in patients with type 1 diabetes','biochemical','serum','','experiment','T1DM(2304)','Triacylglycerol of 1.28 (0.97–1.80)mmol/l','','ESRD','','','HR, 2.30 (1.50 to 3.53)','univariate','','<0.001','Cox','worse','','Loge triacylglycerol'),(80000066,'22960330','miR-21','MIR21','','Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases','miRNA','urine','','experiment','CKD(DN(17),IgAN(17),HTN(22))','25 copies per 100,000 copies of the housekeeping gene','H:L','dialysis','','event-free curves','','','','0.005','log rank','worse','',''),(80000067,'22960330','miR-216a','MIR216A','','Micro-RNA expression in the urinary sediment of patients with chronic kidney diseases','miRNA','urine','','experiment','CKD(DN(17),IgAN(17),HTN(22))','25 copies per 100,000 copies of the housekeeping gene','H:L','dialysis','','event-free curves','','','','0.003','log rank','worse','',''),(80000068,'25862415','CYBA','CYBA','P13498','Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes','gene','plasma','','KASP','T1DM(SURGENE (n=340))','','GG: GA/AA','new cases of microalbuminuria or the progression to a more severe stage of nephropathy','','cumulative incidences','HR, 1.59(1.17 to  2.18) ','multivariate','','0.003','Cox','worse','','rs9932581'),(80000069,'25862415','CYBA','CYBA','P13498','Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes','gene','plasma','','KASP','T1DM(GENEDIAB (n=444) &GENESIS (n=573))','','GG: GA/AA','ESRD','','cumulative incidences','HR, 2.01(1.30 to 3.24)','multivariate','','0.001','Cox','worse','','rs9932581'),(80000070,'26823823','PKC','PRKCA','P17252','Influence of protein kinase C (PKC) on the prognosis of diabetic nephropathy patients','protein','renal tissue','','experiment','DM(92)','','positive:negative','death','','cumulative survival curves','HR, 3.655(1.154 to 11.578)','multivariate','','0.028','Cox','worse','',''),(80000071,'25166721','PEDF','SERPINF1','P36955','Elevated circulating pigment epithelium-derived factor predicts the progression of diabetic nephropathy in patients with type 2 diabetes','protein','plasma','','experiment','T2DM(CKD stage1-3(1071))','','Q1:Q2:Q3:Q4','deterioration in CKD staging and a 25% or greater drop in estimated glomerular filtration rate (eGFR) according to International Society of Nephrology statements.','','cumulative survival curves','HR, 2.75( 1.01 to 7.49)','multivariate','','0.04','Cox','worse','',''),(80000072,'25625802','FGF21','FGF21','Q9NSA1','Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria.','protein','plasma','','experiment','T2DM(CKD stage1-3(1071))','','','eGFR decline (a decline in eGFR category (>=90 [stage 1], 60–89 [stage 2], 45–59 [stage 3a], 30–44 [stage 3b], 15–29 [stage 4], and <15 [stage 5] mL/min/1.73 m2), accompanied by a 25% or greater deterioration in eGFR from baseline . eGFR was calculated using MDRD) ','','','HR, 1.21(1.01 to 1.44)','multivariate','','0.036','Cox','worse','',''),(80000073,'26066409','Insulin ','INS','P01308','Insulin resistance as a predictor of cardiovascular morbidity and end-stage renal disease','score','serum','','experiment','T2DM(119)','Lower tercile(0.34–0.66):Middle tercile(0.67–2.70):Upper tercile(2.80–6.70)','L:M:U','ESRD','2-4 stage','cumulative survival curves','','','','0.017','log rank','worse','early,middle','Insulin resistance (IR)'),(80000074,'22885250','CRP','CRP','P02741','Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients','score','serum','','experiment','T1DM(60)','','','','','','HR, 3.23 (1.1 to 9.8)','multivariate','','0.038','Cox','worse','','Log CRP'),(80000075,'22981148','RBP','RBP4','P02753','Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy','protein','urine','','experiment','T2DM(56)','urinaryMCP-1 of 52ng/g creatinine','H:L','dialysis, doubling of serum creatinine or death ','macroalbuminuric','event-free curves','','','','0.001','log rank','worse','advanced',''),(80000076,'22981148','MCP-1 ','CCL2','P13500','Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy','protein','urine','','experiment','T2DM(56)','urinary RBP of 0.5 mg/g creatinine','H:L','dialysis, doubling of serum creatinine or death ','macroalbuminuric','event-free curves','','','','0.005','log rank','worse','advanced',''),(80000077,'24843765','bilirubin','','','Association of serum bilirubin levels with development and progression of albuminuria, and decline in estimated glomerular filtration rate in patients with type 2 diabetes mellitus','biochemical','serum','','experiment','T2DM(microalbuminuric&ACR)','lowest bilirubin tertile (T1; 0.1–0.4 mg/dL):middle bilirubin tertile (T2; 0.5–0.6 mg/dL):highest bilirubin tertile (T3; 0.7–1.1 mg/dL)','T1:T2:T3','macroalbuminuria','','cumulative incidences','','','','<0.001','log rank','better','',''),(80000078,'24843765','bilirubin','','','Association of serum bilirubin levels with development and progression of albuminuria, and decline in estimated glomerular filtration rate in patients with type 2 diabetes mellitus','biochemical','serum','','experiment','T2DM(ACR cohort(1915))','lowest bilirubin tertile (T1; 0.1–0.4 mg/dL):middle bilirubin tertile (T2; 0.5–0.6 mg/dL):highest bilirubin tertile (T3; 0.7–1.1 mg/dL)','','onset or progression of albuminuria(the transition from normo- to micro- or macroalbuminuria or from micro- to macroalbuminuria)','normo- or microalbuminuria','','HR, 0.24(0.08 to 0.71)','multivariate','','<0.05','Cox','better','early',''),(80000079,'24843765','bilirubin','','','Association of serum bilirubin levels with development and progression of albuminuria, and decline in estimated glomerular filtration rate in patients with type 2 diabetes mellitus','biochemical','serum','','experiment','T2DM(ACR cohort(1915))','','','onset or progression of albuminuria(the transition from normo- to micro- or macroalbuminuria or from micro- to macroalbuminuria)','normo- or microalbuminuria','','HR, 0.77(0.64 to 0.92)','multivariate','','<0.05','Cox','better','early',''),(80000080,'19563389','telomere','','','Telomere length and progression of diabetic nephropathy in patients with type 1 diabetes','score','blood','','experiment','T1DM(132)','terminal restriction fragment of 6.6kb','','a change in albuminuria to a higher level','','','HR, 0.190(0.065 to 0.558)','multivariate','','0.0025','Cox','better','','mean telomere length'),(80000081,'19563389','telomere','','','Telomere length and progression of diabetic nephropathy in patients with type 1 diabetes','score','blood','','experiment','T1DM(132)','terminal restriction fragment of 6.6kb','','a change in albuminuria to a higher level','','','HR, 1.115(1.039 to 1.195)','multivariate','','0.00234','Cox','worse','','proportion of short telomeres'),(80000082,'20522428','CTGF','CTGF','P29279','Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes','gene','serum','','experiment','T1DM(862)','','CC:CG/GC:GG','\"the albumin excretion rate (AER)>=40 mg/24 h or the first renal exam in which AER\r',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(80000083,'20522428','CTGF','CTGF','P29279','Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes','gene','serum','','experiment','T1DM(862)','','','\"the albumin excretion rate (AER)>=40 mg/24 h or the first renal exam in which AER\r',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(80000084,'20522428','CTGF','CTGF','P29279','Genetic variant in the promoter of connective tissue growth factor gene confers susceptibility to nephropathy in type 1 diabetes','gene','serum','','experiment','T1DM(862)','','','\"the albumin excretion rate (AER)>=40 mg/24 h or the first renal exam in which AER\r',NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL,NULL),(80000085,'20736472','PRKCB1','PRKCB','P05771','Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes','gene','serum','','MassARRAY','T2DM(1172)','','','ESRD','','','HR, 2.25(1.31 to 3.87)','multivariate','','0.003','Cox','worse','','rs3760106'),(80000086,'20736472','PRKCB1','PRKCB','P05771','Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes','gene','serum','','MassARRAY','T2DM(1172)','','','ESRD','','','HR, 2.22(1.30 to 3.80)','multivariate','','0.004','Cox','worse','','rs3760106'),(80000087,'20736472','PRKCB1','PRKCB','P05771','Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes','gene','serum','','MassARRAY','T2DM(1172)','','','ESRD','','','HR, 2.26(1.31 to 3.88)','multivariate','','0.003','Cox','worse','','rs2575390'),(80000088,'20736472','PRKCB1','PRKCB','P05771','Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes','gene','serum','','MassARRAY','T2DM(1172)','','','ESRD','','','HR, 2.23(1.30 to 3.81)','multivariate','','0.003','Cox','worse','','rs2575390'),(80000089,'20736472','PRKCB1','PRKCB','P05771','Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes','gene','serum','','MassARRAY','T2DM(1172)','','','ESRD','','','HR, 1.59(1.01 to 2.52)','multivariate','','0.047','Cox','worse','','rs7404928'),(80000090,'20736472','PRKCB1','PRKCB','P05771','Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes','gene','serum','','MassARRAY','T2DM(1172)','','','ESRD','','','HR, 1.78(1.03 to 3.09)','multivariate','','0.04','Cox','worse','','rs4787733'),(80000091,'20736472','PRKCB1','PRKCB','P05771','Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes','score','serum','','MassARRAY','T2DM(1172)','numbei of risk allels(4:3:2:0-1)','4:3:2:0-1','ESRD','','cumulative incidences','HR, 3.18(1.21 to 8.35)','multivariate','','0.02','Cox','worse','','Number of Risk Alleles'),(80000092,'20736472','PRKCB1','PRKCB','P05771','Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes','score','serum','','MassARRAY','T2DM(1172)','numbei of risk allels(4:3:2:0-1)','4:3:2:0-1','ESRD','','cumulative incidences','HR, 4.21(1.55 to 11.42)','multivariate','','0.005','Cox','worse','','Number of Risk Alleles'),(80000093,'20736472','PRKCB1','PRKCB','P05771','Genetic variants of the protein kinase C-beta 1 gene and development of end-stage renal disease in patients with type 2 diabetes','score','serum','','MassARRAY','T2DM(1172)','numbei of risk allels(4:3:2:0-1)','4:3:2:0-1','ESRD','','cumulative incidences','HR, 6.04(2.00 to 18.31)','multivariate','','0.002','Cox','worse','','Number of Risk Alleles'),(80000094,'24603156','NOS3','NOS3','P29474','NOS3 894G>T polymorphism is associated with progression of kidney disease and cardiovascular morbidity in type 2 diabetic patients: NOS3 as a modifier gene for diabetic nephropathy?','gene','serum','','experiment','T2DM(311)','','','progression of DN','','','HR, 1.843(1.088 to 3.119) ','multivariate','','0.023','Cox','worse','','894G>T '),(80000095,'23147199','SDMA','','','ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis','biochemical','plasma','','experiment','T1DM,T2DM(341)','SDMA/GFR ratio of 0.6','','DN progression(a transition from any given stage to a more advanced stage of albuminuria)','','','HR, 5.17(1.77 to 15.00)','multivariate','','0.003','Cox','worse','','SDMA/GFR ratio'),(80000096,'23147199','ADMA','','','ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis','biochemical','plasma','','experiment','T1DM,T2DM(341)','ADMA/GFR ratio of 0.4','','DN progression(a transition from any given stage to a more advanced stage of albuminuria)','','','HR, 7.6(2.17 to 26.7)','multivariate','','0.002','Cox','worse','','ADMA/GFR ratio'),(80000097,'23147199','L-arginine','','','ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis','biochemical','plasma','','experiment','T1DM,T2DM(341)','L-arginine/ADMA/GFR ratio of 114','','DN progression(a transition from any given stage to a more advanced stage of albuminuria)','','','HR, 3.68(1.53 to 8.86)','multivariate','','0.004','Cox','worse','','L-arginine/ADMA/GFR ratio'),(80000098,'18496510','Adiponectin','ADIPOQ','Q15848','Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy','protein','serum','','experiment','T1DM(Adiponectin(373))','serum adiponectin levels of 24.2mg/l','H:L','ESRD','normoalbuminuria,macroalbuminuria','cumulative incidences','HR, 2.72(1.27 to 5.84)','multivariate','','0.01','Cox','worse','',''),(80000099,'18496510','Adiponectin','ADIPOQ','Q15848','Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy','protein','serum','','experiment','T1DM(Adiponectin(373))','','','ESRD','normoalbuminuria,macroalbuminuria','','HR, 1.45(1.01 to 2.09)','multivariate','','0.047','Cox','worse','',''),(80000100,'21220750','uric acid','','','Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study','biochemical','serum','','experiment','DM&highlipidsamples(Men(1470))','Q5>6.5 mg/dL (mean+SE: 7.3+-0.7) ,Q1-4<Q5','Q5:Q1-4','CRF','','cumulative incidences','HR, 1.94(1.20 to 3.14)','multivariate','','0.007','Cox','worse','',''),(80000101,'21220750','uric acid','','','Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study','biochemical','serum','','experiment','DM&highlipidsamples(Women(979))','Q5>5.3 mg/dL (mean+SE: 6.1+-0.6) ,Q1-4<Q5','Q5:Q1-4','CRF','','cumulative incidences','HR, 5.20(1.90 to 14.2)','multivariate','','0.001','Cox','worse','',''),(80000102,'19131352','ADMA','','','Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes','biochemical','plasma','','experiment','T2DM(225)','mean plasma ADMA level of 0.51 +- 0.15 ?mol/l','H:L','development or progression of diabetic nephropathy(transition from any given stage to a more advanced stage of albuminuria)','normo- or microalbuminuria','cumulative incidences','HR, 2.72(1.25 to 5.95)','multivariate','','0.012','Cox','worse','early',''),(80000103,'19131352','ADMA','','','Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes','biochemical','plasma','','experiment','T2DM(225)','','','development or progression of diabetic nephropathy(transition from any given stage to a more advanced stage of albuminuria)','normo- or microalbuminuria','','HR, 1.30(1.04 to 1.63)','multivariate','','0.019','Cox','worse','early',''),(80000104,'21785041','HDL cholesterol','','','Gender differences in the association between HDL cholesterol and the progression of diabetic kidney disease in type 2 diabetic patients','biochemical','serum','','experiment','T2DM(Men(443))','1st(>54mg/dl):2nd(43-53mg/dl):3rd(<42mg/dl)','3rd:2nd:1st','progression to a more advanced stage of albuminuria','normo- or microalbuminuria','cumulative incidences','HR, 2.242(1.190 to 4.227)','multivariate','','0.01','Cox','better','early',''),(80000105,'21785041','HDL cholesterol','','','Gender differences in the association between HDL cholesterol and the progression of diabetic kidney disease in type 2 diabetic patients','biochemical','serum','','experiment','T2DM(Men(443))','','','progression to a more advanced stage of albuminuria','normo- or microalbuminuria','','HR, 0.976(0.958 to 0.994)','multivariate','','0.01','Cox','better','early',''),(80000106,'21785041','HDL cholesterol','','','Gender differences in the association between HDL cholesterol and the progression of diabetic kidney disease in type 2 diabetic patients','biochemical','serum','','experiment','T1DM(Men & Microalbuminuria (164))','','','progression to a more advanced stage of albuminuria','','','HR, 0.969(0.946 to 0.993)','multivariate','','0.01','Cox','better','',''),(80000107,'20083470','ADIPOQ ','ADIPOQ','Q15848','Association of ADIPOQ genetic variants and plasma adiponectin isoforms with the risk of incident renal events in type 2 diabetes','gene','serum','','experiment','T2DM(3086)','','','a doubling of serum creatinine concentration or end-stage renal disease','micro- and macroalbuminuric','','HR, 1.70(1.02 to 2.83) ','multivariate','','0.04','Cox','worse','early','rs17300539'),(80000108,'20083470','ADIPOQ ','ADIPOQ','Q15848','Association of ADIPOQ genetic variants and plasma adiponectin isoforms with the risk of incident renal events in type 2 diabetes','gene','serum','','experiment','T2DM(3086)','','','a doubling of serum creatinine concentration or end-stage renal disease','','','HR, 2.06(1.38 to 3.07) ','multivariate','','0','Cox','worse','','rs1501299'),(80000109,'20083470','ADIPOQ ','ADIPOQ','Q15848','Association of ADIPOQ genetic variants and plasma adiponectin isoforms with the risk of incident renal events in type 2 diabetes','gene','serum','','experiment','T2DM(3086)','','','a doubling of serum creatinine concentration or end-stage renal disease','','','HR, 2.13(1.32 to 3.44)','multivariate','','0.002','Cox','worse','','rs1501299'),(80000110,'21765051','UGB','SCGB1A1','P11684','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','gene','serum','','line array','T2DM(1163)','','','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 1.25(1.009 to 1.550)','multivariate','','0.011','Cox','worse','','587G>A'),(80000111,'21765051','APOB','APOB','P04114','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','gene','serum','','line array','T2DM(1163)','','','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 1.35(1.022 to 1.786)','multivariate','','0.03','Cox','worse','','Thr71Ile'),(80000112,'21765051','PON1','PON1','P27169','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','gene','serum','','line array','T2DM(1163)','','','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 2.60(1.409 to 4.801)','multivariate','','0.002','Cox','worse','','Met55Leu'),(80000113,'21765051','PON2','PON2','P27169','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','gene','serum','','line array','T2DM(1163)','','','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 1.48(1.145 to 1.918)','multivariate','','0.008','Cox','worse','','Ser311Cys'),(80000114,'21765051','PON2','PON2','P27169','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','gene','serum','','line array','T2DM(1163)','','','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 1.56(1.123 to 2.161)','multivariate','','0.031','Cox','worse','','Ser311Cys'),(80000115,'21765051','PON2','PON2','P27169','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','gene','serum','','line array','T2DM(1163)','','','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 1.98(1.066 to 3.695)','multivariate','','0.021','Cox','worse','','Ser311Cys'),(80000116,'21765051','CETP','CETP','P11597','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','gene','serum','','line array','T2DM(1163)','','','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 1.38(1.134 to 1.689)','multivariate','','0.013','Cox','worse','','629C>A'),(80000117,'21765051','CETP','CETP','P11597','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','gene','serum','','line array','T2DM(1163)','','','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 1.58(1.100 to 2.255)','multivariate','','0.004','Cox','worse','','629C>A'),(80000118,'21765051','CETP','CETP','P11597','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','gene','serum','','line array','T2DM(1163)','','','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 1.58(1.155 to 2.153)','multivariate','','0.014','Cox','worse','','629C>A'),(80000119,'21765051','CETP','CETP','P11597','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','gene','serum','','line array','T2DM(1163)','','','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 1.27(1.044 to 1.544)','multivariate','','0.026','Cox','worse','','Ile405Val'),(80000120,'21765051','ITGA2 ','ITGA2','P17301','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','gene','serum','','line array','T2DM(1163)','','','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 2.23(1.336 to 3.729)','multivariate','','0.021','Cox','worse','','873G>A'),(80000121,'21765051','VCAM1 ','CUL5','Q93034','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','gene','serum','','line array','T2DM(1163)','','','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 1.36(1.047 to 1.769)','multivariate','','0.037','Cox','worse','','707T>C'),(80000122,'21765051','number of risk alleles','','','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','score','serum','','line array','T2DM(1163)','0-2 risk alleles:3 risk alleles:4 risk alleles:>=5 risk alleles ','0-2:3 :4 :>=5','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','cumulative incidences','','','','<0.001','log rank','worse','','number of risk alleles of the PON1 Met55Leu, PON2 Ser311Cys, CETP-629C>A, LTA Thr26Asn, LTA Ala252Gl'),(80000123,'21765051','number of risk alleles','','','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','score','serum','','line array','T2DM(1163)','0-2 risk alleles:3 risk alleles:4 risk alleles:>=6 risk alleles','3:0-2','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','cumulative incidences','HR, 1.93(1.253 to 2.958)','multivariate','','0.003','Cox','worse','','number of risk alleles of the PON1 Met55Leu, PON2 Ser311Cys, CETP-629C>A, LTA Thr26Asn, LTA Ala252Gl'),(80000124,'21765051','number of risk alleles','','','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','score','serum','','line array','T2DM(1163)','0-2 risk alleles:3 risk alleles:4 risk alleles:>=5 risk alleles ','4:0-2','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','cumulative incidences','HR, 3.16(1.965 to 5.071)','multivariate','','<0.001','Cox','worse','','number of risk alleles of the PON1 Met55Leu, PON2 Ser311Cys, CETP-629C>A, LTA Thr26Asn, LTA Ala252Gl'),(80000125,'21765051','weighted genetic risk score (wGRS)','','','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','score','serum','','line array','T2DM(1163)','First=0.67 (0.58–1.17):Second=2.52 (1.93–2.52):Third=3.10 (2.75–3.10):Fourth=3.81 (3.25–4.10)','3rd:1st','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 1.68(1.023 to 2.741)','multivariate','','0.04','Cox','worse','','weights(i) = b-coefficient x total number of risk alleles/鈭?[b-coefficient (i) 3 x the number of c'),(80000126,'21765051','weighted genetic risk score (wGRS)','','','Predictive role of multilocus genetic polymorphisms in cardiovascular disease and inflammation-related genes on chronic kidney disease in Type 2 diabetes--an 8-year prospective cohort analysis of 1163 patients','score','serum','','line array','T2DM(1163)','First=0.67 (0.58–1.17):Second=2.52 (1.93–2.52):Third=3.10 (2.75–3.10):Fourth=3.81 (3.25–4.10)','4th:1st','defined as the first estimated glomerular filtration rate <60mL/min/1.73m2 or the first hospitalization with a diagnosis of renal disease','','','HR, 2.45(1.561 to 3.852)','multivariate','','0.0001','Cox','worse','','weights(i) = b-coefficient x total number of risk alleles/鈭?[b-coefficient (i) 3 x the number of c'),(80000127,'26098901','HbA1c','HbA1c','','Extreme Levels of HbA1c Increase Incident ESRD Risk in Chinese Patients with Type 2 Diabetes: Competing Risk Analysis in National Cohort of Taiwan Diabetes Study','protein','serum','','experiment','T2DM(51681)','< 6.0%, 6.0%–6.9%, 7.0%–7.9%, 8.0%–8.9%, 9.0%–9.9%, and 10.0%','< 6.0%:6.0%–6.9%:7.0%–7.9%:8.0%–8.9%:9.0%–9.9%:10.0%','ESRD','','cumulative incidences','','','','<0.001','log rank','worse','',''),(80000128,'26098901','HbA1c','HbA1c','','Extreme Levels of HbA1c Increase Incident ESRD Risk in Chinese Patients with Type 2 Diabetes: Competing Risk Analysis in National Cohort of Taiwan Diabetes Study','protein','serum','','experiment','T2DM(51681)','< 6.0%, 6.0%–6.9%, 7.0%–7.9%, 8.0%–8.9%, 9.0%–9.9%, and 10.0%','< 6.0%:6.0%–6.9%','ESRD','','','HR, 1.99(1.62 to 2.44)','multivariate','','<0.001','Cox','worse','',''),(80000129,'26098901','HbA1c','HbA1c','','Extreme Levels of HbA1c Increase Incident ESRD Risk in Chinese Patients with Type 2 Diabetes: Competing Risk Analysis in National Cohort of Taiwan Diabetes Study','protein','serum','','experiment','T2DM(51681)','< 6.0%, 6.0%–6.9%, 7.0%–7.9%, 8.0%–8.9%, 9.0%–9.9%, and 10.0%','7.0%–7.9%:6.0%–6.9%','ESRD','','','HR, 1.86(1.58 to 2.18) ','multivariate','','<0.001','Cox','worse','',''),(80000130,'26098901','HbA1c','HbA1c','','Extreme Levels of HbA1c Increase Incident ESRD Risk in Chinese Patients with Type 2 Diabetes: Competing Risk Analysis in National Cohort of Taiwan Diabetes Study','protein','serum','','experiment','T2DM(51681)','< 6.0%, 6.0%–6.9%, 7.0%–7.9%, 8.0%–8.9%, 9.0%–9.9%, and 10.0%','8.0%–8.9%:6.0%–6.9%','ESRD','','','HR, 2.08(1.77 to 2.45)','multivariate','','<0.001','Cox','worse','',''),(80000131,'26098901','HbA1c','HbA1c','','Extreme Levels of HbA1c Increase Incident ESRD Risk in Chinese Patients with Type 2 Diabetes: Competing Risk Analysis in National Cohort of Taiwan Diabetes Study','protein','serum','','experiment','T2DM(51681)','< 6.0%, 6.0%–6.9%, 7.0%–7.9%, 8.0%–8.9%, 9.0%–9.9%, and 10.0%','9.0%–9.9%:6.0%–6.9%','ESRD','','','HR, 2.50(2.11 to 2.96)','multivariate','','<0.001','Cox','worse','',''),(80000132,'26098901','HbA1c','HbA1c','','Extreme Levels of HbA1c Increase Incident ESRD Risk in Chinese Patients with Type 2 Diabetes: Competing Risk Analysis in National Cohort of Taiwan Diabetes Study','protein','serum','','experiment','T2DM(51681)','< 6.0%, 6.0%–6.9%, 7.0%–7.9%, 8.0%–8.9%, 9.0%–9.9%, and 10.0%','< 6.0%:6.0%–6.9%','ESRD','','','HR, 4.42(3.80 to 5.14)','multivariate','','<0.001','Cox','worse','',''),(80000133,'24819633','SOD2','SOD2','P04179','Manganese superoxide dismutase (SOD2) polymorphisms, plasma advanced oxidation protein products (AOPP) concentration and risk of kidney complications in subjects with type 1 diabetes','gene','plasma','','KASP','T1DM(SURGENE(340))','','','renal events (new cases of microalbuminuria or progression to a more severe stage of nephropathy)','','event-free curves','HR, 1.99(1.24 to 3.12)','multivariate','','0.004','Cox','worse','','rs4880'),(80000134,'24819633','SOD2','SOD2','P04179','Manganese superoxide dismutase (SOD2) polymorphisms, plasma advanced oxidation protein products (AOPP) concentration and risk of kidney complications in subjects with type 1 diabetes','gene','plasma','','KASP','T1DM(SURGENE(340))','','','renal events (new cases of microalbuminuria or progression to a more severe stage of nephropathy)','','','HR, 1.90(1.19鈥?.98)','multivariate','','0.007','Cox','worse','','rs8031'),(80000135,'24819633','SOD2','SOD2','P04179','Manganese superoxide dismutase (SOD2) polymorphisms, plasma advanced oxidation protein products (AOPP) concentration and risk of kidney complications in subjects with type 1 diabetes','gene','plasma','','KASP','T1DM(SURGENE(340))','','','renal events (new cases of microalbuminuria or progression to a more severe stage of nephropathy)','','','HR, 1.94(1.22 to 3.04)','multivariate','','0.006','Cox','worse','','rs2758329'),(80000136,'25894587','hepcidin','HAMP','P81172','Hepcidin-25 in diabetic chronic kidney disease is predictive for mortality and progression to end stage renal disease','protein','serum','','experiment','T1DM,T2DM(249)','hepcidin <44 ng/ml,44鈥?6 ng/ml,>76 ng/ml','H:M:L','CKD progression (ESRD or doubling of serum creatinine) ','','event-free curves','HR, 1.134(1.041 to 1.235)','multivariate','','<0.05','Cox','worse','',''),(80000137,'18609080','Interleukin-6','IL6','P05231','Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study','protein','plasma','','experiment','T2DM(269)','','','onset of diabetic nephropathy (persistent albuminuria >200 渭g/min in two out of three consecutive overnight urine samples and at least 30 % higher than the baseline level)','microalbuminuria','','HR, 1.72(1.12 to 2.66)','multivariate','','0.014','Cox','worse','early',''),(80000138,'18609080','vWf','VWF','P04275','Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study','protein','plasma','','experiment','T2DM(269)','','','onset of diabetic nephropathy (persistent albuminuria >200 渭g/min in two out of three consecutive overnight urine samples and at least 30 % higher than the baseline level)','microalbuminuria','','HR, 1.69(1.10 to 2.59) ','multivariate','','0.016','Cox','worse','early',''),(80000139,'18609080','sVCAM-1','VCAM1','P19320','Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study','protein','plasma','','experiment','T2DM(269)','','','onset of diabetic nephropathy (persistent albuminuria >200 渭g/min in two out of three consecutive overnight urine samples and at least 30 % higher than the baseline level)','microalbuminuria','','HR, 2.06(1.26 to 3.36)','multivariate','','0.004','Cox','worse','early',''),(80000140,'18609080','sICAM-1 ','VCAM1','P05362','Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study','protein','plasma','','experiment','T2DM(269)','','','onset of diabetic nephropathy (persistent albuminuria >200 渭g/min in two out of three consecutive overnight urine samples and at least 30 % higher than the baseline level)','microalbuminuria','','HR, 1.99(1.04 to 3.82)','multivariate','','0.038','Cox','worse','early',''),(80000141,'18609080','Endothelial Z-score','','','Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study','score','plasma','','experiment','T2DM(269)','Endothelial Z-score of -0.056','H:L','onset of diabetic nephropathy (persistent albuminuria >200 渭g/min in two out of three consecutive overnight urine samples and at least 30 % higher than the baseline level)','microalbuminuria','cumulative incidences','HR, 3.20(1.56 to 6.56)','multivariate','','0.001','Cox','worse','early',''),(80000142,'17907053','THP','UMOD','P07911','Decreased urinary concentration of Tamm-Horsfall protein is associated with development of renal failure and cardiovascular death within 20 years in type 1 but not in type 2 diabetic patients','protein','urine','','experiment','T1DM,T2DM(T1DM(131))','u-THP of 38.2mg/l','H:L','uraemia/dialysis/transplantation','','cumulative incidences','','','','<0.001','log rank','better','',''),(80000143,'21820220','TnT ','TNNT1','P13805','Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD','protein','serum','','experiment','T2DM(1000)','NT-proBNP of 605pg/mL,TnT of 0.01 ng/mL,NT-proBNP of 605pg/mL','HBHT:LBHT:HBLT:LBLT','ESRD','eGFR, 20-60mL/min/1.73 m2','cumulative incidences','','','','<0.001','log rank','worse','advanced',''),(80000144,'21820220','NT-proBNP','NPPB','P16860','Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD','protein','serum','','experiment','T2DM(1000)','NT-proBNP of 605pg/mL,TnT of 0.01 ng/mL,NT-proBNP of 605pg/mL','','ESRD','eGFR, 20-60mL/min/1.73 m2','','HR, 2.20(1.37 to 3.52)','multivariate','','0.001','Cox','worse','advanced',''),(80000145,'21820220','NT-proBNP','NPPB','P16860','Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD','protein','serum','','experiment','T2DM(1000)','NT-proBNP of 605pg/mL,TnT of 0.01 ng/mL,NT-proBNP of 605pg/mL','','ESRD','eGFR, 20-60mL/min/1.73 m2','','HR, 1.90(1.12 to 3.22)','multivariate','','0.01','Cox','worse','advanced',''),(80000146,'21820220','NT-proBNP','NPPB','P16860','Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD','protein','serum','','experiment','T2DM(1000)','NT-proBNP of 605pg/mL,TnT of 0.01 ng/mL,NT-proBNP of 605pg/mL','','ESRD','eGFR, 20-60mL/min/1.73 m2','','HR, 2.820(1.449 to 5.485)','multivariate','','0.01','Cox','worse','advanced',''),(80000147,'21346330','apo E ','APOE','P02649','Apolipoprotein E polymorphism and the progression of diabetic nephropathy in type 2 diabetes','gene','serum','','experiment','T2DM(525)','','E4 carrier:non-E4 carrier','progression of DN(shift to a higher stage of DN or a doubling of the baseline serum creatinine level by the end of the study)','','cumulative incidences','HR, 1.94(1.16 to 3.27)','multivariate','','0.002','Cox','worse','','E4 carrier'),(80000148,'26067713','D-scores','','','A pathological scoring system to predict renal outcome in diabetic nephropathy','score','renal tissue','','experiment','DM(205)','D-score <= 14, 15–18, 19–21, and 22–25 ','<= 14: 15–18:19–21:22–25 ','ESRD','','event-free curves','','','','<0.001','log rank','worse','','The D-scores of glomerular classes 1, 2A, 2B, 3, and 4 were, respectively, 0, 3, 4, 6, and 6. Those '),(80000149,'26067713','D-scores','','','A pathological scoring system to predict renal outcome in diabetic nephropathy','score','renal tissue','','experiment','DM(205)','D-score <= 14, 15–18, 19–21, and 22–25 ','<= 14: 15–18:19–21:22–25 ','ESRD','','','HR, 16.21(1.86 to 140.90)','multivariate','','0.01','Cox','worse','','The D-scores of glomerular classes 1, 2A, 2B, 3, and 4 were, respectively, 0, 3, 4, 6, and 6. Those '),(80000150,'26067713','D-scores','','','A pathological scoring system to predict renal outcome in diabetic nephropathy','score','renal tissue','','experiment','DM(205)','D-score <= 14, 15–18, 19–21, and 22–25 ','<= 14: 15–18:19–21:22–25 ','ESRD','','','HR, 19.78(2.15 to 182.40)','multivariate','','0.008','Cox','worse','','The D-scores of glomerular classes 1, 2A, 2B, 3, and 4 were, respectively, 0, 3, 4, 6, and 6. Those '),(80000151,'26067713','D-scores','','','A pathological scoring system to predict renal outcome in diabetic nephropathy','score','renal tissue','','experiment','DM(205)','D-score <= 14, 15–18, 19–21, and 22–25 ','<= 14: 15–18:19–21:22–25 ','ESRD','','','HR, 45.46(4.63 to 446.68)','multivariate','','0.001','Cox','worse','','The D-scores of glomerular classes 1, 2A, 2B, 3, and 4 were, respectively, 0, 3, 4, 6, and 6. Those '),(80000152,'25154422','MCP-1','CCL2','P13500','Monocyte chemoattractant protein-1 (MCP-1) g.-2518A>G polymorphism and susceptibility to type 2 diabetes (T2D) and end stage renal disease (ESRD) in the North-West Indian population of Punjab','gene','serum','','experiment','T2DM(350)','','','ESRD ','','','HR, 4.03(1.6 to 10.2)','multivariate','','0.011','Cox','worse','','rs1024611'),(80000153,'25154422','MCP-1','CCL2','P13500','Monocyte chemoattractant protein-1 (MCP-1) g.-2518A>G polymorphism and susceptibility to type 2 diabetes (T2D) and end stage renal disease (ESRD) in the North-West Indian population of Punjab','gene','serum','','experiment','T2DM(female(157))','','','ESRD ','','','HR, 2.14(1.19 to 3.86)','multivariate','','0.003','Cox','worse','','rs1024611'),(80000154,'25154422','MCP-1','CCL2','P13500','Monocyte chemoattractant protein-1 (MCP-1) g.-2518A>G polymorphism and susceptibility to type 2 diabetes (T2D) and end stage renal disease (ESRD) in the North-West Indian population of Punjab','gene','serum','','experiment','T2DM(female(157))','','','ESRD ','','','HR, 3.51(1.37 to 9.01)','multivariate','','0.009','Cox','worse','','rs1024611'),(80000155,'21147957','HbA1c','HbA1c','','Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A1c)','protein','serum','','experiment','T2DM(2314)','','','progression of nephropathy','','','HR, 1.201(1.089 to 1.320)','multivariate','','<0.0001','Cox','worse','','u.m. HbA1c( updated mean)'),(80000156,'21147957','glycation gap','','','Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A2c)','score','serum','','experiment','T2DM(2314)','','','progression of nephropathy','','','HR, 1.358(1.168 to 1.577)','multivariate','','<0.0001','Cox','worse','',''),(80000157,'21147957','glycation gap','','','Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A3c)','score','serum','','experiment','T2DM(2314)','GG of characteristic mean calculated for each patient by averaging his or her raw gg value','H:M:L','progression of nephropathy','','cumulative incidences','HR, 2.52','multivariate','','<0.001','Cox','worse','','glycation gap was defined for each patient as the mean of the values for the raw glycation gap (gg) '),(80000158,'21147957','glycation gap','','','Progression of nephropathy in type 2 diabetes: the glycation gap is a significant predictor after adjustment for glycohemoglobin (Hb A4c)','score','serum','','experiment','T2DM(2314)','GG of characteristic mean calculated for each patient by averaging his or her raw gg value','H:M:L','progression of nephropathy','','cumulative incidences','HR, 1.61','multivariate','','0.001','Cox','worse','','glycation gap was defined for each patient as the mean of the values for the raw glycation gap (gg) '),(80000159,'18083536','HGB','CYGB','Q8WWM9','Hemoglobin and overt nephropathy complications in type 1 diabetes','protein','serum','','experiment','T1DM(174)','HGB of 13.75 g/L in women, 15.85 in men','H:L','ESRD','albumin excretion rate >200 渭g/min in multiple urine samples','event-free curves','HR, 0.72(0.61 to 0.85)','multivariate','','0.001','Cox','better','middle,advanced',''),(80000160,'23492569','TKT','TKT','P29401','Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality','gene','serum','','experiment','T2DM(314)','','','','','','','','','','','','','rs11130362'),(80000161,'23492569','FN3K','FN3K','Q9H479','Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality','gene','serum','','experiment','T2DM(314)','','','','','','','','','','','','','rs1056534'),(80000162,'23492569','Combination of risk genotypes','','','Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality','score','serum','','experiment','T2DM(314)','','Combination of risk genotypes:Other combination','Progression of DN','','event-free curves','','multivariate','','0.00645','log rank','worse','','rs11130362 in TKT and rs1056534 in FN3K'),(80000163,'25701507','SLC2A1','SLC2A1','P11166','Association of single nucleotide polymorphisms in the gene encoding GLUT1 and diabetic nephropathy in Brazilian patients with type 1 diabetes mellitus','gene','serum','','experiment','T1DM(155)','','TT/TA:AA','new cases of microalbuminuria or progression to a more severe stage of DN','','event-free curves','HR, 0.22(0.03 to 0.70)','multivariate','','0.009','cox','better','','rs3820589'),(80000164,'25701507','SLC2A1','SLC2A1','P11166','Association of single nucleotide polymorphisms in the gene encoding GLUT1 and diabetic nephropathy in Brazilian patients with type 1 diabetes mellitus','gene','serum','','experiment','T1DM(155)','','','new cases of microalbuminuria or progression to a more severe stage of DN','','','HR, 0.20(0.03 to 0.71)','multivariate','','0.007','cox','better','','rs3820589'),(80000165,'20711718','CNDP1','CNDP1','Q96KN2','A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus','gene','serum','','experiment','T1DM,T2DM(T1DM(864))','','5L–5L: all other genotypes','ESRD(need to start chronic dialysis or kidney transplantation)','','cumulative incidences','HR, 1.71(1.11 to 2.65)','multivariate','','<0.05','cox','worse','','Homozygosity for a five leucine repeat (5L鈥?L)'),(80000166,'20711718','CNDP1','CNDP1','Q96KN2','A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus','gene','serum','','experiment','T1DM,T2DM(T1DM(864))','','5L–5L: all other genotypes','ESRD(need to start chronic dialysis or kidney transplantation)','','cumulative incidences','HR, 2.19(1.21 to 4.01)','multivariate','','<0.05','cox','worse','','Homozygosity for a five leucine repeat (5L鈥?L)'),(80000167,'22266663','TNFR1','TNFRSF1A','P19438','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR1 (pg/ml): 1049 for the 25th percentile, 1310 for the 50th percentile, and 1837 for the 75th percentile','Q4:Q1-3','ESRD','','cumulative incidences','HR, 7.11(2.13 to 23.69)','multivariate','','0.0004','cox','worse','',''),(80000168,'22266663','TNFR1','TNFRSF1A','P19438','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR1 (pg/ml): 1049 for the 25th percentile, 1310 for the 50th percentile, and 1837 for the 75th percentile','Q4:Q1-3','ESRD','','cumulative incidences','HR, 7.05(2.23 to 22.30) ','multivariate','','0.0018','cox','worse','',''),(80000169,'22266663','TNFR2','TNFRSF1B','P20333','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR2 (pg/ml): 2017 for the 25th percentile, 2527 for the 50th percentile, and 3363 for the 75th percentile.','','ESRD','','','HR, 3.82 (1.59 to 9.20) ','multivariate','','0.0008','cox','worse','',''),(80000170,'22266663','TNFR2','TNFRSF1B','P20333','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR2 (pg/ml): 2017 for the 25th percentile, 2527 for the 50th percentile, and 3363 for the 75th percentile.','','ESRD','','','HR, 5.88(2.10 to 16.43)','multivariate','','0.0013','cox','worse','',''),(80000171,'22266663','free TNFa','TNF','P01375','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR2 (pg/ml): 2017 for the 25th percentile, 2527 for the 50th percentile, and 3363 for the 75th percentile.','','ESRD','','','HR, 2.22(1.20 to 4.12)','multivariate','','0.01','cox','worse','',''),(80000172,'22266663','total TNFa','TNF','P01375','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR2 (pg/ml): 2017 for the 25th percentile, 2527 for the 50th percentile, and 3363 for the 75th percentile.','','ESRD','','','HR, 2.53(1.25 to 5.13)','multivariate','','0.01','cox','worse','',''),(80000173,'22266663','total TNFa','TNF','P01375','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR2 (pg/ml): 2017 for the 25th percentile, 2527 for the 50th percentile, and 3363 for the 75th percentile.','','ESRD','','','HR, 2.61(1.42 to 4.81)','multivariate','','0.002','cox','worse','',''),(80000174,'22266663','TNFR1','TNFRSF1A','P19438','Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes','protein','plasma','','experiment','T2DM(410)','TNFR1 (pg/ml): 1049 for the 25th percentile, 1310 for the 50th percentile, and 1837 for the 75th percentile','','ESRD','','','HR, 4.7(1.3 to 17.0)','multivariate','','<0.05','cox','worse','',''),(80000175,'11978681','urinary albumin excretion rate','','','Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study','biochemical','urine','','experiment','T1DM(537)','baseline values above the median for urinary albumin excretion rate (10 mg/24 h) as risk marker','H:L','progression to microalbuminuria or macroalbuminuria','','cumulative incidence','HR, 2.63(1.65 to 4.19)','multivariate','','<0.0001','Cox','worse','',''),(80000176,'11978681','HbA1c','HbA1c','','Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study','protein','plasma','','experiment','T1DM(537)','baseline values above the median for HbA1c(8.6%) as risk marker','H:L','progression to microalbuminuria or macroalbuminuria','','cumulative incidence','HR, 1.13(1.04 to 1.23)','multivariate','','<0.01','Cox','worse','',''),(80000177,'12882861','urinary albumin excretion rate','','','Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: a 10-year prospective study','biochemical','urine','','experiment','T2DM(1408)','normoalbuminuric(AER<20g/min),microalbuminuric (AER 20鈥?00g/min),macroalbuminuric(AER>200g/min)','M:L','incidence of ESRD (need for dialysis) or chronic renal failure','','','HR, 1.86(0.93 to 3.73)','multivariate','','<0.0001','Cox','worse','',''),(80000178,'12882861','urinary albumin excretion rate','','','Low incidence of end-stage renal disease and chronic renal failure in type 2 diabetes: a 11-year prospective study','biochemical','urine','','experiment','T2DM(1408)','normoalbuminuric(AER<20g/min),microalbuminuric (AER 20鈥?00g/min),macroalbuminuric(AER>201g/min)','H:L','incidence of ESRD (need for dialysis) or chronic renal failure','','','HR, 5.52(2.90 to 10.51)','multivariate','','<0.0001','Cox','worse','',''),(80000179,'12631367','Urine albumin:creatinine','','','The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study','biochemical','urine','','experiment','T2DM(1513)','','','doubling of serum creatinine or the development of ESRD ','','K-M','HR, 6.2(4.4 to 8.7)','multivariate','','<0.0001','Cox','worse','',''),(80000180,'12631367','Serum creatinine','','','The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study','biochemical','serum','','experiment','T2DM(1513)','','','doubling of serum creatinine or the development of ESRD ','','K-M','HR, 2.1(1.7 to 2.5)','multivariate','','<0.0001','Cox','worse','',''),(80000181,'12631367','Serum albumin','ALB','P02768','The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study','protein','serum','','experiment','T2DM(1513)','','','doubling of serum creatinine or the development of ESRD ','','K-M','HR, 0.70(0.61 to 0.80)','multivariate','','<0.0001','Cox','better','',''),(80000182,'12631367','Hemoglobin','HBB','P68871','The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study','protein','serum','','experiment','T2DM(1513)','','','doubling of serum creatinine or the development of ESRD ','','K-M','HR, 0.89(0.84 to 0.95)','multivariate','','0.0001','Cox','better','',''),(80000183,'14569094','ACE','ACE','P12821','Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy','gene','blood','','experiment','T1DM(169)','the D allele (ACE/ID)','','doubling of s-creatinine or ESRD','','K-M','HR, 1.81perallele(1.09 to 3.03)','multivariate','','0.02','Cox','worse','','D allele of the ACE/ID polymorphism'),(80000184,'12716817','serum albumin','ALB','P02768','Factors affecting progression of renal failure in patients with type 2 diabetes','protein','serum','','experiment','T2DM(85)','','','doubling of serum creatinine (s-Cr)','','','HR, 0.484(0.284 to 0.823)','multivariate','','0.0074','Cox','better','',''),(80000185,'12716817','hemoglobin','HBB','P68871','Factors affecting progression of renal failure in patients with type 2 diabetes','protein','serum','','experiment','T2DM(85)','','','doubling of serum creatinine (s-Cr)','','','HR, 0.841(0.728 to 0.972)','multivariate','','0.0194','Cox','better','',''),(80000186,'15029097','triglyceride','','','Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes','biochemical','blood','','experiment','T1DM(297)','lowest tertile (range:0.31-0.75 mmol/l), second tertile (range: 0.76-1.14 mmol/l), highest tertile (range: 1.15-11.10 mmol/l).','H:M+L','occurrence of a renal event,the renal event was defined as the progression from one stage of nephropathy to a higher one','','','HR, 2.01(1.07 to 3.77)','multivariate','','0.0294','Cox','worse','',''),(80000187,'15327408','hemoglobin','HBB','P68871','Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy','protein','blood','','experiment','T2DM(1513)','first quartile <11.3 g/dL, second quartile 11.3 to 12.5 g/dL, third quartile 12.6 to 13.8 g/dL, and fourth quartile 鈮?3.8 g/dL','first quartile:fourth quartile','ESRD defined as the need for chronic dialysis or renal transplantation','','K-M(cumulative incidence)','HR, 1.99(1.34 to 2.95)','multivariate','','0.001','Cox','better','',''),(80000188,'15327408','hemoglobin','HBB','P68871','Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy','protein','blood','','experiment','T2DM(1513)','first quartile <11.3 g/dL, second quartile 11.3 to 12.5 g/dL, third quartile 12.6 to 13.8 g/dL, and fourth quartile 鈮?3.8 g/dL','second quartile:fourth quartile ','ESRD defined as the need for chronic dialysis or renal transplantation','','K-M(cumulative incidence)','HR, 1.61(1.08 to 2.41)','multivariate','','0.02','Cox','better','',''),(80000189,'15327408','hemoglobin','HBB','P68871','Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy','protein','blood','','experiment','T2DM(1513)','first quartile <11.3 g/dL, second quartile 11.3 to 12.5 g/dL, third quartile 12.6 to 13.8 g/dL, and fourth quartile 鈮?3.8 g/dL','third quartile:fourth quartile ','ESRD defined as the need for chronic dialysis or renal transplantation','','K-M(cumulative incidence)','HR, 1.87(1.25 to 2.80)','multivariate','','0.002','Cox','better','',''),(80000190,'15327408','hemoglobin','HBB','P68871','Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy','protein','blood','','experiment','T2DM(1513)','as a continuous variable','','ESRD defined as the need for chronic dialysis or renal transplantation','','K-M(cumulative incidence)','HR, 0.90(0.84 to 0.96)','multivariate','','0.0013','Cox','better','',''),(80000191,'12542725','AR','AKR1B1','P15121','Aldose reductase gene polymorphism is associated with progression of diabetic nephropathy in Japanese patients with type 1 diabetes mellitus','gene','blood','','experiment','T1DM(125)','','','incidence of diabetic nephropathy','','K-M','','','','0.031','log rank','worse','','Homozygosity for the Z+2 allele frequenty\r'),(80000192,'15111511','PND','NPPA','P01160','Investigation of the human ANP gene in type 1 diabetic nephropathy: case-control and follow-up studies','gene','','','experiment','T1DM(489(GENEDIAB),301(SURGENE))','','','progression to a further stage of nephropathy','','K-M','HR, 1.93(1.15 to 3.24)','multivariate','','0.012','Cox','worse','','SNP'),(80000193,'14693713','Retinal Vessel Diameters','','','Retinal Vessel Diameters and the Incidence of Gross Proteinuria and Renal Insufficiency in People With Type 1 Diabetes','clinical','','','experiment','T1DM(557)','','4th:1st to 3rd quartiles','Incident gross proteinuria was defined as the development of  鈮?.3 g/l protein excretion in a casual urine specimen','','','RR, 1.53(1.19 to 1.97)','multivariate','','','multivariable logistic regression models','worse','',''),(80000194,'14693713','Retinal Vessel Diameters','','','Retinal Vessel Diameters and the Incidence of Gross Proteinuria and Renal Insufficiency in People With Type 1 Diabetes','clinical','','','experiment','T1DM(557)','','4th:1st to 3rd quartiles','incident renal insufficiency was defined as the development of estimated GFR<60 ml.min鈥?.1.73 m 2','','','RR, 1.51(1.05 to 2.17)','multivariate','','','multivariable logistic regression models','worse','',''),(80000195,'15492856','GSTT1','GSTT1','P30711','Glutathione S-transferase T1 deletion is a risk factor for developing end-stage renal disease in diabetic patients','gene','blood','','experiment','T2DM(230(DM2),475(hypertension))','type 2 diabetes mellitus patients with or without diabetic-related ESRD','type 2 diabetes mellitus patients with diabetic-related ESRD:type 2 diabetes mellitus patients witho','The diagnostic criterion for ESRD was chronic renal failure with serum creatinine >8.0 mg/dl or creatinine clearance <5 ml/min, needed to start dialysis.','','','OR, 2.18(1.29 to 3.70)','multivariate','','0.004','unconditional logistic regression','worse','','homozygous deletion\r'),(80000196,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','II:DI','Persistent microalbuminuria was defined as an AER鈮?0.8 渭g/min on two consecutive assessments','','','HR, 0.62(0.43 to 0.89)','multivariate','','0.009','Cox','better','','insertion/deletion'),(80000197,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','II:DI','severe nephropathy is based on repeated measures of AER and represents the progression from persistent microalbuminuria to an AER鈮?08 渭g/min or renal replacement therapy','','','HR, 0.56(0.32 to 0.96)','multivariate','','0.033','Cox','better','','insertion/deletion'),(80000198,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','TT:CT','Persistent microalbuminuria was defined as an AER鈮?0.8 渭g/min on two consecutive assessments','','','HR, 0.61(0.44 to 0.84)','multivariate','','0.003','Cox','better','','rs1800764'),(80000199,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','TT:CT','severe nephropathy is based on repeated measures of AER and represents the progression from persistent microalbuminuria to an AER鈮?08 渭g/min or renal replacement therapy','','','HR, 0.62(0.39 to 0.98)','multivariate','','0.043','Cox','better','','rs1800764'),(80000200,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','CC:CT','Persistent microalbuminuria was defined as an AER鈮?0.8 渭g/min on two consecutive assessments','','','HR, 0.65(0.49 to 0.88)','multivariate','','0.005','Cox','better','','rs9896208'),(80000201,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','CC:CT','severe nephropathy is based on repeated measures of AER and represents the progression from persistent microalbuminuria to an AER鈮?08 渭g/min or renal replacement therapy','','','HR, 0.54(0.34 to 0.85)','multivariate','','0.008','Cox','better','','rs9896208'),(80000202,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','TIC/TIC:CDT/TIC','Persistent microalbuminuria was defined as an AER鈮?0.8 渭g/min on two consecutive assessments','','','HR, 0.49(0.32 to 0.75)','multivariate','','0.0009','Cox','better','','Haplotype(rs1800764, insertion/deletion, and rs9896208)'),(80000203,'15793268','ACE','ACE','P12821','Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes','gene','','','experiment','T1DM(427)','','TIC/TIC:CDT/TIC','severe nephropathy is based on repeated measures of AER and represents the progression from persistent microalbuminuria to an AER鈮?08 渭g/min or renal replacement therapy','','','HR, 0.41(0.22 to 0.78)','multivariate','','0.006','Cox','better','','Haplotype(rs1800764, insertion/deletion, and rs9896208)'),(80000204,'16123488','HCV','HCV','','Hepatitis C Is a Predictor of Poorer Renal Survival in Diabetic Patients','biochemical','','','experiment','T1DM,T2DM(1127)','HCV status','HCV subjects:Non-HCV subjects','Initiation of renal replacement therapy','','K-M','HR, 3.49(1.27 to 9.57)','multivariate','','0.015','Cox','worse','',''),(80000205,'16249462','CCR5','CCR5','P51681','Risk of Diabetic Nephropathy in Type 1 Diabetes Is Associated With Functional Polymorphisms in RANTES Receptor Gene (CCR5)','gene','blood','','experiment','T1DM(794)','','Male carriers:noncarriers','Patients were considered case subjects if they had persistent proteinuria or if they had ESRD due to diabetic nephropathy','','','OR, 1.9(1.2 to 3.0)','univariate','','0.005','Logistic models','worse','','male carriers of the 59029G allele\r'),(80000206,'16249462','CCR5','CCR5','P51681','Risk of Diabetic Nephropathy in Type 1 Diabetes Is Associated With Functional Polymorphisms in RANTES Receptor Gene (CCR5)','gene','blood','','experiment','T1DM(794)','','Male carriers:noncarriers','Patients were considered case subjects if they had persistent proteinuria or if they had ESRD due to diabetic nephropathy','','','OR, 2.3(1.3 to 4.2)','univariate','','0.009','Logistic models','worse','','male carriers of the 32-bp deletion\r'),(80000207,'15983325','lipoprotein(a) ','LPA','P08519','Prospective Study of Lipoprotein(a) as a Risk Factor for Deteriorating Renal Function in Type 2 Diabetic Patients With Overt Proteinuria','protein','serum','','experiment','T2DM(81)','','','Progression of diabetic nephropathy was defined as a greater than twofold increase of follow-up serum creatinine concentration from the baseline value','','','OR, 1.418(1.040 to 1.934)','multivariate','','0.027','Multiple logistic regression','worse','',''),(80000208,'15677791','ACE','ACE','P12821','Prognostic Effect of Insertion/Deletion Polymorphism of the ACE Gene on Renaland Cardiovascular Clinical Outcomes in Chinese Patients With Type 2 Diabetes','gene','blood','','experiment','T2DM(1281)','','DD versus II','Renal end points were defined as dialysis or doubling of plasma creatinine if the baseline value was 鈮?50渭mol/l or the absolute value was 鈮?00渭mol/l','','K-M(cumulative incidence)','HR, 2.80(1.49 to 5.29)','multivariate','','0.001','Cox','worse','','insertion/deletion (I/D) polymorphism'),(80000209,'27324705','uric acid','','','Hyperuricemia contributes to the faster progression of diabetic kidney disease in type 2 diabetes mellitus','biochemical','serum','','experiment','T2DM(422)','hyperuricemia(serum uric acid(SUA)鈮?420 渭mol/l for men and 鈮?60 渭mol/l for women and/or allopurinol treatment)','High SUA or allopurinol/normal SUA, without treatment','onset or progression of DKD, i.e. (i) the decline of GFR below 60 ml/min per 1.73 m2 during the follow-up period for those with GFR>60 ml/min per 1.73 m2 at baseline or achieving ESRD or (ii) development of overt proteinuria in normo- and microalbuminuric subjects at baseline or (iii) progression of CKD by at least stage for those with CKD III and IV at baseline','','K-M(Time-to-event analysis)','HR, 2.14(1.40 to 3.26)','multivariate','','<0.001','Cox','worse','',''),(80000210,'27500547','IL-6','IL6','P05231','Interleukin-6 gene polymorphisms correlate with the progression of nephropathy in Chinese patients with type 2 diabetes: A prospective cohort study','gene','blood','','experiment','T2DM(568)','','GG : CC + CG','progression to diabetic nephropathy','','K-M','HR, 2.02(1.08 to 3.75)','multivariate','','0.027','Cox','worse','','rs1800796'),(80000211,'27500547','IL-6','IL6','P05231','Interleukin-6 gene polymorphisms correlate with the progression of nephropathy in Chinese patients with type 2 diabetes: A prospective cohort study','gene','blood','','experiment','T2DM(568)','','','progression to diabetic nephropathy','','K-M','HR, 2.37(1.15 to 4.87)','multivariate','','0.019','Cox','worse','','rs2069837'),(80000212,'27500547','IL-6','IL6','P05231','Interleukin-6 gene polymorphisms correlate with the progression of nephropathy in Chinese patients with type 2 diabetes: A prospective cohort study','gene','blood','','experiment','T2DM(568)','','','progression to diabetic nephropathy','','K-M','HR, 2.08(1.12 to 3.89)','multivariate','','0.021','Cox','worse','','rs1524107'),(80000213,'27003829','TNFR1','TNFRSF1A','P19438','High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy','protein','serum','','experiment','T2DM(101)','The distribution in tertiles of the baseline circulating levels was 2165 pg/ml and 2873 pg/ml for the TNFR1','H:M+L','a >50% increase in baseline serum creatinine, end-stage renal disease, or death','','K-M(Time-to-event)','HR, 2.60(1.11 to 6.34)','multivariate','','0.03','Cox','worse','',''),(80000214,'26607824','RAGE','AGER','Q15109','RAGE and CYBA polymorphisms are associated with microalbuminuria and end-stage renal disease onset in a cohort of type 1 diabetes mellitus patients over a 20-year follow-up','gene','blood','','experiment','T1DM(162)','','AA:TA+TT','ESRD','','K-M','HR, 3.3(1.09 to 10.04)','multivariate','','0.035','Cox','worse','','374AA'),(80000215,'26607824','CYBA','CYBA','P13498','RAGE and CYBA polymorphisms are associated with microalbuminuria and end-stage renal disease onset in a cohort of type 1 diabetes mellitus patients over a 20-year follow-up','gene','blood','','experiment','T1DM(162)','','TT+TC:CC','ESRD','','K-M','HR, 3.2(1.13 to 8.53)','multivariate','','0.028','Cox','worse','','242TT+TC'),(80000216,'26818011','HbA1c','HbA1c','','Glycated Hemoglobin and Outcomes in Patients with Advanced Diabetic Chronic Kidney Disease','protein','blood','','experiment','T2DM(2401)','HbA1c >9%','(>9%):(<6%)','ESRD(initiation of hemodialysis, peritoneal dialysis, or renal transplantation)','3-4 stage','','HR, 1.6(1.07 to 2.38)','multivariate','','<0.05','Cox','worse','early,middle',''),(80000217,'26845338','VAP-1','AOC3','Q16853','Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes','protein','serum','','experiment','T2DM(604)','','','ESRD','','K-M by tertile','HR, 1.55(1.12 to 2.14)','multivariate','','<0.01','Cox','worse','',''),(80000218,'26773925','GPX1','GPX1','P07203','Glutathione peroxidase-1 gene (GPX1) variants,oxidative stress and risk of kidney complications in people with type 1 diabetes','gene','','','experiment','T1DM(340)','','','new cases of microalbuminuria or progression to more severe stage of diabetic nephropathy','','','HR, 1.81(1.16 to 2.84) ','multivariate','','0.008','Cox','worse','','rs3448'),(80000219,'26773925','GPX1','GPX1','P07203','Glutathione peroxidase-1 gene (GPX1) variants,oxidative stress and risk of kidney complications in people with type 1 diabetes','gene','','','experiment','T1DM(703)','','','ESRD(defined as the new cases of renal replacement therapy)','','','HR, 3.34(1.69 to 6.98) ','multivariate','','0.0004','Cox','worse','','rs3448'),(80000220,'26952289','sulfate','','','High urinary sulfate concentration is associated with reduced risk of renal disease progression in type 2 diabetes','biochemical','urine','','experiment','T2DM(1004)','1st:4.9 (3.7卤5.8);2nd: 8.0 (7.1卤9.0) ;3rd13.3 (11.4卤16.1)','3rd:2nd:1st','a confirmed doubling of serum creatinine, serum creatinine >6.0 mg/dL, or end-stage renal disease','','K-M','','multivariate','','0.037','log rank','better','',''),(80000221,'26952289','sulfate','','','High urinary sulfate concentration is associated with reduced risk of renal disease progression in type 2 diabetes','biochemical','urine','','experiment','T2DM(1004)','','','a confirmed doubling of serum creatinine, serum creatinine >6.0 mg/dL, or end-stage renal disease','','K-M','HR, 0.81(0.66 to 0.99)','multivariate','','0.036','Cox','better','',''),(80000222,'27033561','adiponectin','ADIPOQ','Q15848','Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria','protein','urine','','experiment','T2DM(200)','','','a decline in the eGFR of >30%','','','HR, 1.5(1.1 to 2.2)','multivariate','','0.007','Cox','worse','',''),(80000223,'16505253','SLC12A3','SLC12A3','P55017','SLC12A3 (solute carrier family 12 member [sodium/chloride] 3) polymorphisms are associated with end-stage renal disease in diabetic nephropathy.','gene','serum','','experiment','T2DM(177)','','A:G','ESRD','','','OR, 1.47(1.05 to 2.06)','','','0.023','','worse','','g.-950A>G');


